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ABSTRACT 
 This thesis explores various methods of modelling psychiatric illness in rats. I used two 
distinct pharmacological manipulations to induce acute states that resemble psychosis, as well as 
a prenatal manipulation via maternal inflammation to produce a neurodevelopmental model. I 
assessed the effects of these manipulations in a variety of behaviour tasks relevant to psychiatric 
illness. 
 The first experiment (Chapter 2) uses a prepulse inhibition (PPI) behaviour test to 
demonstrate the effects of two enantiomers of putative antipsychotic GOV on APO or MK-801 
disrupted sensorimotor gating. The use of APO and MK-801 allow acute manipulation of 
DAergic and glutamatergic systems, respectively; the two neurotransmitter systems implicated in 
the main theories explaining schizophrenia pathology. The l-, but not d- enantiomer of GOV was 
effective in restoring PPI, and effect which may be due to l-GOV’s dual effects of D2 receptor 
antagonism and increased prefrontal cortex (PFC) DA efflux while the d- enantiomer lacks a 
strong D2 antagonistic effect. These results support previous findings that l-GOV may have 
potential for use as an antipsychotic. 
 The second set of experiments are presented in Chapters 3 and 4 and use a 
neurodevelopmental model of maternal immune activation (MIA) during pregnancy. Pregnant 
dams are treated with a single intravenous injection of immune stimulant 
polyinosinic:polycytidylic acid (polyI:C) or saline on gestational day (GD) 15. In the acute phase 
following treatment (48 h), dams that received polyI:C displayed significantly lower body weight 
compared to controls and maternal serum collected 3 h post treatment contained elevated levels 
of immune cytokines IL-6 and CXCL1 as determined by ELISA. When the offspring were 
delivered, pups born to polyI:C-exposed dams were significantly smaller than control pups. 
Long-term follow-up of the adult male offspring in Chapter 3 show the polyI:C offspring display 
a psychiatric-like phenotype characterized by behaviour abnormalities related to the positive, 
negative and cognitive symptoms of schizophrenia. In particular, male polyI:C offspring were 
more sensitive to the locomotor-inducing effects of systemic MK-801 and had deficient social 
interaction behaviour compared to controls. Male polyI:C offspring were selectively impaired at 
visual and crossmodal memory, as well as oddity preference. Two operant tasks were also used 
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to asses cognition in the male offspring. Operant set-shifting and reversal learning used lever-
equipped operant chambers to assess cognitive flexibility and found a selective facilitation in set 
shifting performance with no effect on initial visual cue learning or reversal learning. Testing 
with a touchscreen-based reversal learning task also showed no effect on initial cue learning but 
polyI:C offspring were impaired at reversal learning, specifically in the late phase.  
 The effects of MIA on the behaviour profile of the adult female offspring is highlighted 
in Chapter 4. The females were tested in the same behaviour battery as their male siblings, with 
the exception of the operant tasks. Female offspring displayed a similar schizophrenia-like 
behavior profile, including reduced social interaction, and impaired visual recognition memory. 
Females failed to show a group difference in locomotor response to MK-801 at the dose 
examined, and neither group could perform the crossmodal memory task. When the male and 
female results were analysed together in a sex by treatment design, no significant evidence for 
sex differences were found.  
 In addition to the behaviour effects seen in MIA offspring, we were interested in the 
possibility of a relationship between maternal serum cytokine levels and the severity of the 
behavioural abnormalities in the offspring. Bivariate correlations were conducted on these data, 
but no robust relationships were observed, suggesting that IL-6, TNF-a, and CXCL1 
concentrations 3 h post polyI:C injection are not good indicators of later behaviour effects.   
 This thesis uses these 3 data chapters to highlight concepts of validity in preclinical 
research, and the challenges of modelling complex human psychiatric conditions in rats while 
comparing and contrasting the models used. Overall, a researcher’s choice of model depends on 
many factors, yet both pharmacological and neurodevelopmental approaches achieve sufficient 
levels of validity to advance the understanding of psychiatric illness for the eventual goal of 
improved disease management.     
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CHAPTER 1 
INTRODUCTION 
1.1 Outline of the thesis 
 This thesis takes several approaches to explore pathology, putative treatment, and 
environmental risk factors of psychiatric illness. I use two pharmacological models and a 
neurodevelopmental model to demonstrate various aspects of psychopathology and disease risk 
factors in order to better understand the biological disruptions that result in the characteristic 
behavioural disturbances observed in patients with psychiatric conditions.  
Psychiatric illnesses are often chronic, debilitating, and poorly understood (Winship et al., 2018). 
Treatment options are largely insufficient treatment and success is limited (Lieberman et al., 
2005; Jones et al., 2006; Lally and MacCabe, 2015). Only 14% of patients show recovery within 
5 years of the onset of psychotic episodes, and long-term studies show up to an additional 16% 
recover within 25 years (Insel, 2010).  Schizophrenia is a developmental psychiatric illness with 
multiple symptom domains (positive, negative, and cognitive) and a classic example where 
increased risk has been linked to gestational adversity (Brown and Meyer, 2018). The symptoms 
of schizophrenia are diverse. The distinctive hallucinations and delusions associated with the 
disease are referred to as the positive symptoms, while the negative symptoms include social 
withdrawal, avolition, and anhedonia. Schizophrenia is also characterised by cognitive 
symptoms, exemplified by impairments in working memory, information processing, visual 
learning and memory, and reasoning and problem solving (Young et al., 2009; Winship et al., 
2018). Subsets of the symptoms associated with schizophrenia also tend to be observed in other 
diagnoses. Notably, impaired social functioning is a hallmark of autism, and major depression is 
associated with avolition and anhedonia (Nestler et al., 2002; Silverman et al., 2010). The work 
outlined in this dissertation is largely framed in the context of schizophrenia, but the results may 
apply to the understanding and management of other psychiatric conditions and mood disorders 
with overlapping clinical presentations (Nestler and Hyman, 2010; Sanislow et al., 2010). 
The general goals of my doctoral research were to produce translationally relevant results using 
preclinical rat models to further the understanding mental illness, particularly the characteristic 
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behaviour abnormalities seen in schizophrenia. My first goal was to determine the effects of 2 
enantiomers of govadine (GOV), a compound with potential antipsychotic effects, in 2 
pharmacological models of acute psychosis using a sensorimotor gating behaviour task. My 
second goal was to determine whether acute elevations of relevant cytokines in maternal serum 
following an acute inflammatory event during pregnancy were correlated with the long-term 
behaviour abnormalities seen in their adult offspring. Additional attention was given to the 
presence of sex effects with the goal of determining whether offspring sex was a factor in the 
behaviour outcomes.     
 
1.2 Relevant pharmacology 
1.2.1 The dopamine hypothesis 
 The dopamine hypothesis proposes dysfunction of the DAergic system is the underlying 
cause of schizophrenia, and this remains the most persistent theory of the neurobiology of the 
disease. Dopamine (DA) is a neurotransmitter that binds metabotropic g-protein coupled 
receptors (GPCR). There are 5 subgroups of DA receptors. D1 and D5 are grouped together as 
D1-class and they activate Gas/olf G proteins to increase cAMP production by adenylate cyclase 
(AC) and increase PKA activity, and D2, D3 and D4 are D2-class which activate Gai/o for the 
opposite effect of inactive AC, reduced cAMP, and inactive PKA (Beaulieu and Gainetdinov, 
2011). D1-class increase inhibitory postsynaptic current (IPSC) and D2-class increase excitatory 
postsynaptic current (EPSC). DA has important roles in many neurological functions, with 
movement and reward mechanisms among the most well-known. DA is implicated in numerous 
disorders and its role in schizophrenia is particularly relevant to this thesis.  
 The initial theories of heightened DA activity in schizophrenia were proposed due to 
several early lines of evidence. Typical antipsychotics such as haloperidol are effective at 
treating the positive symptoms of schizophrenia and these act as D2 receptor antagonists, 
suggesting some form of increased D2 receptor activity in disease pathology (Beaulieu and 
Gainetdinov, 2011). Patients with schizophrenia show enhanced sensitivity to treatment with 
DAergic agonists such as apomorphine (APO), amphetamine (AMPH) and methylphenidate 
(Seeman, 2013). AMPH stimulates the release of DA, while APO is a classic, nonspecific DA 
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receptor agonist with high affinity for D1-D5 receptors (Seeman, 2013; Arroyo-García et al., 
2018; Horowski and Löschmann, 2019). Some studies show increased D2 receptor density in the 
basal ganglia compared to healthy controls (Beaulieu and Gainetdinov, 2011; Seeman, 2013). 
Early evidence for the involvement of the mesolimbic DA pathway in particular came from 
clinical findings that used implanted electrodes to show increased activity in limbic regions of 
schizophrenia patients during episodes of psychosis (Heath, 2005). Further following this were 
findings that high dose AMPH treatment induced a state with similarities psychosis, and animal 
studies revealed AMPH, which stimulates DA release from presynaptic terminals, had uniquely 
strong effects on the nucleus accumbens (NAc). Further still, AMPH-induced stereotypy 
observed in rodents could be ameliorated with haloperidol infusion to the NAc (McCutcheon et 
al., 2019). Schizophrenia patients release more DA in response to AMPH treatment than 
controls, although presynaptic D2 receptors, involved in feedback inhibition, are normal 
(Seeman, 2013). Overall, there are various alterations in DA-ergic function observed in 
schizophrenia.  
 The DA hypothesis has some shortcomings. Of particular importance, several 
fundamental symptoms of schizophrenia are not improved by conventional treatments involving 
antagonism at the D2 receptor. Cognitive impairment is a hallmark of schizophrenia, as well as 
negative symptoms which include avolition, anhedonia, and social withdrawal are persistently 
non-responsive to antipsychotics (Moghaddam and Javitt, 2012). These points imply other 
pathological avenues may be relevant.  
 
1.2.2 The glutamate hypothesis 
 The glutamate hypothesis of schizophrenia postulates that abnormalities in the 
glutamatergic system, particularly driven by NMDA (N-methyl-D-aspartate) receptor 
hypofunction, are the underlying cause of the disease. NMDA receptor hypofunction was first 
implicated in the pathology of schizophrenia symptoms with the synthesis of phencyclidine 
(PCP) and ketamine in the 1960s, and the observation that administration to humans produced an 
acute psychotic state (Moghaddam and Javitt, 2012). The state induced by NMDA receptor 
antagonists recapitulates the appearance of schizophrenia, including the positive, negative, and 
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cognitive symptoms. They also exacerbate these symptoms in patients with schizophrenia, while 
other hallucinogens such as LSD do not (Jentsch and Roth, 1999). 
Glutamate is the primary excitatory neurotransmitter of the brain and acts through 
ionotropic and metabotropic receptors (Traynelis et al., 2010; Moghaddam and Javitt, 2012). a-
amino-3-hydroxy-5-methyl-4-isoxazolepropionicacid (AMPA) and NMDA receptors are 
membrane-bound, tetrameric, ionotropic glutamate receptors located on postsynaptic neurons 
and are permeable to cations (K+, Na+, Ca2+). NMDA receptors are classically regarded for their 
Ca2+ permeability which is 10-fold greater than Na+ (Traynelis et al., 2010; Vyklicky et al., 
2014). Upon activation and opening of the pore, Na+ and Ca2+ travel along electrochemical 
gradients into the negatively charged intracellular environment to increase the electrical potential 
of the membrane and initiate depolarization, bringing the cell toward the threshold for firing an 
action potential; in the case of Ca2+, intracellular signalling. In contrast, the opening of K+ 
permeable channels result in efflux to hyperpolarize the cell. AMPA receptors are fast 
depolarizing channels that generate EPSCs to remove the voltage-gated Mg2+ block from NMDA 
receptors. In addition to the initial AMPA receptor-induced depolarization, NMDA receptors 
require simultaneous binding of glycine to the GluN1 subunit and glutamate to the GluN2 
subunit for activation. Other related amino acids and molecules have agonist activity at NMDA 
receptors, such as enantiomers of serine at the glycine binding site and aspartate at the glutamate 
binding site and these also contribute to NMDA receptor signalling (Traynelis et al., 2010). 
NMDA receptor signalling forms a vital aspect of excitatory tone throughout the brain.  
 Accompanying the pharmacological evidence that NMDA receptor hypofunction could 
induce psychiatric symptoms in healthy human participants, additional evidence suggests altered 
glutamatergic transmission in schizophrenia. Cerebral spinal fluid (CSF) concentrations of 
glutamate in schizophrenia patients do not differ from controls, but assessments of post-mortem 
tissue from schizophrenic patients reveal deficient levels of NR1 subunit RNA and protein in the 
hippocampus, and animal models with genetic knockdown of NMDA receptors display 
numerous behaviour abnormalities (Kotecha and Macdonald, 2002; Moghaddam and Javitt, 
2012). Several genetic polymorphisms for genes that code NMDA receptor subunits are 
associated with developing schizophrenia, and patients have altered regulation of glycine and D-
serine levels, both of which modulate NMDA receptor activation (Moghaddam and Javitt, 2012).   
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1.2.2.1 MK-801 and other NMDA receptor antagonists 
 Compounds commonly used to pharmacologically induce NMDA receptor hypofunction 
in research settings include non-competitive antagonists MK-801 (dizocilpine), PCP (PCP), and 
ketamine. These are open channel blockers and ‘trapping’ blockers because they require the 
channel pore to be open in order to access the PCP-binding site, and they can become trapped 
within the channel (Traynelis et al., 2010). The PCP-binding site within the pore is distinct from 
the classic glutamate and glycine binding sites, but antagonists at these sites also induce the 
appearance of psychosis-like symptoms (Moghaddam and Javitt, 2012). 
The consequences of systemic administration of MK-801 and similar compounds is 
generally referred to as NMDA receptor hypofunction, which contributes to the dysregulation of 
glutamatergic transmission through several proposed mechanisms. Interneurons that synapse 
onto cortical glutamatergic cells have a lower threshold for firing action potentials, resulting in 
greater basal depolarization and increased probability that voltage-gated NMDA receptor 
channels will be open, facilitating the binding of open channel blockers on these cells. The 
preferential block of NMDA receptors on interneurons results in dysinhibition which may 
enhance glutamate release, destabilize cortical circuits, and prevent the coordination of cellular 
assemblies (Homayoun and Moghaddam, 2007; Moghaddam and Javitt, 2012). In addition, the 
blockade of NMDA receptors results in increased glutamate availability for binding other 
receptors and increased cellular activation in general. Overall, decreased binding at NMDA 
receptors can result in dysregulation of glutamate signalling in the brain by both reducing 
excitation of interneurons and increased AMPA receptor binding (Homayoun and Moghaddam, 
2007; Moghaddam and Javitt, 2012).  
 In addition, there are links between NMDA receptor hypofunction and altered DA 
transmission (Laruelle, 2014). A recent meta-analysis of ketamine administration studies in 
rodents concluded that acute administration of ketamine results in elevated DA release in the 
cortex, striatum, and NAc, as well as increased DA neuron firing in the ventral tegmental area 
(Kokkinou et al., 2018). This is driven by the previously discussed disinhibition of glutamatergic 
signalling, including increased excitation of pyramidal cells and subsequent binding of AMPA 
receptors on DA-ergic neurons (Kokkinou et al., 2018). The levels of DA release in regions such 
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as the PFC and NAc is similar between ketamine, MK-801, and PCP (Kokkinou et al., 2018). In 
general, NMDA receptor antagonists are able to simulate a state of psychosis when administered 
acutely, and this can be tied to both main hypotheses of the underlying dysfunction in 
schizophrenia by affecting glutamatergic and DAergic transmission.   
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Figure 1.1: Schematic of the influence of NMDA receptor hypofunction on DA 
release. 
 
 
Figure 1.1: [A] A simple circuit of GABAergic, glutamatergic, and DAergic neurons to illustrate 
influences on DA release. [B] NMDA receptor hypofunction, as induced by MK-801 and similar 
drugs, primarily affects GABAergic neurons to result in reduced GABA release, disinhibition of 
the glutamatergic neuron, followed by increased glutamate release and influence on the DA-ergic 
neuron to induce greater DA release. The schematic is original, with the design influenced by 
Kokkinou and colleagues (2018). 
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1.2.3 Management of psychiatric illness 
1.2.3.1 Conventional antipsychotics  
 Antipsychotic medications are the class of compounds used in the management of 
schizophrenia, schizophrenia spectrum disorders (SSDs), and other related illnesses. These 
compounds are recognized as either typical or first-generation antipsychotics (FGA), and 
atypical or second-generation antipsychotics (SGA) (Lally and MacCabe, 2015). FGAs are 
united by their shared pharmacological profile of D2 antagonism with greater receptor affinity 
than DA itself, and typically higher risk of adverse events than SGAs. The adverse events 
associated with FGAs in particular are severe, with a high risk for extrapyramidal side effects 
(EPSEs) including tardive dyskinesia, parkinsonism, akathisia, and acute dystonias. The primary 
pharmacological targets of SGAs are potent antagonism at the serotonin 5HT2a receptor, and 
relatively weak antagonism at the D2 receptor. Compared to FGAs and DA itself, SGAs have 
lower binding affinity and more rapid dissociation from the D2 receptor. The transient binding 
but high receptor occupancy of SGAs was believed to carry a lower risk for side effects and 
greater efficacy in reducing symptoms, including the negative and cognitive symptoms which 
FGAs did not improve (Seeman, 2002; Meltzer et al., 2003; Lally and MacCabe, 2015). Several 
studies have now failed to find a difference between FGAs and SGAs efficacy, and while fewer 
EPSEs occur with SGAs, more systemic metabolic adverse events, such as weight gain, are seen. 
Ultimately, changes in quality of life and treatment discontinuation rates are similar between the 
two groups (as high as 75% within 2 years of hospital discharge; Lieberman et al., 2005; Jones et 
al., 2006; Lally and MacCabe, 2015).  
Antipsychotic treatment is more effective than placebo, with 28% of schizophrenia 
patients experiencing symptom relapse within a year, compared to 68% who received placebo. 
30% of patients with schizophrenia do not respond to either FGAs or SGAs and are classified as 
having treatment resistant schizophrenia (TRS) for which the only available and effective 
medication is clozapine. Clozapine is beneficial for up to 70% of TRS patients within a year of 
treatment, yet its use is relatively restricted due to the risk of life-threatening agranulocytosis and 
other adverse events (Lally and MacCabe, 2015). At present, the antipsychotic 
pharmacotherapies available do not fully meet the needs of patients, and no true innovation has 
occurred since the introduction of clozapine in the 1950s. Of the 3 symptom domains, only the 
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positive symptoms are reliably improved by treatment. Negative symptoms and cognitive 
impairment are core features of schizophrenia and remain unaffected by current treatment 
options. In addition, serious adverse events are common, as is treatment discontinuation (Young 
et al., 2009; Moghaddam and Javitt, 2012; Lally and MacCabe, 2015). There remains a need for 
innovative approaches to the pharmacological management of schizophrenia and related 
psychiatric illnesses (Lally and MacCabe, 2015).  
Due to the increasing interest in the glutamate hypothesis, other novel drug targets are 
under exploration as antipsychotics. Despite indications that NMDA receptor hypofunction is 
implicated in the pathology of schizophrenia, targeting the NMDA receptor directly is a poor 
treatment strategy due to the harmful effects of indiscriminately enhanced NMDA activity. 
Sustained activation of NMDA receptors is neurotoxic, and the highly dynamic glutamate 
synapse responds rapidly to enhanced signalling with glutamate reuptake (Moghaddam and 
Javitt, 2012). Other strategies show greater promise by targeting glutamatergic transmission 
indirectly, such as allosteric modulation of presynaptic metabotropic glutamate receptors, are a 
current focus of innovation (Moghaddam and Javitt, 2012). Another approach continues to 
consider the DA hypothesis with novel manipulations that take advantage of the dichotomous 
effects of D1 and D2 receptors.  
 
1.2.3.2 Govadine 
There is a growing interest in a family of compounds derived from traditional Chinese 
medicine called tetrahyroprotoberberines for putative efficacy as antipsychotics. One such 
synthetic compound is govadine (GOV; Lapish et al., 2012, 2014). GOV exists as two 
enantiomers with distinct, but complementary effects. Early preclinical studies in rats have begun 
to characterize the behaviour effects of GOV as a racemic mixture and as separate  d- and l-
enantiomers with evidence supporting benefits for all 3 symptom domains of schizophrenia 
(Lapish et al., 2012, 2014). Both enantiomers have high affinity for D1 DA receptors and 
increase DA efflux in the medial prefrontal cortex (mPFC), but l-GOV also has a high affinity for 
D2 receptors and increases DA efflux in the NAc as well (Lapish et al., 2012). l-GOV appears to 
act like a typical antipsychotic in that is shares several well-established characteristics of D2 
antagonists, such as impairment of conditioned avoidance responding, reversal of AMPH-
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induced hyperlocomotion and induces catalepsy. d-GOV displays cognitive-enhancing properties 
demonstrated by improving performance in the radial arm maze, blocking acquisition and 
reinstatement of conditioned place preference (to food and AMPH reward), as well as facilitates 
CPP extinction. Both enantiomers reverse AMPH-induced disruptions in latent inhibition, and 
social interaction deficits in the neonatal ventral hippocampal lesion model (Lapish et al., 2012, 
2014). Interestingly, l-GOV has also shown efficacy in reversing MK-801 induced deficits in 
visual-spatial memory (Lins et al., 2015). The promising evidence for the potential of d- and l-
GOV in managing the positive, negative, and cognitive symptoms of schizophrenia justify 
further investigation of these compounds.  
 
1.3 Inflammation in pregnancy and offspring psychiatric outcomes 
 Psychiatric illnesses are complex and appear to occur as a result of combined genetic and 
environmental influences. The genetic contribution to schizophrenia etiology has long been 
evident due to the observable occurrence of increased risk in individuals with a diagnosed 
relative compared to those with no family history of schizophrenia. In identical twins, if one 
receives a diagnosis of schizophrenia, the other twin has an approximately 50% chance of also 
developing the disease. Despite the high heritability of schizophrenia, more recent genetics 
studies have not found a strong link to any single gene or polymorphism, and rather many weak 
associations have been detected. Further, the degree of heritability is not high enough to infer a 
purely genetic etiology, and exposure to environmental factors must also be considered (Insel, 
2010). Gestational adversity encompasses a variety of insults that include maternal 
inflammation, maternal malnutrition, gestational diabetes, and neonatal hypoxia (Grissom et al., 
2014; Brown and Meyer, 2018). This thesis includes studies of the impact of maternal 
inflammation on long-term psychiatric behaviour profiles of the offspring.  
        
1.3.1 Early epidemiological evidence 
 Epidemiological studies demonstrate links between gestational and neonatal adverse 
events and elevated risks for the later development of schizophrenia in the offspring. These 
associations arose following observation of increased incidence of schizophrenia in the adult 
offspring of mothers from regions that experienced famine or widespread viral infections during 
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their pregnancies. Notable consideration has been given to the findings from a Finnish birth 
cohort. This study linked individuals in the second trimester of development during an influenza 
pandemic of 1957 with increased likelihood of receiving treatment at a psychiatric hospital with 
a diagnosis of schizophrenia by the age of 26 (Mednick, 1988; Brown, 2006). This initial study 
had several key limitations, such as lacking direct evidence that these individuals’ mothers were 
infected, and gestational age during the epidemic was presumed based on birthdate with no data 
on preterm births; however, the study garnered attention and formed the basis for additional 
research (Brown, 2006).  
 
1.3.2 Clinical prospective birth cohort studies 
The association presented by Mednick and colleagues (1988) was eventually 
corroborated with the analysis of a richer dataset that included maternal serum collected 
throughout pregnancy, enabling confirmation of infection via the presence of antibodies to 
common viruses at the time, along with known gestational timing (Brown et al., 2004a). First 
trimester influenza exposure was associated with a 7-fold increase in risk of offspring developing 
an SSD, while broader definitions showed infection in the first half of pregnancy had a 3-fold 
increase in risk (Brown et al., 2004a).  
Further studies continued to assess outcomes in prospective research cohorts. A notable 
analysis of long-term prospective data by Ellman and colleagues (2009) involved analysis of 
blood samples collected at birth, followed by various physical, cognitive, and psychological 
evaluations from birth to age 7. Maternal exposure to influenza infection in utero was 
serologically confirmed by the presence of antibodies for seasonal influenza viruses, and 
perinatal exposure to influenza infection was associated with lower scores on tests of cognitive 
performance in 7-year-old offspring that eventually received a psychiatric diagnosis compared to 
those that were not exposed (Ellman et al., 2009).  
Autism spectrum disorders (ASD) have also been linked to maternal inflammation in 
pregnancy. Similar to the earlier studies that looked for associations with schizophrenia 
prevalence, there are mixed findings, although a review determined finding an association 
between infection in pregnancy and the occurrence of ASD depends on whether the studies 
included analysis of multiple covariates (Gardener et al., 2009). A more recent meta-analysis 
  
12 
assessed the relationship between maternal infection and offspring autism risk, with numerous 
confounding variables taken into account. Jiang and colleagues (2016) found that maternal 
infection is associated with a 12% increase in risk, although they acknowledged several 
limitations, including a lack of high-quality studies to include in their analysis. The final 
conclusion of the meta-analysis is conservative, stating that maternal infection may be associated 
with ASD, but notes given the prevalence of infection in pregnant women even a modest 
increase in risk could have substantial implications in disease prevalence (Jiang et al., 2016).   
 
1.3.3 The cytokine hypothesis   
In addition to the relationship between maternal influenza in pregnancy and SSD, 
infection via other pathogens (viral upper respiratory infections, herpes simplex virus-2 (HSV-2), 
measles, mumps, rubella, toxoplasma gondii) in pregnancy have been explored and linked to 
psychiatric illness risk in the offspring. Most of the risk-associated pathogens, including 
influenza, are not teratogenic (although there are exceptions such as rubella and toxoplasma 
gondii) which suggests there is an indirect, common mechanism for inflammation to impact fetal 
neurodevelopment. Cytokines are a candidate for this indirect mechanism (Brown, 2006).   
Inflammatory events such as infection by a pathogen initiate a complex cascade of events 
to stimulate the release of immune proteins known as cytokines. Cytokines, a large family of 
proteins, glycoproteins, and peptides involved in signalling immune cells for recruitment and 
trafficking, are released mainly by peripheral immunocompetent cells during an immune 
response, but they are also produced by neurons and glia (Na et al., 2014). Although cytokines 
are most well known for their signalling roles in initiating an immune response, they also have 
roles in development, and maternal peripheral cytokines can cross the placenta and enter the 
developing CNS of the fetus where they have diverse influences (Deverman and Patterson, 
2009). In very early development, a family of cytokines from the transforming growth factor beta 
(TGFb) family influence induction of the neuroepithelium, the source of neuroepithelial cells 
which give rise to neurons, astrocytes and oligodendrocytes. Inhibition of this signalling in mice 
results in a lack of forebrain development (Bachiller et al., 2000). Cytokines have also been 
implicated in the conversion of embryonic stem cells to neural stem cells in vitro. Once the cells 
of the neuroepithelium convert to radial glial cells, the gp130 family of cytokines encourage self-
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renewal to maintain the RGC pool. TGFb signalling plays a role in the differentiation of tyrosine 
hydroxylase positive (TH+) DAergic neurons in the ventral midbrain by promoting conversion to 
this phenotype (Roussa et al., 2006; Deverman and Patterson, 2009). These findings illustrate 
that cytokines are implicated in neurodevelopmental processes, and altered cytokine signalling 
during critical time periods can influence neurodevelopment.   
Chemokines are a subgroup of cytokines known to impact neurodevelopment. Within the 
immune system, chemokines use potent cellular attracting properties to recruit immune 
mediators to the site of an inflammatory insult. Chemokine receptors are constitutively expressed 
in CNS cells with roles in neurodevelopment, including directing neuronal migration, 
differentiation, and axonal pathfinding (Deverman and Patterson, 2009). The developmental 
roles of cytokine receptor CXCR4 and ligand SDF-1 has been amenable to investigation due to 
monogamous binding, and genetic knockout models display various developmental 
abnormalities in the cerebellum and dentate gyrus of the hippocampus. Other chemokine and 
chemokine receptor interactions are widely polygamous, complex, and dynamic, and 
understanding of their roles in development are still unfolding (Deverman and Patterson, 2009). 
While the mechanisms by which cytokines regulate and influence neurodevelopment are not 
fully known, heightened levels of inflammatory mediators, such as cytokines, during pregnancy 
may be responsible for long-term effects on the embryo that result in increased risk for the later 
development of psychiatric illness (Bergdolt and Dunaevsky, 2019).   
Evidence that cytokines mediate the effects of infection during pregnancy on the eventual 
emergence of psychopathology in the offspring came from more prospective clinical studies that 
collected maternal blood samples during pregnancy for long-term follow-up. One study found a 
significant association between second/third trimester levels of IL-8, a chemokine, in pregnant 
women and their offspring’s risk for schizophrenia, where levels of IL-8 were approximately 
twice as high in pregnancies where offspring eventually developed schizophrenia. This 
association was not seen for the other cytokines measured; tumor necrosis factor-a (TNF-a), IL-
1b, or IL-6 (Brown et al., 2004b). Another study used magnetic resonance imaging of the 
offspring as adults to determine the volumes of ventricular regions, and cortical, limbic, and 
subcortical structures. Among those offspring that developed SSDs, higher levels of interleukin-
8 (IL-8) in maternal serum were associated with increased ventricular CSF volume, decreased 
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left entorhinal cortex volume, and decreased right posterior cingulate volume. These data were 
the first to demonstrate a relationship between measured maternal cytokine elevations and the 
neuroanatomical abnormalities in offspring that developed SSD (Ellman et al., 2010). Another 
study found significantly higher levels of cytokine TNF-a, but not IL-1b, IL-2, IL-6, or IL-8, in 
late pregnancy in cases that eventually developed schizophrenia (Buka et al., 2001). Maternal 
serum cytokine elevations have been related to childhood psychiatric symptoms, with higher IL-
8 levels in the first trimester associated with greater externalizing symptoms in the offspring, and 
higher IL-1ra (receptor antagonist) levels in the second trimester associated with greater 
internalizing symptoms in female offspring (Mac Giollabhui et al., 2019). Further research has 
associated elevated baseline cytokines in pregnancy with offspring outcomes, even in the 
absence of overt maternal illness. Working memory impairments and negative emotional affect 
were retrospectively linked to elevated IL-6 in maternal systemic circulation in children aged 2 
years and 6 months respectively, and maternal IL-6 levels predict brain connectivity in newborns 
(Gustafsson et al., 2018; Rudolph et al., 2018). 
In addition to studies of inflammation related to pregnancy and development, there is 
evidence of general immune disruption in patients with schizophrenia. Subjects with 
schizophrenia, and those at high risk of psychosis, have an altered profile of immune proteins in 
CSF indicative of higher baseline inflammation compared to healthy controls (Hayes et al., 
2014). Long-term changes in baseline inflammatory mediators are also seen in animal models 
(Garay et al., 2013). 
 
1.4 Animal models 
1.4.1 Modelling psychiatric illness 
The complex and heterogeneous nature of psychiatric illness challenges clinicians and 
researchers to categorize, diagnose, and develop animal models. The Diagnostic and Statistical 
Manual of Mental Disorders 5 (DSM-5) is the gold standard for the clinical diagnostic criteria of 
psychiatric illnesses. While the DSM-5 is a valuable resource for clinicians, the criteria are 
limited in their ability to inform preclinical research. The description of SSDs are illustrative of 
these challenges. Schizophrenia and related disorders are characterized by the presence of 
hallucinations, delusions, disorganized thoughts and speech, and behaviour often described as 
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inappropriate or bizarre. Distinct diagnoses include schizophrenia, schizoaffective disorder, 
delusional disorder, brief psychotic disorder, schizophreniform disorder, and substance-induced 
psychotic disorder (Beers, 2006). These conditions have a high degree of similarity and are often 
distinguished by the specific cluster of symptoms present in an individual, the duration or 
severity of symptom presentation (< 1 month, 1-6 months, or > 6months), or whether the 
symptoms cannot be better described with any other diagnosis. For example, the presence of 
non-bizarre delusions in the absence of other symptoms is the distinguishing characteristic that 
separates delusional disorder from schizophrenia. In addition, the DSM-5 diagnostic criteria 
require only a subset of criteria be met to form a diagnosis. This means two patients with no 
overlapping symptoms can receive the same diagnosis, complicating the process of accurately 
replicating disease features in any single model. This is further exacerbated as symptoms may 
overlap between distinct psychiatric diagnoses, such as major depressive disorder, which exhibits 
shared SSD symptoms including social withdrawal, avolition, and anhedonia (Nestler and 
Hyman, 2010). Despite the challenges of modelling psychiatric illness, several models are 
routinely used including acute pharmacological manipulations of relevant neurotransmitter 
systems, such as DA and glutamate, or early life insult to ‘prime’ for aberrant neurodevelopment, 
and these have led to valuable contributions to the understanding of such diseases.  
 
1.4.2 Validity in models 
Model systems are expected to demonstrate several levels validity for their use in 
research. Face validity refers to the ability of a model system to represent or resemble a disease 
or aspect of a disease. This can include key features such as biochemical, anatomical, or 
behavioural abnormalities present in disease relative to the control, or healthy condition (Nestler 
and Hyman, 2010). A key challenge in achieving face validity in psychiatric illness is the lack of 
biomarkers that could be objectively measured in a model, as well as the difficulty of fully 
representing the many factors present in complex, human psychiatric illness (Nestler and Hyman, 
2010).  
Construct validity refers to the manufacture or development of a model with respect to 
disease etiology or underlying disease pathology. Etiological validity requires the origins of a 
disease and the cause of abnormality in a model to be identical (Young et al., 2009). This can be 
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achieved using genetically modified animals where a known gene of interest is knocked down or 
overexpressed (Nestler and Hyman, 2010). Subjecting a laboratory animal to a known disease 
risk factor such as adolescent stress or maternal immune activation is another method to produce 
a model with some degree of etiological validity.  In contrast, models produced by acute drug 
administration lack etiological validity for neurodevelopmental diseases but meet validity on 
other levels, such as construct validity by altering a neurotransmitter system known to be 
disrupted in disease. It is difficult to demonstrate full validity in models of psychiatric illness due 
to the complex gene-environment interactions that contribute to disease etiology (Nestler and 
Hyman, 2010). 
Predictive or pharmacological validity is demonstrated when a known treatment for a 
disease, such as medication, is effective in correcting abnormalities reflective of disease 
symptoms in the model. Further complicating the application of predictive validity to animal 
models of psychiatric illness is the original use of rodent behaviour testing as a screening tool for 
drug discovery, rather than an indicator of modelled symptoms. Drug screens were developed 
based on the effects of known drugs on rodent behaviour with the hope that an experimental 
compound that induced similar behaviour effects would indicate its potential to treat psychiatric 
illness. However, the affected behaviour in rodents and the human disease were not necessarily 
intended to indicate disease symptoms or suggest that the behavioural abnormality and disease 
had similar underlying pathology, yet this is often how such screening tasks have been 
interpreted in the literature (Nestler and Hyman, 2010).   
 
1.4.3 Acute pharmacological models  
 Several pharmacological agents induce a state that resembles acute psychosis when 
administered systemically and are commonly used to model psychiatric illness in research. An 
example of this is NMDA receptor antagonists, such as PCP, ketamine, and MK-801. In humans, 
acute administration of NMDA receptor antagonists induced all three symptoms domains seen in 
schizophrenia – positive, negative and cognitive; and this observation was instrumental in 
generating interest in the role of NMDA receptors in the disease (Jentsch and Roth, 1999). 
NMDA receptors have since been studied extensively in both human and animal subjects. Effects 
of acute systemic administration of NMDA receptor antagonists include increased extracellular 
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DA, glutamate and serotonin in animal models, and local infusion in the mPFC decreased 
extracellular g-amino-butyric acid (GABA) in rats (Moghaddam et al., 1997; Jentsch and Roth, 
1999; Greene, 2001; Bubenikova-Valesova et al., 2008). Acute MK-801 administration in 
rodents achieves face validity by producing abnormalities that resemble all three symptom 
domains as revealed by sophisticated behavioural testing, although it lacks the 
neurodevelopmental time course of disease progression (Adell et al., 2012). Behaviour effects of 
systemic NMDA receptor antagonists in animal studies include impaired working memory, PPI, 
social interaction, increased locomotion, and stereotypy (Jentsch and Roth, 1999). The finding 
that mRNA for parvalbumin (PV) is reduced in PV interneurons as soon as 24h following acute 
MK-801 treatment indicates that this acute pharmacological model can cause reduced patterns of 
GABAergic markers, one of the most robust findings seen in post-mortem schizophrenia cortical 
tissue (Romón et al., 2011). This supports that acute MK-801 administration mirrors relevant 
underlying disease factors and achieves a level of construct validity as a model of schizophrenia 
(Adell et al., 2012). 
Enhanced DA receptor signalling with AMPH or APO is another common 
pharmacological approach to model schizophrenia. These models became popular following the 
observation that typical antipsychotic drugs block D2 receptors, and elevated midbrain DA 
concentrations are associated with the onset of psychotic episodes (Laruelle and Abi-Dargham, 
1999). Hyperdopaminergia is commonly mimicked pharmacologically in rats by administration 
of APO, which has high affinity as an agonist at D1-like and D2-like receptors, but higher 
affinity at D2-like. It is important to note additional, direct effects of APO on serotonergic 
system with affinity for 5-HT1A and 5-HT2A receptors, and adrenergic system (Auffret et al., 
2018). In both healthy human participants and patients with schizophrenia, elevated DA after 
AMPH treatment measured by positron emission tomography was associated with the severity of 
positive symptoms, with schizophrenic patients having increased sensitivity to the effects of 
AMPH (Laruelle and Abi-Dargham, 1999).  
In animal models, heightened sensitivity to psychostimulants following enhanced 
DAergic activity, or MK-801-induced stereotypies taken to indicate positive symptoms of 
schizophrenia (see section 1.5, Behaviour Testing) can be reversed with haloperidol and other 
antipsychotics indicating predictive validity (Swerdlow et al., 1996). The acute MK-801-induced 
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negative symptoms do not respond to conventional treatments, but this is also predictive of 
effects in human patients because negative symptoms are not improved with current medications 
(Adell et al., 2012).  
 A notable drawback of acute pharmacological models is the lack of etiological validity. 
Schizophrenia follows a developmental time course, and this is lacking in acute drug models. 
Nonetheless, acute pharmacological models allow effects to be associated with the pharmacology 
of the compound used, are efficient means of inducing behaviour abnormalities consistent with 
psychiatric illness and have utility in screening for antipsychotic effects of potential therapeutic 
compounds (Bubenikova-Valesova et al., 2008; Nestler and Hyman, 2010). Acute MK-801 and 
APO are both used in Chapter 2 in order to assess the differential effects of the novel, putative 
antipsychotic GOV in the DAergic and glutamatergic dysfunction models of psychosis.  
 
1.4.4 Neurodevelopmental models 
As introduced in section 1.3, a body of evidence including epidemiology, 
neuropathology, and brain imaging studies resulted in the classification of schizophrenia as a 
neurodevelopmental disorder (Piontkewitz et al., 2012). It is generally accepted that an early life 
insult increases risk for psychosis disorders, and this has led to the development of rodent 
neurodevelopmental models. The standard protocol for developing the Maternal Immune 
Activation (MIA) model is to administer an immune stimulant to a pregnant rat or mouse 
(Piontkewitz et al., 2011a). This basic protocol can be modified by varying several parameters, 
including the type of immune stimulant used, the gestational timing of the insult, the dose of the 
immune stimulant, and route of administration of the maternal treatment. While the timing of the 
insult varies across studies and research groups, gestational day (GD) 15 is commonly used in 
rats. As reported by Zuckerman and colleagues (2003), limbic cortical neurons are proliferating 
and migrating during GD15, and earlier administration of the insult on GD13 resulted in 
unacceptably high rates of miscarriage. Administration on GD17 was also considered, but 
offspring behaviour effects were comparable to those see in the GD15 treatment group. Kentner 
and colleagues (2019) review the many procedural variations of the MIA model and suggests a 
standardized list of modifiable factors for researchers to include for full transparency and to 
facilitate understanding of how these parameters influence outcomes in the offspring. 
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Polyinosinic:polycytidylic acid (polyI:C), a single stranded RNA molecule and viral mimetic 
with agonist activity at Toll-like receptor 3 (TLR3) is the most common compound used to 
induce MIA. Previous studies have confirmed that treatment with polyI:C during pregnancy 
increases peripheral pro-inflammatory cytokines including IL-1β, IL-6, CXCL1 (the rodent 
homologue of IL-8), and TNF in the maternal circulation (Meyer et al., 2006; Hsiao and 
Patterson, 2011; Ballendine et al., 2015), imitating the effects of viral infection and inducing an 
acute inflammatory state. Lipopolysaccharide (LPS), a molecule found on the membrane of 
Gram-negative bacteria and which is also recognized by the innate immune system, is another 
common immune stimulant used in MIA (Arsenault et al., 2014; Wischhof et al., 2015). Other 
studies have used live pathogens, although these are less common due to many neuroscience 
laboratories lacking the expertise and access to the appropriate containment level standards 
required for this work (Kentner et al., 2019). Following maternal treatment, blood or tissue 
samples may be collected from the pregnant animals and embryos for further analysis of the 
effects of inflammation, or the offspring may be retained as research subjects after birth and 
followed throughout their lifespan. 
MIA offspring display an array of behavioural, neuroanatomical, and functional brain 
changes reminiscent of schizophrenia (Meyer and Feldon, 2009; Piontkewitz et al., 2011a; 
Howland et al., 2012; Zhang et al., 2012; Meyer, 2014; Sangha et al., 2014; Ballendine et al., 
2015; Lins et al., 2016). Structural brain changes documented in imaging studies emerge and 
diverge from control animals along a time frame that coincides with the onset of behaviour 
abnormalities at a post-pubertal developmental age and matches typical symptom emergence in 
humans (Zuckerman and Weiner, 2003; Ellman et al., 2010; Piontkewitz et al., 2011a). These 
structural changes include enlarged lateral ventricles and reduced hippocampal volume in 
polyI:C-exposed offspring at adulthood (PND 120) whereas no treatment differences were seen 
pre-puberty (PDN 35; Piontkewitz et al., 2012). The behavioural abnormalities seen in the rat 
offspring from polyI:C-exposed pregnancies include altered locomotor behaviour with and 
without the addition of psychotomimetic drug treatment. Some studies report reduced 
spontaneous locomotion and attenuated or exaggerated response to the hyperlocomotive effects 
of AMPH or MK-801 (Zuckerman et al., 2003; Zuckerman and Weiner, 2005; Bronson et al., 
2011; Howland et al., 2012; Vorhees et al., 2012; Van den Eynde et al., 2014). There are also 
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mixed reports on the effects of MIA with several findings of impaired PPI and startle in the 
offspring, although this has not been reliably replicated (Fortier et al., 2004; Wolff and Bilkey, 
2010, 2008; Dickerson et al., 2010, 2013, 2014; Howland et al., 2012; Klein et al., 2013; 
Ballendine et al., 2015; Hadar et al., 2015; Vorhees et al., 2015). Other behaviour abnormalities 
relevant to psychiatric illness include reduced social interaction, and impaired latent inhibition 
(Zuckerman and Weiner, 2003, 2005; Zuckerman et al., 2003; Lee and Green, 2016). Reduced 
working memory span (Murray et al., 2017), impaired associative memory (Ballendine et al., 
2015), and mixed results regarding operant cognitive flexibility tasks (Zuckerman and Weiner, 
2005; Zhang et al., 2012) have been revealed in MIA offspring using various learning and 
memory tasks. Hippocampal-dependent maze-based tasks of cognitive flexibility are impaired in 
MIA offspring and accompany enhanced paired-pulse facilitation and persistent long-term 
potentiation in the dentate gyrus, suggesting a link between altered hippocampal plasticity and 
impaired rule-switching (Savanthrapadian et al., 2013).  
IL-6 is implicated in rodent models, as mice treated with IL-6 alone display behaviour 
abnormalities in tasks of latent inhibition and PPI, and blocking IL-6 alongside a synthetic 
inflammatory agent during pregnancy prevents the emergence of these abnormalities in the 
offspring, as does the use of IL-6 KO mice (Smith et al., 2007). The offspring of pregnant rats 
injected with human IL-6 display deficits in spatial learning and memory in the Morris Water 
Maze task, as well as neuron loss in the hippocampus (Samuelsson et al., 2006). Inflammation 
induced in pregnant rats using turpentine results in offspring with increased TH and DA in the 
NAc, as well as heightened sensitivity to the locomotor effects of AMPH, each of which is 
ameliorated when IL-6 antiserum is administered alongside the turpentine (Aguilar-Valles et al., 
2012). There is some evidence from preclinical research that individual differences in maternal 
immune response are important in determining the degree of effects seen in the offspring. 
Pregnant rats that lose weight following administration of an immune stimulant have increased 
TNF-a, and their offspring show more severe deficits than those from dams that gained weight 
and did not have elevated TNF-a (Missault et al., 2014).    
The rat MIA model of psychiatric illness meets several criteria for validity for 
schizophrenia. Etiological validity is achieved because heightened inflammation in pregnancy is 
a risk factor for the later development of schizophrenia in offspring (Brown and Meyer, 2018; 
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Kentner et al., 2019). Construct validity is met by the presence of underlying pathology such as 
an impaired DA system and abnormal mPFC-HPC coherence in MIA offspring (Dickerson et al., 
2010; Luchicchi et al., 2016). However, there are ways in which MIA falls short of achieving 
true etiological validity. While inflammation in pregnancy is a risk factor for SSD, the true 
etiology of schizophrenia is likely multifaceted, and a single cause is unlikely for most cases. 
There are also known genetic risk factors not discussed here, although two-hit gene-environment, 
or stress-inflammation interaction models have been used by others (Giovanoli et al., 2013, 
2014). To imply early-life exposure to inflammation only is the cause of psychiatric illness in 
humans would be oversimplified, therefore full etiological validity is not achieved. However, 
inflammatory insult is relevant to the development of psychiatric illness and the MIA model is 
valuable for discerning the influence of inflammation on offspring outcomes, and this relevance 
to the human disease contributes to construct validity. MIA has face validity in that all 3 
schizophrenia symptom domains are represented in the model, as well as anatomical and 
biochemical abnormalities with a neurodevelopmental time course (Piontkewitz et al., 2011a; 
Luchicchi et al., 2016). The behaviour tasks that represent positive symptoms, such as AMPH-
induced hyperlocomotion, respond to conventional antipsychotic drugs but cognitive 
impairments do not, an effect that mirrors the efficacy of these drugs in human patients and 
achieves predictive validity (Kentner et al., 2019). The final indicator of predictive validity is 
whether putative antipsychotic treatments with efficacy in improving negative and cognitive 
behaviour abnormalities in the MIA model translate to symptom improvement in human patients. 
MIA was used to model psychiatric illness in chapters 3 and 4 in order to determine if individual 
maternal cytokines levels are related to the severity of offspring psychiatric phenotype as 
analyzed with behavioural testing. 
  
1.5 Rodent behaviour testing 
1.5.1 Introduction to behaviour assays 
 Behaviour phenotyping is necessary in the study of complex psychiatric illness and 
neurodevelopment disorders (Silverman and Ellegood, 2018). Many disease models rely on the 
presence of disease-relevant biomarkers for validation, but clear biological indicators are lacking 
from many psychopathologies, and diagnoses are dependent on analysis of patient behaviour. 
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When improving functional outcomes in a patient population with behaviour alterations is of 
interest, animal models of such diseases should display relevant behaviours (face validity; further 
discussion in section 1.4, Animal models). The goal of translating preclinical animal research to 
inform the treatment of patient populations depends on the relevance of the assays used, and in 
the case of psychiatric illness, behaviour outcomes are paramount.  
In addition to utility in the validation of disease models, behaviour assays have been used 
to screen compounds for potential therapeutic efficacy. In the case of antipsychotic compounds, 
direct observation of antipsychotic effects in a rodent model is challenging due to the complex 
nature of the clinical presentation of psychosis. The knowledge that D2 receptor antagonism was 
a common feature among first generation antipsychotics allows researchers to look for other 
behavioural evidence of antagonist activity at this pharmacological target, such as of catalepsy 
and Parkinsonian-like effects, to indicate potential efficacy as an antipsychotic (Nestler and 
Hyman, 2010).  
 Careful design of a rodent task battery is necessary for specific interpretation of 
behaviour effects. For example, if a test relies on the ability of an investigator to discern a rat’s 
inclination to explore a novel environment as an indicator of an anxiety-like phenotype, the rat 
must not have a deficit in motor function, which is a known effect of typical antipsychotics. In 
this case, a basic assessment of locomotor activity is necessary to ensure the appropriate 
conclusions are drawn (Young et al., 2009). Similar to animal models, behaviour tasks can be 
assessed based on validity (section 1.4.2). In a behaviour task, construct validity, or determining 
whether a task measures what it is intended to measure is critical, but also incredibly challenging 
to achieve with certainty. Etiological validity is present when the biological phenomenon that 
underlies the effect is the same in the human and model. Predictive validity in the context of a 
behaviour test depends on the ability of a pharmacological agent effective in treating a human 
symptom also reversing the deficit or abnormality observed in the task (Young et al., 2009).   
The behaviour tasks selected for the experiments outlined in data chapters 2 - 4 were 
intended to facilitate observation of the three symptom clusters of schizophrenia – positive 
symptoms, negative symptoms, and cognitive impairment. 
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1.5.2 Positive symptoms 
 The positive symptoms of schizophrenia refer to hallucinations and delusions, often 
described as characteristics that are present in schizophrenia that are not observed in a typical or 
healthy mental state (Nestler and Hyman, 2010). These symptoms also respond well to treatment 
with antipsychotic medication. Evaluating psychosis in rodents is often considered controversial 
due to the challenge of defining rodent behaviours consistent with hallucinations or delusions 
where the symptomatic behaviour may be uniquely human in nature. To circumvent this 
challenge, modeling the positive symptoms has relied on linking human symptoms and rodent 
behaviours that correlate with similar neurobiological features. Positive symptoms are believed 
to reflect abnormal and elevated DA levels, particularly in presynaptic subcortical DAergic 
neurons, and indeed several methodologies reveal evidence of this hyperDA-ergic state in 
schizophrenia. Specifically, increased DA synthesis in the striatum of schizophrenia patients is 
indicated by accumulation of [18F]DOPA (Laruelle, 2014b). Schizophrenia patients also show 
greater DA release in response to AMPH than controls, and acute psychosis co-occurs with 
elevations in DA (Nestler and Hyman, 2010).  In rodents, heightened locomotor activity in an 
open field is used as a proxy for psychosis as locomotion correlates with increased DA 
transmission, particularly in the ventral striatum (Meyer and Feldon, 2009). This has been 
compared to the elevated striatal DA levels seen in schizophrenia patients using single photon 
and positron emission tomography (Kegeles et al., 2010; Nestler and Hyman, 2010).  
 In addition to the relationship with DA levels, locomotor activity in rodents can be 
modified by pharmacological agents that manipulate neurotransmitter systems known to be 
disrupted in schizophrenia. DA is again a notable example which can be altered through agents 
such as AMPH and APO to enhance locomotion in rodents (Meyer and Feldon, 2009; Nestler 
and Hyman, 2010). These locomotor effects are blocked by typical antipsychotic compounds 
with D2 receptor antagonist activity, indicating predictive validity for this test (Nestler and 
Hyman, 2010). Glutamatergic manipulations are also relevant and NMDA receptor antagonists 
such as MK-801, PCP, and subanesthetic doses of ketamine are often used to induce a 
hyperlocomotive state, although NMDA receptor antagonism results in downstream elevations in 
striatal DA release as well (Figure 1.1; Meyer and Feldon, 2009; Moghaddam and Javitt, 2012; 
Kokkinou et al., 2018). The effects of glutamatergic manipulations in locomotor activity are 
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demonstrated to be variable across models of psychiatric illness and both hyper- and 
hypolocomotion have been reported. These effects have been attributed to the presence of 
NMDA receptor hypofunction in some models, or elevations in DA release downstream of the 
NMDA receptor to attempt to explain hypo- and hyperlocomotion, respectively (Zuckerman and 
Weiner, 2005; Giovanoli et al., 2013; Missault et al., 2014; Vorhees et al., 2015). MK-801 
induced hyperlocomotion was used to detect positive symptom/psychosis-like behaviour in rats 
throughout this thesis (chapters 3 and 4).        
 
1.5.3 Negative symptoms 
 The negative symptoms of schizophrenia are deficits in normal functions, including 
impoverished speech, social withdrawal, and avolition. Negative symptoms do not respond well 
to current treatment options and symptom origins are believed to be heterogeneous (Nestler and 
Hyman, 2010; Lee and Green, 2016). Social withdrawal or isolation is a negative symptom 
common in patients with schizophrenia (Lee and Green, 2016). Deficits in social behaviour are 
also a defining feature of autism, including impaired facial recognition (Silverman et al., 2010; 
Kennedy and Adolphs, 2012). 
 The task used to assess social behaviour in this thesis was the three-chambered 
Sociability Task and is described in detail in Chapters 3 and 4. In brief, a rat is allowed to 
explore a rectangular area divided into left, centre, and right compartments with the freedom to 
move between them. Either the left or right chamber contained a round cage that held a stranger 
rat, while the opposite side contained an identical but empty cage. Control rats show preference 
for exploring the cage containing a stranger and time spent in exploration of each cage can be 
compared across treatment groups. There are several task variations to assess social behaviour 
with one of the most common being the Social Interaction test in which 2 stranger rats are placed 
in an arena together. This is distinct from the three chambered task because the rats are free to 
approach and contact one another. The advantage of this is that different social behaviours can be 
clearly observed and scored by a trained investigator (grooming, sniffing, aggression, play) to 
produce a richer dataset (Silverman et al., 2010). The downside is that rats must be assessed in 
pairs and this makes it difficult to produce an individual measure of social behaviour which was 
necessary for the planned cytokine correlation analysis in Chapters 3 and 4. 
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Social behaviour appears to depend on multiple brain areas. Studies in humans with 
lesions reveal the temporal lobe is critical for processing faces, and the mPFC is involved in 
perceiving or understanding the beliefs or intentions of others. Amygdala damage also results in 
social deficits that are linked with recognizing emotions in others and modulating emotional 
outputs, although this may be an artifact of the broader role of the amygdala in emotional 
regulation and saliency, and not specific to sociability (Kennedy and Adolphs, 2012). In general, 
the neural regulation of social behaviour is diffusely represented throughout the brain and closely 
linked with other processes including cognition and emotional valence (Kennedy and Adolphs, 
2012). Patients with schizophrenia do not prioritize social stimuli over non-social stimuli, do not 
attend to social cues as readily as non-social cues, and do not show improved memory for social 
stimuli. This was observed alongside reduced activation in the dorsomedial PFC (dmPFC) 
compared to healthy controls (Lee and Green, 2016). 
Genetic mouse models of autism display impairments in various measures of social 
behaviour, including reciprocal social interactions, sociability, and preference for social novelty, 
as well as communication deficits indicated by reduced vocalizations (Silverman et al., 2010). 
Genetic and pharmacologically-induced NMDA receptor hypofunction also produce social 
deficits in mice. Furthermore, GABAb agonist baclofen restores social interaction in NMDA 
receptor knockdown mice (NR1neo -/-; Lee and Green, 2016). Taken together, social impairment 
seen in rodent models appears related to the loss of excitation/inhibition balance associated with 
NMDA receptor and GABAergic hypofunction and associated with the glutamate hypothesis of 
schizophrenia (Lee and Green, 2016).     
 
1.5.4 Cognitive impairment 
  Cognitive impairment is a core symptom of schizophrenia, often present in the 
prodromal phase of the illness and persisting when psychosis is otherwise managed (Keefe and 
Fenton, 2007; Young et al., 2009; Nestler and Hyman, 2010). Seven affected cognitive domains 
have been identified: attention/vigilance; working memory; reasoning and problem solving; 
processing speed; visual learning and memory; verbal learning and memory; and social cognition 
(Nuechterlein et al., 2004; Young et al., 2009). Using rodent behaviour tests to examine 
symptoms of cognitive impairment is benefitted by the history of research into cognitive 
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processes in general. There are numerous well-studies rodent behaviour tasks sensitive to 
specific cognitive processes. In a well-controlled and designed behaviour test battery, deficits in 
performance can be taken to indicate cognitive impairment (Young et al., 2009).  
 Common cognitive tasks for rodents rely on innate and spontaneous rodent behaviour. An 
example is the spontaneous object recognition task (SOR) in which a rat is allowed to explore 
two identical copies of an object in an otherwise empty arena or Y-maze, and following a 
variable delay is reintroduced to the area with one copy of the original object alongside a novel 
object. Due to an innate and reliable preference for novelty, control rats spend a greater amount 
of time exploring the novel object and this is interpreted by an investigator to imply memory for 
the original object is intact. This task allows for various manipulations to further investigate 
mechanisms of memory and has been used extensively to understand aspects of cognition (Lyon 
et al., 2012; Warburton and Brown, 2015). Common variations include object-location memory, 
object-in-place memory and temporal order memory (Warburton and Brown, 2015). 
The two variations of spontaneous exploration behaviour tasks seen in this thesis are 
Crossmodal Object Recognition Memory (CMOR) and Oddity Discrimination, or Odd Object 
Preference Task. The procedure for CMOR is described in detail in the subsequent data chapters 
3 and 4. Briefly, the task occurs in a Y-maze and consists of three distinct trials; a tactile, visual, 
and CMOR, conducted in that order on separate consecutive days following two days of 
habituation to the test apparatus. Each trial is further divided into a sample and test phase, like 
the classic version of SOR. The sample phase presents two identical copies of an object in each 
arm of the maze. The test phase, one hour later, presents a third copy of the first object and a 
novel object. The tactile test occurs in red light conditions, which prevents the rats’ visual 
observation of the objects. The visual test occurs in white light, but clear Plexiglas barriers 
inserted in front of the objects prevent tactile exploration. The CMOR phase has a tactile sample 
phase and a visual test phase. The objects used are unique to each trial (Winters and Reid, 2010; 
Cloke et al., 2015).  
It is increasingly recognized that sensory integration is altered in various psychiatric 
conditions, including schizophrenia and autism. Some evidence for impaired multisensory 
integration in patients with schizophrenia and autism includes reduced susceptibility to the 
McGurk effect, a phenomenon where the presentation of incongruent audio and visual stimuli 
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produce the perception that of a single stimulus that combines the two conflicting stimuli. In 
addition, cognitive performance is enhanced in healthy participants when congruent information 
is acquired through multiple modalities, an effect that is dampened in patients with schizophrenia 
(Cloke et al., 2015). Lesion studies in rats have contributed to understanding the brain regions 
involved in the CMOR task, as well as the unimodal tactile and visual memory tests. The 
posterior parietal cortex (PPC) appears necessary for tactile memory performance while the 
perirhinal cortex (PRh) in the temporal lobe is necessary for visual recognition memory. 
Orbitofrontal cortex (OFC) lesions selectively impair CMOR while sparing performance of the 
visual and tactile unimodal tasks, consistent with the anatomical convergence of various sensory 
modalities in this region. This impairment is delay-dependent and not seen when the test phase 
immediately followed the sample phase, suggesting the role of the OFC is mnemonic and not 
necessary for the integration of visual and tactile modalities (Cloke et al., 2015). Further research 
has begun to assess the roles of other areas with anatomical convergence of sensory inputs. Two 
candidate regions are the claustrum and retrosplenial cortex which, when lesioned, selectively 
impair CMOR. Despite the well-known role of the hippocampus in memory, hippocampal 
lesions do not impair CMOR (Cloke et al., 2015). CMOR has been studied using MIA models 
and selective disruptions in the crossmodal phase are seen while tactile and visual memory 
remain intact (Ballendine et al., 2015; Paylor et al., 2018). Systemic MK-801 and ketamine 
administration impair CMOR, but not visual or tactile memory at short delays, indicating 
relevance to the glutamate hypothesis of schizophrenia (Cloke et al., 2016).  
The procedure for oddity discrimination is described in detail in data chapters 3 and 4. 
Briefly, the task occurs in a square arena with Velcro in each of the 4 corners. After three days of 
arena habituation, the task occurs in a single phase. 3 identical objects, and one different or ‘odd’ 
object, are fixed in place to the Velcro and the rat is allowed to explore for 5 minutes. Control 
rats explore the odd object at a greater than chance level. Oddity discrimination is a relatively 
novel behaviour task, particularly the variation of the task used here, and little is known of the 
neural underpinnings of task performance. Like CMOR, sensory integration is believed to 
contribute to oddity discrimination task performance, but there is no separation of sensory 
modalities and no mnemonic component. The PRh has been implicated due to a well validated 
role in visual discrimination, and studies on variations of the oddity discrimination task provide 
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evidence for a role of PRh in perception, yet this remains controversial (Bussey and Saksida, 
2005; Buckley and Gaffan, 2006; Suzuki, 2009). Despite the lack of data on this particular 
variant of oddity discrimination, the PRh has been implicated in object identification and 
discrimination, abilities on which this task likely depends (Murray and Richmond, 2001). Object 
recognition maps onto the cognitive domain of visual learning and memory, which is impaired in 
patients with schizophrenia and reduced temporal lobe volume is a common anatomical 
alteration seen in patients (Young et al., 2009; Ellman et al., 2010; Lyon et al., 2012).  
The procedure for the operant set shifting and reversal task (OSST) is described in detail 
in Chapter 3. Briefly, the task is conducted in modular metal chambers where one wall is 
equipped with 2 stimulus lights (left and right), each located above a corresponding retractable 
lever. A food reward port was located between the levers. Rats are initially trained to press the 
levers in order to receive an appetitive reward, then to press the lever (left or right) the 
corresponds to a visual cue, i.e. the illuminated stimulus light. On a subsequent day, the rule 
changes (set shift) and the rats must select the lever opposite to their preferred side in order to 
receive a reward. On another subsequent day, the rule changes once more and the rats must select 
the opposite side as the previous day (reversal). The pairwise discrimination and reversal 
learning task (PD/RL) bears many similarities to OSST and is also described in detail in Chapter 
3. PD/RL uses a touchscreen chamber and displays 2 visual stimuli, one is always rewarded and 
the other is never rewarded. Once the rat has reached a performance criterion the initially 
unrewarded stimulus becomes rewarded, and the initially rewarded stimulus becomes 
unrewarded, requiring the rat to switch behavioural response to continue receiving a food reward 
(reversal) and again is trained until a criterion is met.   
  Both OSST and PD/RL are tests of executive function that require cognitive flexibility, 
the ability to solve problems by responding to changing demands over time by shifting behaviour 
appropriately; a previous strategy is disengaged and the initial response is inhibited, while a new 
strategy learned and employed (Young et al., 2009). Set-shifting requires a participant to shift 
response from one stimulus dimension to a to a previously irrelevant dimension 
(extradimensional shift, EDS), while reversal learning requires a shift in response to another 
stimulus within the same dimension (intradimensional shift, IDS). The Wisconsin Card Sort Task 
(WCST) and Neuropsychological Assessment Battery – Mazes tasks demonstrated human 
  
29 
patients with schizophrenia display abnormalities in executive function, particularly taking more 
time to change strategy and making more errors by reverting to a previously correct strategy, 
known as perseveration, compared to controls (Waltz, 2017). Patients with frontal lobe damage 
are profoundly impaired at strategy shifting with a characteristic high rate of perseverative errors. 
The data from patients with schizophrenia are somewhat more variable than those of clinical 
lesion studies. While increased perseveration are observed, patients with schizophrenia also 
make more errors of other kinds, and impaired cognitive flexibility has come to be known as a 
hallmark of cognitive dysfunction in schizophrenia (Floresco et al., 2009; Waltz, 2017). 
OSST and PD/RL are cognitive flexibility tasks adapted for automated testing of rodents 
using modular lever boxes or a computerized touchscreen chamber system, respectively. Both 
tasks involve learning an initial visual cue, then OSST includes an extradimensional shift (from 
visual cue to spatial cue), then an intradimensional shift (from spatial cue to the opposite spatial 
cue), while PD/RL only includes an intradimensional shift (from one visual stimulus to the other 
visual stimulus). There are three types of errors that can be made during OSST. The first are the 
previously described perseverative errors, defined as the reverting to selecting the previously 
rewarded choice, indicative of a failure to disengage a presently irrelevant strategy. Once a rat 
has begun to disengage from a previous strategy and is perseverating less than 25% of the time, 
selection of the previously relevant stimulus is then considered a regressive error, the presence of 
which indicates difficulty in novel strategy maintenance. Finally, a never reinforced error is the 
employment of a strategy that has never been rewarded and serves to represent the ability to 
abandon incorrect strategies (Floresco et al., 2009).      
Rodent studies have been instrumental in delineating the neurological underpinnings of 
cognitive flexibility, building upon the early studies in human lesion patients. Lesion or 
inactivation of the mPFC, homologous to the primate dorsolateral PFC (dlPFC), impairs set-
shifting and increases perseveration, indicating importance of that region for disengaging a 
previous strategy. Reversal learning, but not set-shifting, is impaired with lesion or inactivation 
of the OFC, revealing this region is involved in linking a stimulus to a rewarded outcome 
(Floresco et al., 2009). The striatum is a major input region of the mPFC and have also been 
implicated in behavioural flexibility, with the NAc core facilitating the adoption of novel 
strategies by suppressing ineffective responses and the NAc shell ignores irrelevant stimuli, 
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while the dorsal striatum enacts goal directed behaviour and may be involved in responding to 
changing rules (Floresco et al., 2009; Bissonette and Roesch, 2017). These regions have been 
implicated in psychiatric illness, particularly the circuits involved in the psychopathology of 
schizophrenia (Floresco et al., 2009). Altered cognitive flexibility has been demonstrated in 
rodent models of schizophrenia including MIA in OSST, as well as pharmacological models 
MK-801, PCP, AMPH, or APO in PD/RL and MK-801 and ketamine in OSST (Floresco et al., 
2009; Talpos et al., 2012; Zhang et al., 2012).  
 
1.5.5 Prepulse inhibition 
 Prepulse inhibition (PPI) requires a separate consideration as is does not represent a 
symptom of schizophrenia per se, yet it is highly relevant to characterising psychiatric 
phenotypes, and screening compounds for antipsychotic potential. PPI is the reduced response to 
a startling stimulus when closely preceded by a low-intensity stimulus and is a measure of 
sensorimotor gating, an inhibitory mechanism believed to regulate sensory input. PPI has the rare 
benefit using the same testing paradigm across multiple species including humans, often using 
auditory tones and subsequent startle reflex, but blink reflex (air pulses into the eye) and 
crossmodal paradigms have also been used. The neural circuitry regulating PPI involves limbic, 
cortical, striatal, and pontine brain regions (Swerdlow et al., 2001b). 
Deficits in PPI are not specific, and are seen across various psychopathologies including 
schizophrenia, Alzheimer’s disease, Huntington’s disease, and Tourette’s syndrome, but notably 
not impaired in bipolar disorder or major depressive disorder (Swerdlow et al., 2016b). PPI can 
be disrupted with administration of DA agonists AMPH or APO, and NMDA receptor 
antagonists such as MK-801, and the ability of a compound to reverse PPI deficits is predictive 
of antipsychotic activity (Swerdlow et al., 2006a). These effects reveal relevance to the 
neurotransmitter systems altered in schizophrenia as well as predictive validity. Further, typical 
antipsychotic compounds reverse PPI deficits when disrupted by DA agonists, but not NMDA 
receptor antagonists. Atypical antipsychotics have mixed results in their ability to ameliorate 
NMDA receptor antagonist-induced deficits, but there are reports of reversal by clozapine, 
chlorpromazine, olanzapine and quetiapine (Bakshi et al., 1994; Swerdlow et al., 1996, 1998; 
Chapter 2 includes further discussion of PPI and the effects of antipsychotic drugs). In the 
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context of schizophrenia, PPI is occasionally linked to positive symptoms due to the reliable 
effect of DA agonists in disrupting the typical inhibition of startle when followed by a prepulse. 
This is comparable to the use of locomotor activity as a positive symptom proxy due to its 
relationship to biological correlates such as cortico-striatal DA levels, despite lacking a direct 
resemblance to psychosis. PPI may also bear relevance to cognition, as sensorimotor gating has 
been considered a pre-cognitive process, necessary for sustained attention, sensory processing, 
and the prevention of cognitive fragmentation (Swerdlow et al., 2006a; Scholes and Martin-
Iverson, 2009; Young et al., 2009). More recently however, this view has been challenged as a 
large meta-analysis was unable to correlate PPI with cognitive performance in human patients 
with schizophrenia, and PPI does not decrease with normal ageing, although it is associated with 
lower Global Assessment of Function scores and measures of thought disorder suggesting there 
is value in PPI deficits as an indicator of abnormal sensory processing  (Swerdlow et al., 2006b; 
Young et al., 2009). Overall, behavioural assessment of PPI bears relevance to multiple domains 
of psychiatric illness, is easily tested in rodents, and has translational relevance to human disease 
with similar testing paradigms across species, and predictive validity for screening compounds 
for potential antipsychotic activity. 
Despite many positive aspects of PPI for research, there are also a number of limitations. 
PPI is sensitive to species and strain effects, and the vast number of possible parameter 
manipulations results in a literature that is complex and difficult to generalize. In addition, 
despite the predictive validity of PPI in regard to antipsychotic efficacy, homology of the 
underlying circuitry cannot be assumed across species and this has been exemplified in 
comparing mice to rats (Swerdlow et al., 2001b, 2016b).    
 
1.6 General hypotheses 
The general hypotheses of this thesis are:  
(A) l-GOV, but not d-GOV, will reverse PPI impairments caused by APO and MK-801; (B) Serum 
concentrations of inflammatory proteins collected from pregnant dams will correlate with the 
severity of their offspring’s behavioural phenotype relevant to psychopathology; (C) Male 
polyI:C offspring will display a greater degree of pathology than females.  
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1.7 Thesis objectives 
1) Establish the ability of putative antipsychotics d- and l-GOV to attenuate PPI impairments 
due to DA receptor hyperfunction following acute APO treatment (Chapter 2). 
2) Establish the ability of putative antipsychotics d- and l-GOV to attenuate PPI impairments 
due to NMDA receptor hypofunction following acute MK-801 treatment (Chapter 2). 
3) Determine the long-term effects of inflammation in pregnancy on male offspring 
behaviour related to psychiatric illness, and whether phenotype severity is correlated with 
maternal serum concentrations of cytokines CXCL1 or IL-6 (Chapter 3). 
4) Determine the long-term effects of inflammation in pregnancy on female offspring 
behaviour related to psychiatric illness, and whether phenotype severity is correlated with 
maternal serum concentrations of cytokines CXCL1 or IL-6 (Chapter 4). 
5) Assess the male and female behaviour outcomes for sex effects (Chapter 4). 
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CHAPTER 2 
DISSOCIABLE EFFECTS OF THE D- AND L- ENANTIOMERS OF 
GOVADINE ON THE DISRUPTION OF PREPULSE INHIBITION BY MK-
801 AND APOMORPHINE IN MALE LONG-EVANS RATS1 
2.1 Abstract  
Rationale The search for novel antipsychotic drugs to treat schizophrenia is driven by the poor 
treatment efficacy, serious side effects, and poor patient compliance of current medications. 
Recently, a class of compounds known as tetrahydroprotoberberines, which includes the 
compound d,l-govadine (d,l-GOV), have shown promise in preclinical rodent tests relevant to 
schizophrenia. To date, the effect of GOV on PPI, a test for sensorimotor gating commonly used 
to assess the effects of putative treatments for schizophrenia, has not been determined.  
Objectives The objective of the present study was to determine the effects of each enantiomer of 
GOV (d- and l-GOV) on PPI alone and its disruption by the distinct pharmacological compounds 
apomorphine and MK-801.  
Methods Male Long-Evans rats were treated systemically with d- or l-GOV and apomorphine or 
MK-801 prior to PPI. The PPI paradigm employed here included parametric manipulations of the 
prepulse intensity and the interval between the prepulse and pulse.  
Results Acute MK-801 (0.15 mg/kg) significantly increased the startle response to startle pulses 
alone, while both MK-801 and APO (0.2 mg/kg) significantly increased reactivity to prepulse-
alone trials. Both MK-801 and APO disrupted PPI. In addition, d-GOV alone significantly 
disrupted PPI in the APO experiment. Pretreatment with l-, but not d-, GOV (1.0 mg/kg) blocked 
 
1 Lins BR, Marks WN, Phillips AG, Howland JG (2017) Dissociable effects of the d- and l- enantiomers of 
govadine on the disruption of prepulse inhibition by MK-801 and apomorphine in male Long-Evans rats. 
Psychopharmacology (Berl) 234:1079–1091. 
 
Lins and Marks were co-first authors who contributed equally to the manuscript; Phillips supplied govadine and 
edited the manuscript; Howland designed and supervised the experiments and co-wrote the manuscript. This 
manuscript is peer-reviewed and published. 
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the effect of APO and MK-801 on PPI. Treatment of rats with l-GOV alone (0.3, 1.0, 3.0 mg/kg) 
also dose-dependently increased PPI.  
Conclusions Given the high affinity of l-GOV for DA D2 receptors, these results suggest that 
further testing of l-GOV as an antipsychotic is warranted.  
 
2.2 Introduction  
Schizophrenia is a debilitating psychiatric disorder that affects approximately 1% of the 
global population. Current treatment options are not effective for all symptoms of the disorder 
and as a result, novel compounds with potential for use in schizophrenia are currently under 
development. One family of compounds known as tetrahydroprotoberberines (THPBs), derived 
from traditional Chinese medicine, have unique DA-related activity (Jin et al., 2002; Yang et al., 
2007; Natesan et al., 2008; Lapish et al., 2012; Zhai et al., 2012). GOV is a synthetic THPB that 
exists as two enantiomers, d- and l-GOV (d-GOV, l-GOV), each with distinct pharmacological 
profiles (Lapish et al., 2012; Zhai et al., 2012). Affinity for D1 and D2S classes of DA receptors 
is comparable between d- and l-GOV. However, a large difference in affinity for the D2L receptor 
exists between l-GOV (165 nM) and d-GOV (1340 nM). Affinities for other receptor types that 
are comparable between the two enantiomers are low in relation to these different classes of DA 
receptors (Lapish et al., 2014). Studies using microdialysis determined l-GOV increases DA 
efflux in both the prefrontal cortex (PFC) and NAc, whereas d-GOV only increases DA efflux in 
the PFC (Lapish et al., 2014). Previous research using rats suggests GOV may have the unique 
ability to improve the three major symptom categories seen in schizophrenia: positive, negative, 
and cognitive (Lapish et al., 2012, 2014). When examined separately, l-GOV, but not d-GOV, 
blocks AMPH-induced hyperlocomotion, impairs conditioned avoidance responding, and 
induces catalepsy similarly to antipsychotic drugs with high affinity for the D2L receptor. In 
contrast, d-GOV displays primarily pro-cognitive effects by reducing errors on the delayed-
spatial win-shift task and improving temporal order memory at a long delay. Both enantiomers 
successfully reversed social interaction deficits, a measure of negative symptoms, as well as 
AMPH-disrupted latent inhibition (Lapish et al., 2014). l-GOV, but not d-GOV, reverses MK-
801- induced impairments in a touch-screen visuo-spatial paired associates learning task (Lins et 
  
35 
al., 2015). These data encourage further investigation of GOV enantiomers as a putative 
treatment for schizophrenia.  
PPI refers to the reduced motor response to a startling stimulus, such as an auditory tone 
or “pulse,” when the startling stimulus is preceded by another low-intensity sensory input in 
close temporal proximity (Koch and Schnitzler, 1997; Geyer et al., 2001; Yeomans et al., 2006). 
Therefore, PPI is a common measure of sensorimotor gating used in studies of humans or 
animals including rodents and has cross-species validity, face validity, ease of implementation, 
and reliability. The predictive validity of PPI is related to the finding that compounds which 
reverse drug-induced PPI disruptions in rodents very often have antipsychotic efficacy in humans 
(Swerdlow et al., 2006a, 2016b, 2016a). PPI is commonly measured with auditory pulses and 
prepulses, although other cross-modal paradigms have been developed. PPI is impaired in 
several psychiatric illnesses including schizophrenia (Braff et al., 1978; Braff and Geyer, 1990; 
Grillon et al., 1992), obsessive compulsive disorder (Swerdlow et al., 1993), Huntington’s 
disease (Swerdlow et al., 1995), and Tourette’s syndrome (Castellanos et al., 1996).  
The neural circuitry regulating PPI includes an array of limbic, cortical, striatal, pallidal, 
and pontine brain areas collectively known as the “CSPP” circuitry (Swerdlow et al., 2001b, 
2016b, 2016a). Multiple sequential and parallel connections including the temporal cortex, 
mPFC, ventral striatum, ventral pallidum, and pontine tegmentum converge at the nucleus 
reticularis pontis caudalis in order to regulate PPI. The complete anatomical circuitry of PPI is 
extensive and includes a network of additional brain regions (reviewed in Swerdlow et al., 
2001b). PPI is disrupted following systemic administration of the DA agonists APO and AMPH 
(Geyer et al., 1987; Mansbach et al., 1988) and noncompetitive NMDA receptor antagonists such 
as MK-801 (dizocilpine) (Mansbach and Geyer, 1989, 1991; Al-Amin and Schwarzkopf, 1996; 
Bast et al., 2000). The effects of typical and atypical antipsychotic drugs on PPI have been 
studied extensively. Typical antipsychotics such as haloperidol, a D2 antagonist, effectively 
reverse deficits in PPI induced by acute pharmacological challenge with APO (Swerdlow and 
Geyer, 1993) but not MK-801 or PCP (Geyer et al., 1990; Keith et al., 1991; Johansson et al., 
1994). In contrast, atypical antipsychotics reverse the impairments following either APO or MK-
801 treatment, although some inconsistencies have been reported. APO-induced deficits are 
blocked by clozapine (Swerdlow and Geyer, 1993) whereas clozapine, quetiapine, and 
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olanzapine either improve (Bakshi et al., 1994; Bakshi and Geyer, 1995; Swerdlow et al., 1996, 
1998; Zhang et al., 1997; Bubeníková et al., 2005) or do not affect acute MK-801- induced 
impairments in PPI (Bast et al., 2000). Zotepine and risperidone do not restore PPI following 
MK-801 treatment (Swerdlow et al., 1996; Varty et al., 1999; Bubeníková et al., 2005). Further, 
PPI disrupted by either MK-801 or PCP is resistant to reversal by specific antagonism of D1, D2, 
or 5- HT2 receptors (Keith et al., 1991; Bakshi et al., 1994). When administered alone, 
olanzapine and clozapine also decrease PPI in some studies (Bubeníková et al., 2005) but not 
others (Depoortere et al., 1997). The distinctions in PPI disruption caused by APO or MK-801 
and the different approaches needed to ameliorate them may be relevant to different 
schizophrenia patient populations, with those compounds that reverse effects of MK-801 having 
the prospect of antipsychotic efficacy for individuals resistant to current therapies (Al-Amin and 
Schwarzkopf, 1996).  
Given the distinct effects of typical and atypical antipsychotic drugs on the disruption of 
PPI by APO and MK-801, we tested the effects of each enantiomer of GOV on these drug-
induced disruptions of PPI. PPI can fluctuate depending on the interaction of drug treatment with 
specific PPI protocol parameters in both clinical populations and rodents (Duncan et al., 2001; 
Swerdlow et al., 2008, 2016b, 2016a; Howland et al., 2012; Ballendine et al., 2015; Chandna et 
al., 2015; Pinnock et al., 2015). Therefore, the PPI protocol employed a range of prepulse-pulse 
intervals (30, 50, 80, and 140 ms) and prepulse intensities (3, 6, and 12 dB). We hypothesized 
that l-GOV, but not d-GOV, would block the PPI impairments caused by APO, consistent with its 
strong DA D2L receptor antagonist activity. The heterogeneity of antipsychotic drug effects on 
the MK-801-induced disruption of PPI in previous reports made it difficult to develop a clear a 
priori hypothesis regarding the effects of d- or l-GOV in this paradigm. We also measured the 
effects of all drugs on the startle response and prepulse-elicited reactivity (Yee and Feldon, 
2009). Given the effectiveness of l-GOV in blocking the PPI impairments caused by APO and 
MK-801, we also conducted a dose-response experiment of the effects of l-GOV (0.3, 1.0, 3.0 
mg/kg) alone on PPI. 
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2.3 Materials and methods  
2.3.1 Animals  
Adult male Long-Evans rats (Charles River Laboratories, Quebec, Canada) weighing 
325–500 g throughout the course of testing were group housed (two per cage) in standard 
polypropylene cages in a temperature-controlled (21 °C) colony room on a 12:12 h light/dark 
cycle with food (Purina Rat Chow) and water available ad libitum. Experimental procedures 
were carried out during the light phase (lights on at 0700 hours). All experimental procedures 
were conducted in accordance with the Canadian Council on Animal Care and were approved by 
the University of Saskatchewan Animal Research Ethics Board.  
 
2.3.2 Drug preparation  
Apomorphine (0.2 mg/kg, Howland et al. 2004; Sigma, St. Louis, MO) was dissolved in 
0.1% ascorbic acid in water. MK-801 (0.15 mg/kg; Lins et al. 2015; Abcam, Toronto, Ontario) 
was dissolved in water. d- and l-GOV were synthesized by the Sammis Lab (Department of 
Chemistry, University of British Columbia) and dissolved in a 1 mg/mL solution of 50% 
dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO) and 50% water. Each drug was administered 
at a volume of 1 mL/ kg bodyweight. Initially, we elected to use a single dose of d- and l-GOV 
based on previous findings reporting dose-response effects of GOV in several paradigms 
associated with symptoms of psychotic behaviour. In these cases, in the absence of drug effect at 
a dose of 1.0 mg/kg, doses up to 10 times greater also failed to yield effects (Lapish et al., 2014). 
A recent study by our group on the effects of each enantiomer of GOV in a visual-spatial 
learning and memory task showed l-GOV (1.0 but not 0.3 or 3.0 mg/kg) effectively reversed 
MK-801 induced impairments whereas d-GOV had no effect at doses up to 3.0 mg/kg (Lins et al., 
2015). Based on these data, we chose to administer 1.0 mg/kg of each enantiomer in conjunction 
with APO and MK-801 to assess effects on PPI and startle reactivity. Positive effects of l-GOV 
(1.0 mg/kg) encouraged a separate dose-response experiment with l-GOV (0.3, 1.0, and 3.0 
mg/kg) alone using the same PPI protocol. It should be noted that the use of a single dose of 
GOV with APO and MK-801 is a limitation for the study and a full dose-response 
characterization of the effects of d- and l-GOV on disrupted PPI would be valuable. 
 
  
38 
2.3.3 Behavioural testing  
Rats were handled in small groups for 5 min/day at least three times before the first PPI 
session. The PPI testing procedure was conducted according to a previously published protocol 
(Howland et al., 2012; Ballendine et al., 2015). Two SR-Lab startle boxes (San Diego 
Instruments, San Diego, CA, USA) were used. Each testing session began with 5-min 
acclimatization during which a background noise (70 dB) was presented and remained constant 
for the entire testing period. After acclimatization, six pulse-alone trials (120 dB, 40 ms) were 
presented to obtain steady startle amplitude. Following the 6 pulse-alone trials, 84 trials of three 
types were presented in pseudorandom order: pulse-alone (6 trials; 120 dB, 40 ms); prepulse + 
pulse (72 trials; parameters described below); or no stimulus (6 trials). Prepulse + pulse trials 
began with a 20-ms prepulse of 3, 6, or 12 dB above background noise (70 dB). Four different 
prepulse—pulse intervals of 30, 50, 80, or 140 ms—were used between the onset of the prepulse 
and the onset of the 120-dB pulse. Six trials of each prepulse × prepulse-pulse interval 
combination were presented. Each testing session ended with another six pulse-alone trials (120 
dB, 40 ms). The inter-trial interval varied from 3 to 14 s (average 7.5 s) in random order. After 
each session, the startle boxes were cleaned with 40% ethanol.  
In experiment one, rats (n = 20) received six treatments in a counterbalanced, Latin 
square, within-subjects design: vehicle, d-GOV, l-GOV, APO, APO + d-GOV, and APO + l-GOV. 
GOV was administered 15 min prior to APO which was given immediately prior to PPI 
(Howland et al., 2004). In experiment two, a separate group of rats (n = 19) was tested similarly 
to experiment one using the following treatments: vehicle, d-GOV, l-GOV, MK-801, MK-801 + d-
GOV, and MK-801 + l-GOV. GOV was administered immediately prior to MK-801, 15 min 
before starting PPI (Lapish et al., 2014; Lins et al., 2015). In experiment three, a third cohort of 
rats (n=12) was tested in the same PPI protocol using three doses of l-GOV (0.3, 1.0, and 3.0 
mg/kg) as well as vehicle injections 15 min prior to PPI. All injections were administered via the 
subcutaneous (s.c.) route except for MK-801, which was administered intraperitoneally (i.p.). In 
all experiments, PPI sessions were conducted every 3–4 days until all treatments were complete. 
Repeated treatments with APO or MK-801 were administered a minimum of 6 days apart to 
reduce potential sensitization effects.  
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2.3.4 Statistical analyses  
The data were analyzed using the Statistical Package for the Social Sciences (SPSS) 
version 21 for Windows (IBM, Chicago, IL). Greenhouse-Geisser corrections were used for 
instances of sphericity violations (Mauchley’s Test) for all repeated measures analysis of 
variance (ANOVA) with no adjustments otherwise. Post hoc analyses were performed using 
Tukey’s test. Statistical significance for all comparisons was p ≤ 0.05. PPI was calculated by 
averaging the startle amplitudes for each trial type, and the percent PPI for each prepulse 
intensity was calculated using the formula: [100 − (100 × startle amplitude on prepulse + pulse 
trials)/(startle amplitude on pulse-alone trials)]. PPI was observed for the 50-, 80-, and 140-ms 
interval whereas the 30-ms interval produced prepulse facilitation. Therefore, data for the 30-ms 
interval were analyzed separately from the other intervals (Howland et al., 2012; Ballendine et 
al., 2015). The data from both experiments 1 and 2 were first analyzed with repeated measures 
ANOVAs (drug treatment, d-GOV or l-GOV, prepulse-pulse interval and prepulse intensity as 
factors). Additional analysis was conducted on experiment 2 data with separate ANOVAs where 
d-GOV and l-GOV were analyzed separately. The data from experiment 3 was analyzed with a 
repeated measure ANOVA (l-GOV dose, prepulse-pulse interval and prepulse intensity as 
factors). Startle data were analyzed with repeated measures ANOVAs (drug treatment, d-GOV or 
l-GOV, and pulse block as factors for experiments 1 and 2 or l-GOV dose and pulse block as 
factors for experiment 3) for each experiment. Non-significant main effects and interactions are 
not reported.  
 
2.4 Results  
2.4.1 Disruption of PPI by apomorphine is blocked by l-GOV but not d-GOV  
Startle As shown in Figure 2.1 a, rats displayed robust startle to presentation of the 120-
dB tones following all treatments. A significant main effect of pulse block was observed 
(F(1.03,19.56)=44.15, p<0.001) indicating habituation of startle over the testing session. None of the 
drug treatments affected startle (statistics for interactions not shown).  
We also assessed the effects of the treatments on baseline reactivity during trials in which 
no stimulus was presented or the prepulses (3, 6, 12 dB) were presented alone (Figure 2.1 b). 
Significant main effects of both APO (F(1,19)=73.78, p<0.001) and GOV (F(2,38)=17.07, p<0.001) 
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on reactivity were found. These main effects were qualified by a significant APO by GOV 
interaction (F(1.48,28.10)=4.72, p=0.026) that showed startle reactivity only significantly increased 
with the APO and APO + d-GOV treatments but not with the APO and l-GOV treatments.  
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Figure 2.1: Effects of d- and l -GOV (1.0 mg/kg) on startle and its modulation 
by apomorphine (APO) or MK-801 (MK).  
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Figure 2.1: (a) Amplitude of startle (arbitrary units) when rats were treated with APO (0.2 
mg/kg) and d- or l-GOV. Neither APO nor either enantiomer of GOV affected startle (arbitrary 
units) before, during, or after the PPI trials were presented. (b) The effects of APO and each 
enantiomer of GOV on reactivity during the no stimulus and 3-, 6-, and 12-dB prepulse-alone 
trials. Reactivity was significantly increased by Apo (*p<0.05). d-GOV had no effect on the 
APO-elicited increase while (#p<0.05) l-GOV significantly reduced it. (c) Amplitude of acoustic 
startle (arbitrary units) when rats were treated with MK (0.15 mg/kg) and d- or l-GOV. MK-801 
treatment significantly increased the startle during the first block of pulse-alone trials, but not 
during the second or third block (*p<0.05). Collapsed across MK treatment, l-GOV significantly 
decreased startle relative to d-GOV and vehicle treatments (#p<0.05). (d) The effects of MK and 
each enantiomer of GOV on reactivity during the no stimulus and 3-, 6-, and 12-dB prepulse-
alone trials. Regardless of GOV treatment, MK-801 treatment significantly increased reactivity 
(*p<0.05). Collapsed across MK-801 treatment, l-GOV significantly decreased reactivity relative 
to vehicle and d-GOV treatments (#P<0.05). 
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PPI Rats in all treatment conditions displayed varying levels of PPI (Figure 2.2 a, b) that 
were determined by both prepulse-pulse interval (F(2,38)=19.45, p<0.001) and prepulse intensity 
(F(1.34,25.52)=180.02, p<0.001). The main effects of APO (F(1,19)=5.18, p=0.035) and GOV 
(F(2,38)=6.10, p=0.005) were both statistically significant. A significant APO by GOV interaction 
qualified these main effects (F(2,38)=5.60, p=0.007) and revealed disrupted PPI in APO-treated 
animals relative to vehicle-, l-GOV-, and APO + l-GOV-treated animals collapsed across all 
prepulse-pulse intervals and prepulse intensities (Figure 2.2 a; p<0.05). Overall, d-GOV 
significantly decreased PPI relative to l-GOV (Figure 2.2 a; p<0.05). Prepulse-pulse interval did 
not significantly interact with any of the treatment groups (all p>0.05) and thus the means were 
collapsed across prepulse-pulse interval (Figure 2.2 b). A significant APO by GOV by prepulse 
intensity interaction (F(4,76)=2.52, p=0.048) revealed the effects of APO and d- or l-GOV 
depended on the prepulse intensity (Figure 2.2 b). Post hoc analyses revealed that at the 3-dB 
prepulse intensity APO treatment significantly impaired PPI relative to vehicle, d-GOV, l-GOV, 
and APO + l-GOV treatments (p<0.05). Also, APO + d-GOV significantly reduced PPI relative to 
the vehicle treated animals (p<0.05). At the 6-dB prepulse intensity, APO, d-GOV, and APO + d-
GOV treatments all significantly reduced PPI relative to vehicle treatment (p<0.05). At the 12-
dB intensity, APO and APO + d-GOV treatments significantly reduced PPI relative to vehicle 
treatment (p<0.05).  
When trials conducted with the 30-ms interval were examined (Figure 2.3 a), significant 
main effects of prepulse intensity (F(1.49,28.21)=42.26, p<0.001) and APO were found (F(1,19)=5.12, 
p=0.036). A significant APO by prepulse intensity interaction (F(1.54,29.28)=4.44, p=0.029) 
followed up by post hoc analysis revealed that regardless of treatment with either GOV 
enantiomer, APO significantly reduced PPI relative to nonAPO-treated animals for the 3- and 6-
dB intensities (p<0.05). Post hoc tests also demonstrated that significant PPI facilitation was 
observed for all treatments at the 12 dB prepulse intensity relative to the 3- and 6-dB intensities 
(p<0.05).  
 
2.4.2 PPI impairments caused by MK-801 are reversed by l-GOV but not d-GOV  
Startle Similar to results observed for the APO-treated rats, habituation of startle to the 
pulse was confirmed by significant main effects of pulse block (Figure 2.1 c; F(1.06,19.15)=64.78, 
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p<0.001). A significant main effect of MK-801 (F(1,18)=30.51, p<0.001) and a significant MK-
801 by pulse block interaction (F(1.17,21.08)=11.40, p=0.002) revealed MK-801 treatment only 
significantly increased startle during the first block of startle-alone trials, but not during the 
second or third block (p<0.05). A significant main effect of GOV (F(2,36)=6.67, p=0.003) was 
also found. Collapsed across MK-801 treatment, l-GOV significantly decreased startle relative to 
d-GOV and vehicle treatment (p<0.05).  
When reactivity on trials with no stimulus or 3-, 6-, or 12- dB prepulses alone was 
examined (Figure 2.1d), reactivity significantly increased across all groups as prepulse-alone 
intensity increased (F(3,54)=4.89, p=0.004). A significant main effect of MK-801 revealed that, 
regardless of GOV treatment, MK-801 treatment significantly increased reactivity (F(1,18)=4.57, 
p=0.046). A significant main effect of GOV (F(2,36)=8.95, p=0.001) was also observed. Post hoc 
analyses revealed that collapsed across MK-801 treatment, l-GOV significantly decreased 
reactivity relative to vehicle and d-GOV treatment (p<0.05).  
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Figure 2.2: Percent PPI displayed for the tests when rats were treated with 
either APO and d-GOV or l-GOV, or MK and d-GOV or l-GOV. 
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Figure 2.2: (a) Data are displayed for the average across prepulse intensity and prepulse-pulse 
interval with APO and d-GOV or l-GOV. APO treatment disrupted PPI relative to vehicle 
(*p<0.05), l-GOV and APO + l-GOV (**p<0.05) treated animals collapsed across all prepulse-
pulse intervals and prepulse intensities. Overall, d-GOV significantly decreased PPI relative to l-
GOV (#p<0.05). (b) The effects of APO and d- or l-GOV on PPI at the 3-, 6-, and 12-dB prepulse 
intensities averaged across prepulse-pulse interval. At the 3-dB prepulse intensity, APO 
treatment significantly impaired PPI relative to vehicle (*p<0.05), d-GOV, l-GOV, and APO + l-
GOV treatments (**p<0.05). Also, APO + d-GOV significantly reduced PPI relative to vehicle 
treatment (*p<0.05). At the 6-dB prepulse intensity, APO, d-GOV, and APO + d-GOV treatments 
all significantly reduced PPI relative to vehicle treatment (#p<0.05). At the 12-dB intensity, APO 
and APO + d-GOV treatments significantly reduced PPI relative to vehicle treatment (&p<0.05). 
(c) PPI averaged across prepulse intensity and prepulse-pulse interval with MK and d-GOV or l-
GOV. MK significantly reduced PPI relative to vehicle treatment (*p<0.05). (d) The effects of 
MK and d- -or l-GOV on PPI at the 3-, 6-, and 12-dB prepulse intensities averaged across 
prepulse-pulse interval. MK treatment impaired PPI at the 3- and 6-dB prepulse intensity, but not 
at the 12-dB intensity (*p<0.05). At the 3-dB prepulse intensity, MK and MK + l-GOV 
treatments resulted in significantly reduced PPI relative to vehicle treatment (**p<0.05). MK + l-
GOV treatment resulted in increased PPI relative to MK treatment alone (#p<0.05). At the 6-dB 
intensity, MK significantly reduced PPI relative to both vehicle (&p<0.05) and MK + l-GOV 
treatment (##p<0.05). At the 12-dB intensity, MK-801 significantly reduced PPI compared to 
vehicle treatment (&&p<0.05). 
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PPI Significant main effects of prepulse-pulse interval (F(1.48,26.67)=6.29, p=0.010) and 
prepulse intensity (F(1.49,26.74)=216.19, p<0.001) indicate that all animals displayed different 
levels of PPI for the varying levels of interval and intensity (Figure 2.2 c, d). As prepulse-pulse 
interval did not significantly interact with any of the treatment groups (all p>0.05), the remaining 
means and analyses were collapsed across prepulse-pulse interval. Significant main effects of 
MK-801 (F(1,18)=14.54, p=0.001) and MK-801 by intensity interaction (F(2,36)=9.18, p=0.001) 
were found (Figure 2.2 d). As is well established, MK-801 disrupted PPI in a manner that was 
significantly related to the prepulse intensity (Reijmers and Peeters 1994; Vorhees et al. 1996). 
MK-801 impaired PPI at the 3- and 6-dB prepulse intensity, but not at the 12- dB intensity 
(p<0.05).  
In the omnibus ANOVA, the main effect of GOV (F(2,36)=3.05, p=0.060) and MK-801 by 
GOV interaction (F(2,36)=2.68, p=0.082) failed to reach significance; however, inspection of the 
graphical results appeared to indicate an effect of l-GOV on MK-801 disrupted PPI. Due to 
increased risk of type II error as a result of multiple comparisons in the omnibus ANOVA, we 
performed a secondary repeated measure ANOVA which assessed the effects of each GOV 
enantiomer on PPI separately. Dissociable effects of the enantiomers on the MK-801- induced 
disruption of PPI were apparent. Inspection of the results for the d-GOV enantiomer produced the 
same effects observed for the omnibus ANOVA, specifically, a main effect of MK-801 
(F(1,18)=12.88, p=0.002), a main effect of prepulse-pulse interval (F(2,36)=4.49, p=0.018), a main 
effect of prepulse intensity (F(2,36)=200.12, p<0.001), and an MK-801 by prepulse intensity 
interaction (F(2,36)=10.00, p<0.001). Inspection of the l-GOV analysis also revealed a main effect 
of MK-801 (F(1,18)=16.09, p=0.001), a main effect of prepulse-pulse interval (F(2,36)=5.84, 
p=0.006), a main effect of prepulse intensity (F(2,36)=169.36, p<0.001), and a MK-801 by 
prepulse intensity interaction (F(2,36)=11.00, p<0.001). Additionally, this analysis revealed a 
significant MK-801 by l-GOV interaction (F(1,18)=5.74, p=0.028) and a significant MK-801 by l-
GOV by intensity interaction (Figure 2.2 d; F(1.43,25.8)=5.29, p=0.020). Post hoc analyses indicate 
that at the 3-dB prepulse intensity, MK-801 and MK-801 + l-GOV treatments resulted in 
significantly reduced PPI relative to vehicle treatment (p<0.05). Further post hocs revealed that 
MK-801 + l-GOV treatment resulted in increased PPI relative to MK-801 treatment alone 
(p<0.05). At the 6-dB intensity, MK-801 significantly reduced PPI relative to both vehicle and 
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MK-801 + l-GOV treatment (p<0.05). At the 12-dB intensity, post hoc analysis revealed that 
MK-801 significantly reduced PPI compared to vehicle treatment (p<0.05).  
Analysis of the 30-ms interval (Figure 2.3 b) revealed a significant main effect of 
prepulse intensity (F(2,36)=51.41, p<0.001) and MK-801 (F(1,18)=12.25, p=0.003). Post hoc 
analysis of a significant prepulse intensity by MK-801 interaction (F(2,36)=4.06, p=0.026) 
indicated that, collapsed across GOV treatment, PPI facilitation was observed in the vehicle 
animals at the 12-dB intensity relative to the 3-dB intensity. Alternatively, MK-801 treatment 
collapsed across all GOV treatments resulted in a shift towards PPI facilitation at the 12-dB 
intensity relative to the 6-dB intensity. Further analysis of the 30-ms data revealed a significant 
prepulse intensity by GOV interaction (F(4,72)=2.90, p=0.028); however, no meaningful changes 
in PPI produced by GOV treatment were observed at varying levels of prepulse intensity. 
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Figure 2.3: Percent PPI on trials with a short (30-ms) prepulse-pulse interval 
when rats were treated with either APO and d-GOV or l-GOV or MK and d-
GOV or l-GOV. 
 
 
 
Figure 2.3: (a) APO significantly reduced PPI relative to non-APO treated animals for the 3- 
and 6-dB intensities (*p<0.05). Collapsed across GOV treatments, PPI facilitation was observed 
in the vehicle animals at the 12-dB intensity relative to the 3- dB intensity (*p<0.05). (b) MK 
treatment collapsed across all GOV treatments resulted in PPI facilitation at the 12-dB intensity 
relative to the 6-dB intensity (#p<0.05). 
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2.4.3 Dose-dependent effects of l-GOV on startle and PPI 
Startle Consistent with results obtained for the APO and MK-801-treated rats, 
habituation of startle to the tone was observed (Figure 2.4 a; main effect of pulse block: 
F(2,22)=53.81, p<0.001). A significant main effect of treatment (F(3,33)=5.75, p=0.003) revealed 
that the 1.0 and 3.0 mg/ kg doses of l-GOV significantly decreased startle amplitude relative to 
vehicle treatment (p<0.05).  
Examination of startle reactivity to the no stimulus or 3-, 6-, or 12-dB prepulses alone 
(Figure 2.4 b) showed a significant main effect of treatment (F(1.72,18.88)=10.44, p=0.001). Post 
hoc analyses revealed that the 1.0 and 3.0 mg/kg doses of l-GOV produced significantly 
decreased reactivity to all prepulse intensities relative to vehicle treatment (p<0.05). Analyses 
further revealed that 3.0 mg/kg of l-GOV also significantly decreased reactivity relative to the 0.3 
mg/kg dose (p<0.05).  
PPI Similar to the first two experiments, significant main effects of prepulse-pulse 
interval (F(2,22)=4.54, p=0.22); prepulse intensity (F(2,22)=374.00, p<0.001); and a significant 
prepulse-pulse interval by prepulse intensity interaction (F(2.18,24.01)=9.29, p=0.001) demonstrate 
that all animals had varying degrees of PPI across the levels of interval and intensity (Figure 2.4 
d). Prepulse-pulse interval did not significantly interact with l-GOV dose (p>0.05). However, a 
significant main effect of treatment (F(3,33)=4.11, p=0.014) and an interaction between treatment 
and prepulse intensity (Figure 2.4 d; F(6,66)=3.32, p=0.006) were found. A significant treatment 
by prepulse-pulse interval by prepulse intensity interaction was also observed (F(12,132)=2.23, 
p=0.014). Post hoc analyses revealed that at the 3-dB intensity, treatment with 0.3 mg/kg of l-
GOV significantly decreased PPI relative to the 1.0 and 3.0 mg/kg doses (p<0.05).  
Analysis of the 30-ms interval trials (Figure 2.4 e) revealed a significant main effect of 
prepulse intensity (F(1.36,14.98)=88.66, p<0.001) and treatment (F(3,33)=3.74, p=0.020). Although 
all treatment groups showed increasing evidence of PPI as prepulse intensity increased, rats 
treated with 3.0 mg/kg of l-GOV showed consistently higher PPI overall relative to animals 
treated with 0.3 mg/kg of l-GOV (p<0.05). 
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Figure 2.4: Effects of l-GOV (0.3, 1.0, 3.0 mg/kg) or vehicle on startle, startle 
reactivity, percent PPI long-interval trials, and percent PPI short-interval 
trials. 
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Figure 2.4: (a) Amplitude of startle (arbitrary units) when rats were treated with varying doses 
of l-GOV. Both the 1.0 and 3.0 mg/kg dose of l-GOV significantly decreased startle before, 
during, and after the PPI trials were presented (*p<0.05). (b) The effects of l-GOV dose on 
reactivity during the no stimulus and 3-, 6-, and 12-dB prepulse-alone trials. Both the 1.0 and 3.0 
mg/kg dose of l-GOV significantly decreased reactivity relative to vehicle treatment during the 
no stimulus and all prepulse-alone trials (*p<0.05). The 3.0 mg/kg dose of l-GOV also 
significantly decreased reactivity relative to the 0.3 mg/kg dose across all trials (#p<0.05). (c) 
Average PPI across all prepulse-pulse intervals and prepulse intensities for each dose of l-GOV. 
(d) The effects of each dose of l-GOV on PPI at the 3-, 6-, and 12-dB prepulse intensities 
averaged across prepulse-pulse interval. The 0.3 mg/kg dose of l-GOV resulted in significantly 
decreased PPI relative to the 1.0 and 3.0 mg/kg doses at the 3 dB intensity (*p<0.05). (e) Percent 
PPI for the 30 ms prepulse-pulse intervals when rats were treated with each dose of l-GOV. 
Averaged across all prepulse intensities, the 0.3 mg/kg dose of l-GOV significantly decreased PPI 
relative to the 3.0 mg/kg dose (*p<0.05). 
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2.5 Discussion  
The present study tested the effects of the d- and l- enantiomers of GOV on PPI alone and 
when disrupted by APO and MK-801. APO disrupted PPI (Figure 2.2) without significant effects 
on startle (Figure 2.1) whereas MK-801 increased startle (Figure 2.1) and also disrupted PPI 
(Figure 2.2). Interestingly, both drugs increased reactivity during trials in which a pulse was not 
presented (Figure 2.1), effects which were blocked by l-GOV, but not d-GOV. l-GOV, but not d-
GOV, blocked the disruptive effects of APO (Figure 2.2) and MK-801 (Figure 2.2) on PPI at 
varying prepulse intensities (3, 6, and 12 dB). As previously reported, trials with a short 
prepulse-pulse interval (30 ms) had low levels of PPI, particularly for trials with 3- and 6-dB 
prepulses (Figure 2.3). MK-801 and APO tended to reduce PPI for these trials. The enantiomers 
of GOV did not significantly affect PPI on short interval trials; however, d-GOV alone 
significantly disrupted PPI at the long-interval relative to l-GOV. Taken together, these results 
suggest that l-GOV functions much like atypical antipsychotic drugs in blocking the effects of 
APO and MK-801 on PPI (Swerdlow and Geyer, 1993).  
 
2.5.1 The effects of apomorphine and MK-801 on PPI in Long-Evans rats  
The PPI protocol employed in the present experiments used a range of intervals between 
prepulses and the startling pulse because previous research has shown interval-specific effects of 
some manipulations (Jones and Shannon, 2000; Fendt et al., 2001; Yeomans et al., 2010; 
Pinnock et al., 2015). Our results for the long-interval trials (50, 80, 140 ms between the prepulse 
and pulse) confirm the well-documented impairments of PPI caused by the direct DA D2R 
agonist APO and NMDA receptor antagonist MK-801 in previous studies using long prepulse-
pulse intervals (Geyer et al., 2001). Previous studies have shown that hooded rats, including the 
Long-Evans (used here) and Lister strains are less sensitive to the disruptive effects of APO, but 
not MK-801, on PPI than the Sprague-Dawley and Wistar strains (Kinney et al., 1999; Swerdlow 
et al., 2000; Weiss et al., 2000; Qu et al., 2009). We observed a robust disruption in PPI 
following APO treatment. This was observed using a moderate dose of APO (0.2 mg/kg) which 
has been shown to impair PPI in Long-Evans rats in some studies (Howland et al., 2004) but not 
others (Swerdlow et al., 2001a). Short-interval trials (30-ms prepulse-pulse interval) were 
characterized by lower PPI than long-interval trials, particularly for the trials with 3- and 6-dB 
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prepulses. We and others have observed this pattern previously (Swerdlow et al., 2000; van den 
Buuse and Gogos, 2007; Jones et al., 2010; Howland et al., 2012; Ballendine et al., 2015). 
Interestingly, startle was in fact increased during short interval prepulse-pulse trials (i.e., a form 
of prepulse facilitation) following MK-801 and APO consistent with previous studies using MK-
801 (Al-Amin and Schwarzkopf, 1996; Brosda et al., 2011) or ketamine (Mansbach and Geyer, 
1991) with short intervals between prepulse and pulse.  
MK-801 (0.15 mg/kg) significantly increased the startle to the 120-dB pulse throughout 
the test session, an effect that has been reported previously following the same dose in Sprague 
Dawley and Wistar rats (Varty et al., 1999 but also see Wiley et al., 2003). Interestingly, startle 
reactivity on no-stimulus and prepulse-alone trials was significantly enhanced by both APO and 
MK-801. Others have reported no effect of APO on reactivity in Long-Evans rats (Swerdlow et 
al., 2001a) although increased reactivity has been noted in Sprague-Dawley rats (Swerdlow et 
al., 2001a, 2004) and C57BL/6 mice (Yee et al., 2004b). The effects of NMDA receptor 
antagonists on prepulse-elicited reactivity have not been consistent with the enhancement 
produced by APO (Yee et al., 2004a; Yee and Feldon, 2009) although to the best of our 
knowledge, the effects of MK-801 on prepulse-elicited reactivity in rats have not been reported 
previously. The increase in reactivity caused by APO and MK-801 may reflect a generalized 
increase in locomotor behaviour caused by these drugs. Interestingly, l-GOV has been shown 
previously to block AMPH-induced locomotion (Lapish et al., 2014). Therefore, testing the 
effects of l-GOV on locomotor behaviour induced by APO or MK-801 in an open field may show 
a generalized effect of l-GOV on locomotor behaviour caused by a range of psychotomimetic 
drugs.  
 
2.5.2 Selective effects of the d- and l- enantiomers of GOV on the disruptions in PPI 
induced by apomorphine and MK-801  
Previous studies have demonstrated that l-GOV induces deficits in conditioned avoidance 
responding and attenuates AMPH-induced locomotion (Lapish et al., 2014). In contrast, d-GOV 
has no such effects; however, it improves working memory and temporal order memory. Despite 
these differences in cognitive and behavioural effects, both enantiomers act to improve social 
interaction and latent inhibition in animal models of schizophrenia (Lapish et al., 2012, 2014). 
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The present results are novel and show that l-GOV blocks the disruptive effect of either APO or 
MK-801 on PPI. As well, l-GOV reduces the APO- and MK-801-induced increases in reactivity. 
d-GOV has no effect on these measures, although it did reduce PPI for long-interval trials. While 
the mechanism underlying the reduction in PPI following d-GOV will be difficult to discern, it 
may relate to the enantiomer’s unique effects on DA release and receptor antagonism (Lapish et 
al., 2014b). Well-documented side effects of typical antipsychotics are extrapyramidal symptoms 
(EPS) which include Parkinsonism, dystonia, akathisia, and tardive dyskinesia (Porsolt et al., 
2010). In rodents, catalepsy is a common behavioural measure used to assess the potential for a 
neuroleptic drug to induce EPS (Porsolt et al., 2010; Lapish et al., 2014b). In a previous study l-
GOV, but not d-GOV, induced catalepsy in a dose-dependent manner; however, minimal effects 
were observed at 0.3 and 1.0 mg/kg with an increase in immobility at the 3.0 mg/kg dose. This 
effect is consistent with its profile as a putative antipsychotic and D2 antagonist (Lapish et al., 
2014b). In the dose-response study (Figure 2.4), 1.0 and 3.0 mg/kg of l-GOV reduced startle 
reactivity, which may reflect a generalized effect on locomotor activity consistent with effects 
reported for haloperidol and clozapine by Hoffman et al. (1993). However, dose-dependent 
changes in PPI were relatively subtle, while a non-significant increase in PPI was noted 
following higher doses of l-GOV, an effect also found with haloperidol (Hoffman et al., 1993). 
Disrupted PPI following APO treatment has been linked to activation of the mesolimbic DA 
system (Geyer et al., 2001). Consistent with this theory are findings showing that typical 
antipsychotic drugs such as haloperidol, which are potent D2 receptor antagonists, block the 
effects of APO on PPI (Swerdlow and Geyer, 1993; Geyer et al., 2001). Thus, the effects of l-
GOV on the APO-induced disruption of PPI may be attributable to its demonstrated similarity to 
typical antipsychotics, as an antagonist with high affinity for D2 receptor and its effects in 
behavioural assays such as conditioned avoidance responding (Lapish et al., 2014b). In keeping 
with this theory, the failure of d-GOV to block the effect of APO on PPI may be related to its 
relatively lower affinity for D2 receptors.  
In contrast to the reversal of APO-induced PPI impairment, typical antipsychotics such as 
haloperidol do not block PPI impairment when induced by MK-801 (Keith et al., 1991; Hoffman 
et al., 1993; Bast et al., 2000). Therefore, the D2 receptor antagonism caused by l-GOV is not a 
likely explanation for the reversal of the MK-801-induced PPI impairment. In some studies, 
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atypical antipsychotics such as clozapine block the effects of acute MK-801 (or other NMDA 
receptor antagonists) on PPI (Bakshi et al., 1994; Geyer et al., 2001; Bubeníková et al., 2005 but 
see Hoffman et al., 1993; Bast et al., 2000) raising the possibility that serotonin and/or 
muscarinic receptor mechanisms may be involved. At psychotomimetic doses, non-competitive 
NMDA receptor antagonists such as MK-801 disrupt neural circuits by reducing GABAergic 
transmission which leads to disinhibition of pyramidal neurons and increased midbrain DA 
efflux (Laruelle et al., 1999; Kegeles et al., 2000; Balla et al., 2001, 2003; Homayoun and 
Moghaddam, 2007; Vinson and Conn, 2012). l-GOV’s reversal of the MK-801-induced PPI 
impairment may be explained by its unique ability to simultaneously enhance DA efflux in the 
PFC and block D2 receptors (Lapish et al., 2014b). Stimulation of D1 receptors increases 
inhibitory neurotransmission in the PFC while D2 receptor stimulation decreases it (Seamans et 
al., 2001; Gorelova et al., 2002). Differential DA signaling is regulated in a concentration 
dependent manner (Trantham-Davidson et al., 2004). D1 receptor signaling is proposed to cause 
a prolonged increase in IPSC through activation of adenylyl cyclase (AC) and protein kinase A 
(PKA), which inhibit K+ channels in parvalbumin-containing interneurons. Blocking D2 
receptors in the presence of high DA concentration increases inhibitory postsynaptic currents, an 
effect that is prevented by D1 receptor antagonists (Gorelova et al., 2002). Thus, D2 receptor 
signaling may occlude D1 receptor signaling during periods of high DA concentration and this 
occlusion can be prevented with D2 antagonism (Gorelova et al., 2002). As l-GOV blocks D2 
receptors while increasing DA efflux, the resulting increase in D1 receptor binding and signaling 
may lead to increased PKA and ultimately, increased excitability in parvalbumin-containing 
interneurons to counteract the effects of MK-801. Such a mechanism is supported by findings 
that NMDA receptor antagonist-induced PPI deficits are reversed by the GABA receptor agonist 
baclofen (Bortolato et al., 2004) and D1 receptor agonist A77636 (Bubenikova-Valesova et al., 
2009). Additionally, infusion of the GABA-A channel blocker picrotoxin into the mPFC via 
intracranial cannulae disrupts PPI and is reversed by pretreatment with haloperidol in Wistar rats 
(Japha and Koch, 1999). It is important to note that this effect may be strain dependent as it was 
not replicated in Lister hooded rats (Pezze et al., 2014). Activation of D1 receptors also 
stimulates the translocation of NMDA receptors to the postsynaptic membrane (Dunah et al., 
2004) and secondary messengers which phosphorylate NMDA receptors subunits to potentiate 
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the NMDA-evoked response (Missale et al., 2006) providing additional mechanisms through 
which l-GOV may reverse the effects of NMDA receptor antagonism. d-GOV, which is not a 
potent D2 receptor antagonist (Lapish et al., 2014b), lacks the ability to restore the PPI deficits in 
both drug conditions.  
 
2.6 Conclusion  
These data are consistent with the potential use of enantiomers of GOV as treatments for 
schizophrenia. l-GOV, a D2 receptor antagonist which increases DA efflux, was effective in 
restoring deficits in PPI induced by MK-801 or APO to control levels. In contrast, d-GOV, the 
enantiomer associated with cognitive enhancement, did not reverse the disruption of PPI by 
either drug. A dose-response study revealed l-GOV reduced startle amplitude, reactivity, and PPI 
in the dose-dependent manner. 
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CHAPTER 3 
PROSPECTIVE ANALYSIS OF THE EFFECTS OF MATERNAL 
IMMUNE ACTIVATION ON RAT CYTOKINES DURING PREGNANCY 
AND BEHAVIOUR OF THE MALE OFFSPRING RELEVANT TO 
SCHIZOPHRENIA2 
3.1 Abstract  
Influenza during pregnancy is associated with the development of psychopathology in the 
offspring. We sought to determine if maternal cytokines produced following administration of 
viral mimetic polyI:C to pregnant rats were predictive of behavioural abnormalities in the adult 
offspring. Timed-pregnant Sprague-Dawley rats received a single intravenous injection of 4 
mg/kg polyI:C or saline on GD15. Blood was collected for serum analysis of cytokine levels 
with ELISA. Male offspring were tested in a battery of behavioural tests at adulthood and 
behaviour correlated with maternal cytokine levels. Maternal serum levels of CXCL1 and IL-6, 
but not TNF-a or CXCL2, were elevated in polyI:C-treated dams. PolyI:C-treated dams 
experienced post-treatment weight loss and polyI:C pups were smaller than controls at postnatal 
day 1. Various behaviour alterations were seen in the polyI:C-treated offspring. Male polyI:C 
offspring had enhanced MK-801-induced locomotion, and reduced sociability. PolyI:C offspring 
failed to display crossmodal and visual memory, and oddity preference was also impaired. Set-
shifting, assessed with a lever-based operant conditioning task, was facilitated while 
touchscreen-based reversal learning was impaired. Correlations were found between maternal 
 
2 Lins BR, Hurtubise JL, Roebuck AJ, Marks WN, Zabder NK, Scott GA, Greba Q, Dawicki W, Zhang X, Rudulier 
CD, Gordon JR, Howland JG (2018) Prospective analysis of the effects of maternal immune activation on rat 
cytokines during pregnancy and behaviour of the male offspring relevant to schizophrenia. eNeuro.0249-18.2018. 
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serum concentrations of CXCL1, acute maternal temperature and body weight changes, neonatal 
pup mass, and odd object discrimination and social behaviour. Overall, while the offspring of 
polyI:C-treated rats displayed behaviour abnormalities, maternal serum cytokines were not 
related to the long-term behaviour changes in the offspring. Maternal sickness effects and 
neonatal pup size may be better indicators of later effects in the offspring.  
 
3.1.1 Significance statement  
 Psychiatric pathology is complex, poorly understood, and often results in chronic illness. 
Many psychiatric conditions are believed to occur as a result of genetic and environmental 
factors. Gestational adversity such as inflammation in pregnancy may act as a priming 
experience for the later emergence of psychopathologies, and accurate identification of risk 
factors may advise early interventions. We sought to characterize long-term behaviour effects in 
the offspring of rats exposed to an inflammatory event during pregnancy and relate these effects 
to the serum levels of relevant cytokines CXCL1, IL-6, and TNF-a. Our results suggest that 
these maternal cytokines are not strongly related to offspring behaviour outcomes, and other 
measures may have greater value as predictors of behaviour outcomes.  
 
3.2 Introduction 
Inflammation during pregnancy is associated with increased risk of various 
psychopathologies in the offspring (Brown et al., 2004a; Brown, 2006; Fineberg and Ellman, 
2013). The association between inflammation and psychiatric illness was initially demonstrated 
through epidemiological studies where influenza outbreaks preceded an increase in SSDs as 
cohorts that were in utero during the epidemic reached adulthood (Brown, 2012). Inflammation 
in pregnancy has since been linked to additional pathologies in the offspring including bipolar 
disorder and autism (Atladóttir et al., 2010, 2012; Parboosing et al., 2013; Jiang et al., 2016; 
Scola and Duong, 2017). Heterogeneity of the pathogens (viral, bacterial, parasitic) associated 
with psychiatric outcomes suggests the maternal immune response may mediate the effects on 
the developing offspring (Brown and Patterson, 2011). This hypothesis has been corroborated 
through prospective studies where maternal serum levels of IL-8/CXCL8, a cytokine with 
cellular attracting properties in the chemokine family, were elevated during the second trimester 
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in pregnancies where the offspring developed an SSD (Brown et al., 2004b). Subsequent 
research implicated exposure to IL-8 in utero with abnormalities in the offspring’s brains 
including increased ventricular cerebrospinal fluid and decreased cortical volumes (Ellman et al., 
2010). Increased TNF-a in late pregnancy has also been linked to schizophrenia in the offspring 
(Buka et al., 2001). A study in humans demonstrated retrospective estimations of maternal IL-6 
levels during pregnancy using newborn functional brain connectivity determined by magnetic 
resonance imaging (MRI) and gestational IL-6 levels were predictive of performance in a 
working memory task at 2 years old (Rudolph et al., 2018). A second study that followed human 
pregnancies and offspring at 6 months of age found maternal inflammatory cytokines (IL-6, 
TNF-a, MCP-1) mediated an effect of maternal depressive symptoms on negative affect in the 
offspring (Gustafsson et al., 2018). 
Systemic treatment of pregnant rodents or nonhuman primates with an immune stimulant 
such as the synthetic double-stranded RNA molecule polyI:C induces various brain changes in 
the offspring reminiscent of psychiatric illness (Meyer et al., 2009; Piontkewitz et al., 2012; 
Meyer, 2014). PolyI:C increases pro-inflammatory cytokines such as IL-1β, IL-6, CXCL1 
(rodent homologue of IL-8), and TNF-a in maternal circulation (Meyer et al., 2006; Hsiao and 
Patterson, 2011; Ballendine et al., 2015). A mouse study showed a causal role for IL-6 in the 
development of the offspring’s psychopathology as administration of IL-6 alone resulted in 
abnormal offspring behaviour and abnormalities could be prevented with concomitant 
administration of an IL-6 antibody (Smith et al., 2007). However, few studies have prospectively 
analyzed the relationship between increased maternal cytokines during pregnancy and behaviour 
of the offspring. In one study with rats, dams that lost weight following polyI:C had significantly 
higher serum TNF-a than those that gained weight. Offspring of dams that lost weight had 
reduced sucrose preference but no significant changes in PPI or locomotor responses to AMPH 
or MK-801 (Missault et al., 2014).  
Improved understanding of the relationship between maternal serum cytokines and 
offspring phenotype has potential to impact psychiatric disease prevalence through screening and 
early intervention, yet there is a lack of prospective data correlating maternal inflammation with 
offspring behavioural phenotypes (Jiang et al., 2016). The present study assessed the effects of 
maternal polyI:C on acute cytokine elevations in the dams and subsequent behavioural 
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abnormalities in the offspring. The cytokines analysed were based on those previously indicated 
as relevant in the literature: IL-6, IL-8/CXCL1, and TNF-a as well as CXCL2 as a negative 
control (Brown et al., 2004b; Smith et al., 2007; Ellman et al., 2010; Missault et al., 2014; 
Ballendine et al., 2015; Scola and Duong, 2017). To assay behaviour related to the positive 
symptoms of schizophrenia we used locomotor activity in response to a novel environment and 
the NMDA receptor antagonist MK-801 (Zuckerman and Weiner, 2005; Howland et al., 2012; 
Giovanoli et al., 2013). For negative symptoms we used a spontaneous test sociability test 
(Bitanihirwe et al., 2010). Cognitive impairment was assessed using PPI of the acoustic startle 
response (Meyer et al., 2009; Howland et al., 2012; Ballendine et al., 2015), a crossmodal 
recognition memory battery (CMOR) (Winters and Reid, 2010; Ballendine et al., 2015), a 
spontaneous oddity task (Bartko et al., 2007a), and two operant conditioning procedures which 
assess visual discrimination, strategy set-shifting, and reversal learning (Zhang et al., 2012; 
Ballendine et al., 2015; Bryce and Howland, 2015). Our hypothesis was that maternal pro-
inflammatory cytokines would correlate with behavioural deficits in the offspring with higher 
cytokine concentrations relating to a more severe behaviour phenotype. 
 
3.3 Materials and methods 
3.3.1 Animals 
Timed-pregnant Sprague-Dawley rat dams (n=43) arrived at the animal holding facility 
on GD7. Dams were singly housed in standard polypropylene cages in a temperature controlled 
(21°C) colony room on a 12/12 h light/dark cycle (lights on at 07:00 h) with food (Purina Rat 
Chow) and water available ad libitum. Following arrival, dams were left undisturbed until 
treatment on GD15. All procedures were carried out during the light phase and behavioural 
experiments were conducted on adult male offspring (n=121). Experimental procedures were 
approved by the University of Saskatchewan Animal Research Ethics Board. 
3.3.2 Maternal treatments and blood samples 
Maternal treatment generally followed previously established protocols in Long Evans 
rats (Figure 3.1 A). On GD15, dam weight and rectal temperature were recorded. Dams were 
anesthetized with isoflurane (5% induction, 2.5% maintenance) for <10 minutes and received a 
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single intravenous (i.v.) tail vein injection of either 0.9% saline or polyI:C (4 mg/kg, high 
molecular weight, InVivoGen, San Diego, CA, USA). Dams were anesthetized a second time as 
described above 3 h following initial treatment and a blood sample (<1.5 mL total and <6% total 
blood volume) was drawn using a sterile catheter (BD Insyteä Autogaurdä, 24 GA 0.75 IN 0.7 
x 19 mm, REF 381412) from the opposite tail vein used to inject polyI:C. Warm physiological 
saline was administered once following polyI:C or saline treatment (3 mL), and a second time 
after blood collection (volume = the blood sample). Blood samples coagulated at room 
temperature for 1 h and spun at 10,000xG for 5 min to separate the serum. Serum was pipetted 
and stored at -80 °C until analysis and ELISAs were performed for CXCL1 (GROα/KC; R&D 
Systems, Minneapolis, MN), CXCL2 (GROβ/MIP-2; R&D Systems), IL-6 (PeproTech, Rocky 
Hill, NJ), and TNF-a (PeproTech) per the manufacturer’s instructions. Difficulty with blood 
collection of 3 polyI:C treated dams resulted in small serum volumes collected for these rats and 
they were not included in IL-6 ELISA, and 1 was also excluded from TNF-a ELISA. While the 
offspring from these dams were included in behavioural testing, their behaviour could not be 
correlated with these cytokine levels.   
Aside from maternal weight and temperature monitoring 8, 24, and 48 h following 
treatment, dams were undisturbed for the remainder of their pregnancy. Of the original n=43 
dams, 7 were euthanized within 48 h following polyI:C injection due to hypothermia. Four 
additional dams experienced body temperature below 36°C but otherwise showed alert behaviour 
and were given access to a warming pad on their home cage for 24 h until their temperature 
returned to normal. Three dams did not produce viable litters. Ultimately, offspring from a total 
of n=33 litters were included (n=17 polyI:C treated dams and n=16 saline treated dams). On 
postnatal day (PND) 1, litters were weighed, sexed, and culled to a maximum of 10 (6 males 
where possible). On PND23, pups were weaned and housed in same-sex sibling groups of 2 or 3 
in standard housing as previously described. 
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Figure 2.1: Timelines for pregnant dam treatment and male offspring 
behaviour testing, plus acute effects of treatment on pregnant dams and 
neonates. 
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Figure 3.1: [A] Schematic illustrating the timeline of maternal treatment and offspring 
behaviour testing. [B] Schematic illustrating the division and order of male offspring behaviour 
testing. [C] Maternal weight loss was observed following the administration of polyI:C or saline. 
At all three time points measured (8, 24, 48 h), dams treated with polyI:C had a significantly 
lower percent of their original body weight than those that received saline. [D] Maternal body 
temperature was slightly elevated in the polyI:C treated dams 8 hours following injection, yet 
this effect was not significant. [E] Maternal serum cytokine concentrations were determined 
using ELISA and revealed a significant increase in CXCL1 and IL-6 3 h after polyI:C treatment. 
No differences were seen for CXCL2 or TNF-a. [F] On postnatal day 1, the pups (males and 
females combined) of dams treated with polyI:C weighed significantly less than those of the 
dams that received saline. 
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3.3.3 Behavioural Testing 
Behavioural tests were conducted according to published protocols or modified from 
published protocols. Typically, 2 males per litter were used in each behaviour task. An exception 
is PPI where 3 male offspring per litter were included, except for the two largest litters where 4 
and 5 were included. To account for the non-independent relationship between littermates, 
effects were averaged across siblings to produce one value per litter. 
Rats were handled for a minimum of 3 sessions prior to behaviour testing. Handling 
included exposure to investigators and emphasized picking up and moving the rats until these 
motions could be carried out with ease, as well as habituation to travel by cart between the 
animal housing and behaviour testing locations. All work with the rats including husbandry and 
behaviour testing occurred during the light phase (07:00-19:00 hrs) with the majority of 
behaviour testing performed between 08:00-17:00. Testing began at 8 weeks of age (young 
adulthood) and was completed by 15 weeks of age. All offspring were first tested for PPI before 
being further divided into two groups for subsequent tests (Figure 3.1 B). One group (n=68) 
completed CMOR and sociability before being assigned to complete either the operant set 
shifting task (OSST, n=37) or touchscreen pairwise discrimination and reversal learning (PD/RL, 
n=38). The second group of randomly selected male rats (n=30) from the same litters were tested 
in oddity discrimination followed by MK-801 induced locomotor activity. Ethanol (40%) was 
used to clean all behaviour testing equipment between rats. 
PPI: PPI measures the percent attenuation of motor response to a startling tone when that tone is 
preceded by a brief prepulse (Figure 3.2 A). Two SR-LAB startle boxes (San Diego Instruments, 
San Diego, CA, USA) were used. Each session had a constant background noise (70 dB) and 
began with 5 min of acclimatization, followed by 6 pulse-alone trials (120 dB, 40 ms). Pulse-
alone (6), prepulse + pulse (36) and no stimulus (6) trials were then presented in a pseudorandom 
order, followed by 6 additional pulse-alone trials. Prepulse + pulse trials began with a 20 ms 
prepulse of 3, 6, or 12 dB above background (70 dB). Prepulse–pulse intervals (time between the 
onset of the prepulse and the 120-dB pulse) were short (30 ms) or long (80 ms). The inter-trial 
interval varied randomly from 3 to 14 s (Meyer et al., 2009; Howland et al., 2012; Ballendine et 
al., 2015).   
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Sociability Task: The testing apparatus was a rectangular arena (150 x 40 cm) of black 
corrugated plastic divided into three compartments, one middle start compartment (30 x 40 cm) 
and two ‘stranger’ compartments on either side (60 x 40 cm, see Figure 3.3 A). The walls 
dividing the middle compartment from the stranger compartments were clear Plexiglas (extended 
12 cm from each wall leaving a 16 cm opening to move between compartments) and removable 
black opaque barriers which, when inserted, prevented entry into the stranger compartments. 
Each stranger compartment contained a circular mesh cage (18 cm diameter, 20 cm height) with 
hinged lid (3/4” plywood, painted matte black). The height of the cage was extended 20 cm with 
vertical metal rods to discourage climbing. The task began with 10 min habituation with the 
barriers removed. The test rat was then contained in the middle section with the barriers in place 
and a stranger rat was placed in one of the mesh cages. The barriers were removed, and the test 
rat explored for an additional 10 min. Interaction was scored when the face of the rat was 
oriented toward the holding cage at a maximum distance of 2 cm. Data were manually scored 
with a stopwatch by a blinded investigator and locomotor activity was recorded with EthoVision 
software. All stranger rats were sex, age, and treatment matched to the test rat (Bitanihirwe et al., 
2010). 
Locomotor Activity: The apparatus was a square arena (40 x 40 x 60 cm) made of black 
corrugated plastic (Figure 3.3 D). A camera mounted to the ceiling recorded all activity and 
EthoVision software was used to track activity. Rats were tested 4 at a time, with each rat placed 
in 1 of 4 separate arenas for 30 min of habituation. Immediately following, rats were 
administered MK-801 (0.2 mg/kg; i.p.; Howland et al. 2012) and placed back into the arena for 
an additional 120 min. Activity was recoded with Noldus Ethovision XT 11.5 software 
(Zuckerman and Weiner, 2005; Howland et al., 2012; Giovanoli et al., 2013). 
Visual, Tactile, and CMOR: This task uses spontaneous exploratory behaviour to assess visual 
memory, tactile memory, and visual-tactile sensory integration (Winters and Reid, 2010; Jacklin 
et al., 2012). The testing apparatus was a Y-shaped maze with 1 start arm and 2 object arms (10 
× 27 cm) made of white corrugated plastic (Figure 3.4 A). A white plastic guillotine-style door 
separated the start arm from the object arms, and Velcro at the distal end of the object arms fixed 
objects in place. A removable, clear Plexiglas barrier could be inserted in front of the objects. A 
tripod positioned above the apparatus held a video camera that recorded the task activity. Rats 
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were habituated to the apparatus twice for 10 min. Lighting alternated during habituation 
between white light (used during visual phases) and red light (used during tactile phases) for 5 
min each with the order counterbalanced, and the clear barriers were in place for one day of 
habituation and removed for the other with order counterbalanced between all rats. Test days 
consisted of a 3 min sample phase with two identical copies of an object attached with Velcro to 
the maze, a 60 min delay, and then a 2 min test phase with a third copy of the original object and 
a novel object placed in the maze. Rats began each phase in the start arm; the guillotine door was 
opened and closed once the rat entered the object arms. This task consisted of 3 distinct tests 
performed on 3 separate days; consistently in the following sequence: tactile memory (day 1), 
visual memory (day 2) and crossmodal memory (day 3). Red light illuminated the tactile phases 
allowing the rats’ behaviour to be recorded while preventing the rats’ visual assessment of the 
objects and the removal of the clear barriers allowed for tactile exploration. White light was used 
during visual phases, but clear Plexiglas barriers in front of the objects prevented tactile 
exploration. CMOR had a tactile sample phase (red light, no barriers) and a visual test phase 
(white light, clear barriers). Recognition memory was defined as significantly greater exploration 
of the novel object than the familiar object. Behaviour recordings were manually scored with a 
stopwatch by investigators blind to the treatment status of the rats and identity of the objects 
(Winters and Reid, 2010; Ballendine et al., 2015). 
Oddity Discrimination: The testing apparatus was a square arena (60 x 60 x 60 cm) constructed 
of white corrugated plastic with Velcro in each of the 4 corners. Two days of habituation to the 
arena (10 min sessions) preceded the test day. On test day, 3 identical objects made of glass or 
plastic and one different, or ‘odd’ object were fixed to the Velcro locations (Figure 3.4 C) and 
the rats’ activity were recorded for 5 min using a video camera mounted to the ceiling. Object 
exploration times were manually scored using a stopwatch by an investigator blind to the 
treatment status of the rats (Bartko et al., 2007a). Object examination was counted when a rat’s 
face was oriented toward the object at a maximum distance of 2 cm.   
OSST: Eight operant conditioning chambers (MedAssociates Systems, St. Albans, VT, USA) in 
sound-attenuating cubicles were used. The chambers contained two retractable levers and two 
stimulus lights positioned on either side of a food port (Figure 3.5 A) used to deliver food 
rewards (Dustless Precision Pellets, 45 mg, Rodent Purified Diet; BioServ, Frenchtown, NJ). A 
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100 mA house light illuminated the chamber. Sessions began with levers retracted and the 
chamber in darkness (inter-trial state), with the exception of lever training days in which the trial 
began with levers exposed to allow for baiting with ground reward pellets. Rats were tested once 
each day. Lever training. Rats were trained to press the levers as described previously and 
immediately after reaching criterion, side preference was determined. Visual-cue discrimination. 
Rats were trained to press the lever indicated by a stimulus light illuminated above it. Trials 
began with an illumination of one stimulus light, followed 3 s later by the house light and 
insertion of both levers. A correct press of the lever underneath the illuminated stimulus light 
caused retraction of both levers and the delivery of a reward pellet. An incorrect press returned 
the chamber to the inter-trial state with no reward. Strategy set-shift. The visual-cue rule from the 
previous stage was reinforced with 20 trials where the rat was required to press the lever below 
the illuminated stimulus light. Subsequently, rats were required to change their response from the 
visual cue to a spatial cue (the lever opposite to their side preference, regardless of whether the 
stimulus light was illuminated) to receive a reward pellet. Reversal learning. Rats were required 
to press the lever opposite to the one rewarded during set-shifting. Criterion was 10 consecutive 
correct responses for each testing day (Floresco et al., 2008; Zhang et al., 2012; Thai et al., 2013; 
Ballendine et al., 2015).  
PD/RL: Eight touchscreen-equipped operant conditioning chambers (Bussey-Saksida Touch 
Systems, Lafayette Instrument Company, Lafayette, IN, USA) in sound attenuating cubicles 
were used. The chambers were trapezoidal in shape with the wider end consisting of a 
touchscreen monitor (30.5 × 24.1 × 8.25 cm, see Figure 3.5 D). Opposite the monitor was a food 
port for the delivery of food rewards. A roll-out shelf above the chamber contained a reward 
magazine and an overhead camera which provided a live feed of activity via output to an external 
monitor. The touchscreen monitor was covered with a polycarbonate mask with 2 rectangular 
windows that prevented contact with locations on the touchscreen irrelevant to the task.  A 
response shelf extended 7 cm from the screen, was located below the touchscreen windows, and 
prevented unintentional touchscreen access. All training and testing was conducted per the 
manufacturer’s instructions and utilized the ABET II software that accompanied the chambers. 
Pretraining: All protocols closely followed those recommended by the manufacturer and are 
previously published (Bryce and Howland, 2015). Rats were habituated to the chamber on 2 
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consecutive days with 5 reward pellets in the food port and the house light illuminated for 30 
min. Criterion was reached if all pellets were consumed within 30 min. On the first day of task 
training, one food pellet was delivered every 30 s, as signified by a tone and illumination of the 
food port. During this stage of training, one of the touchscreen windows was illuminated 
pseudorandomly such that the same window was not illuminated for more than two consecutive 
trials. If the rat touched the illuminated screen, 3 reward pellets were delivered. In all stages of 
training and testing, each trial was preceded by a 20 s inter-trial interval that was initiated once 
the rat’s nose entered the illuminated food port. During the second stage of training, the rat was 
required to nose poke the illuminated touchscreen window to receive a reward. Following this 
stage, the rat was required to nose poke into the illuminated port to initiate the illumination of a 
touchscreen window. Again, a reward was delivered if the rat then nose-poked the illuminated 
window. Criterion for these three stages was 100 trials in 1 h. Like the previous stages of 
training, the final stage of pretraining required initiation of the trial and the touching of the 
illuminated window to receive a food reward.  However, touching the unilluminated window 
resulted in a 5 s timeout followed by the inter-trial interval. Trials that were incorrectly 
completed were followed by correction trials, whereby the same window was repeatedly 
illuminated until the correct selection was made and a food reward was delivered. Criterion was 
100 trials completed in 1 h with a minimum of 80% correct for 2 consecutive days. Once 
criterion was reached, training on the full version of the task began. Pairwise Discrimination: 
Pairwise discrimination involved presentation of two distinct black and white images, one in 
each window of the screen. Each image could be presented in either location. One image was 
always correct, with its selection resulting in a food reward, regardless of its location (S+) while 
the other was always incorrect (S-). A correct choice resulted in presentation of a tone and 
illumination of the food port. An incorrect choice resulted in a 5 s delay followed by a correction 
trial. Rats repeated visual discrimination training daily until they reached a criterion of 100 trials 
completed in 1 h with ³85% correct for 2 consecutive days. Reversal Learning: Reversal 
learning occurred following successful completion of pairwise discrimination. The protocol for 
reversal learning was identical to pairwise discrimination except the previously unrewarded 
stimulus (S-) was now the correct choice (S+), and the previous correct choice was now 
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unrewarded and punished with a 5 s time out. Criterion was reached when the rat completed 100 
trials in 1 h with ³85% correct for 2 consecutive days.  
 
3.3.4 Statistical Analyses 
A between-subjects design was used, and analyses were conducted with independent 
samples t-tests and ANOVAs using Statistical Package for the Social Science version 22 (IBM, 
Armonk, NY). Significant Time by Treatment interactions in Locomotor activity and maternal 
body weight were further analyzed with a priori pairwise comparisons to compare saline and 
polyI:C groups at each ordinal timepoint. Outliers were defined as having a performance metric 
falling more than 2 standard deviations from the mean and these were removed from analysis on 
a case by case basis.  
Sphericity violations were accounted for using the Greenhouse-Geisser adjustment. The 
use of one- and two-tailed tests is specified for each task. As mentioned, there is evidence that 
siblings are less variable than unrelated rats (Zorrilla, 1997; Lazic, 2013; Giovanoli and Meyer, 
2013b) so sibling effects were averaged to produce one value per litter. Bivariate correlations 
were used to analyze the relationships between maternal serum concentrations of inflammatory 
cytokines, other acute sickness measurements, and offspring behavioural task performance and 
the False Discovery Rate correction (Benjamini-Hochburg) was applied to grouped families of 
multiple comparisons. P values ≤0.05 were considered significant. 
 
3.4 Results 
3.4.1 Effects of polyI:C treatment on the pregnant dams and neonatal offspring 
PolyI:C treatment significantly affected acute maternal body weight changes measured as 
% change from baseline immediately prior to treatment (Figure 3.1 C). A repeated measures 
Analysis of Variance (ANOVA) revealed significant effects of Time (F(1.51,46.90)=56.17, 
p<0.001), Treatment (F(1,31)=30.52, p<0.001) as well as a Time by Treatment interaction 
(F(1.51,46.90)=16.91, p<0.001) in a repeated measures ANOVA. The polyI:C-treated dams had 
reduced body weight compared to the saline dams at 8 (p<0.01), 24 (p<0.001), and 48 h 
(p<0.001) after treatment. Body temperature was not significantly affected by treatment (p>0.05) 
although a main effect of time was observed (F(2.28,70.72)=8.91, p<0.001) and no time by treatment 
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interaction (p>0.05) (Figure 3.1 D). CXCL1 (t(16.04)=-3.41, p<0.01) and IL-6 (t(27)=-2.62, p<0.05) 
were significantly elevated in the polyI:C-treated dams (Figure 3.1 E). Neither CXCL2 nor TNF-
a were affected by maternal treatment (p>0.05). On PND 1, pups from polyI:C-treated dams 
weighed significantly less than the saline pups (Figure 3.1 F; t(31)=2.93, p<0.01) but there was no 
difference in litter size prior to culling to a maximum of 10 (saline = 11.94 ± 3.04; polyI:C = 
12.00 ± 3.35; t(31)=0.56, p>0.05). Pups were weighed once per week until weaning and the pup 
size difference was not seen at any other date (PND1: saline = 8.34 ± 0.16 g, polyI:C = 7.48. ± 
0.28 g; PND7: saline = 22.98 ± 0.45 g, polyI:C = 22.10 ± 0.38 g; PND14: saline = 41.98 ± 0.74 
g, polyI:C = 41.23 ± 0.76 g; PND21: saline = 75.85 ± 1.30, polyI:C = 75.40 ± 1.08 g) There was 
no significant difference in number of pups born per litter between the groups (polyI:C: 12.00 ± 
0.81, saline: 11.94 ± 0.96; p>0.05).  
 
3.4.2 Maternal polyI:C treatment failed to significantly affect startle or PPI  
 Startle responses to acoustic stimuli were assessed by measuring startle alone and PPI in 
saline (n=17 litters) and polyI:C offspring (n=17 litters). Startle to the 120 dB pulses alone 
decreased during the session (main effect of Time: F(1.14,36.56)=55.18, p<0.001; Figure 3.2 B) but 
no Treatment interaction was present. For prepulse trials with a 30 ms (short) interval, a main 
effect of Prepulse Intensity on PPI (F(1.42,45.47)=21.86, p<0.001; Figure 3.2 C) was found with no 
effect of treatment. Overall, PPI was greater at 12 dB compared to 3 and 6 dB (p<0.001). For 
trials with an 80 ms (long) prepulse-pulse interval, a main effect for Prepulse Intensity was found 
(F(1.28,34.62)=96.19, p<0.001; Figure 3.2 D) for PPI, but no effect of Treatment and no interaction. 
Overall, PPI increased with louder prepulses. 
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Figure 3.2: Effects of maternal polyI:C on acoustic startle and PPI in the male 
offspring. 
 
Figure 3.2: [A] Illustration of the apparatus used to measure PPI. In the top panel, no prepulse 
precedes the 120 dB tone and startle to the tone is high. The bottom panel highlights the typical 
reduction in startle response when the acoustic tone is preceded by prepulse of 3, 6, or 12 dB. [B] 
Offspring displayed a reduction in startle to the pulse alone trials with time, where each 
timepoint was significantly different than the others as indicated with asterisks. Pairwise 
comparisons showed higher startle reactivity in the polyI:C offspring compared to controls at the 
‘after’ timepoint, indicated by a pound symbol (#). [C] No effect of treatment on PPI was seen 
for trials with a 30 ms prepulse-pulse interval. A main effect of prepulse intensity was seen with 
12 dB producing greater PPI than 3 and 6 dB, indicated by asterisks. [D] No effect of treatment 
was seen for PPI on trials with an 80 ms prepulse-pulse interval. A main effect of prepulse 
intensity resulted in significantly greater PPI for trials with louder prepulses, indicated by 
asterisks. 
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3.4.3 PolyI:C offspring have reduced sociability 
 All offspring (n=16 saline litters, n=16 polyI:C litters) displayed a significant preference 
for the stranger cage (Figure 3.3 B; statistics not shown). PolyI:C offspring displayed a 
sociability deficit with less time exploring the stranger cage (t(30)=2.25, p<0.05; Figure 3.3 C). 
There was no significant difference in total (stranger plus empty cage) exploration (t(30)=2.03, 
p>0.05; Figure 3.3 C). 
 
3.4.4 Male polyI:C-treated offspring demonstrate heightened sensitivity to MK-801 
Locomotor data obtained from polyI:C (n=13 litters) and saline (n=17 litters) offspring 
were analyzed with repeated measures ANOVAs (Figure 3.3 E). Results revealed a main effect 
of Time (F(2.73,76.54)=7.67, p<0.001; Figure 3.3 E). While the main effect of Treatment failed to 
reach significance (F(1,28)=4.14, p=0.051),  a significant Time by Treatment interaction was 
observed (F(2.73,76.54)=2.87, p<0.05). Differences between the groups arose following MK-801 
injections where polyI:C offspring travelled greater distances than the saline counterparts 
(p£0.05).  
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Figure 3.3: The effects of maternal polyI:C treatment on social behaviour and 
MK-801 induced locomotion in male offspring. 
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Figure 3.3: [A] Schematic of the arena used for sociability testing. A black rectangular arena is 
divided into three sections where the two on the ends contain identical cages and are divided by a 
middle section. The stranger rat is held in one of the two cages and the test rat is free to explore 
the entire arena (for more detail, see Materials and Methods). [B] Social interaction behaviour 
represented as a discrimination ratio. [C] When exploration time is divided into total exploration, 
stranger exploration, or empty cage exploration, polyI:C offspring spend significantly less time 
interacting with the stranger cage. [D] Schematic representing a rat in an open arena where 
locomotor activity was tracked over the course of a 30-min habituation and an additional 120-
min following MK-801 injection. [E] PolyI:C offspring travelled a significantly greater distance 
than their saline counterparts following MK-801 treatment and the timepoints where a significant 
difference arose as determined by pairwise comparisons are indicated with asterisks.  
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3.4.5 PolyI:C offspring perform tactile object recognition memory but not crossmodal 
object recognition memory 
 All CMOR data is presented as a discrimination ratio (ExplorationNovel – 
ExplorationFamiliar / ExplorationTotal) for the first minute of the test phase (n=15 saline litters, 17 
polyI:C litters). Both groups demonstrated significant tactile object recognition memory (saline: 
t(14)=13.70, p<0.001; polyI:C t(13)=5.15, p<0.001; Figure 3.4 B). Neither group performed above 
chance exploration for visual memory (saline: t(14)=1.54, p>0.05; polyI:C t(13)=0.16, p>0.05). In 
the crossmodal phase, saline offspring show significant preference for the novel object 
(t(14)=2.50, p<0.05) while polyI:C do not (t(16)=0.21, p>0.05, Figure 3.4 B). There were no 
differences in total object exploration times between groups in the sample and test phases (Table 
3.1; statistics not shown). 
 
3.4.6 PolyI:C-treated offspring are significantly impaired in oddity discrimination 
When analyzed with a one sample t-test, saline (n=15 litters) offspring explored the odd 
object at a greater than chance level (t(14)=6.05, p<0.001) but polyI:C offspring (n=15 litters) did 
not (t(14)=1.20, p>0.05). When the groups were compared directly with an independent samples t-
test, saline offspring spent a significantly greater % exploration with the odd object compared to 
polyI:C offspring (t(28)=3.92, p<0.001; Figure 3.4 D). PolyI:C offspring spent a greater amount of 
time in total exploration of all objects compared to saline (saline: 67.81±4.78 s; polyI:C: 
84.08±5.46 s; t(28)=-2.24, p<0.05).  
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Figure 3.4: [A] Schematic of the CMOR battery including the visual (top), tactile (middle), and 
crossmodal (bottom) variants. Each variant contains a sample phase with two identical objects 
and a test phase with one familiar object from the sample phase plus one novel object (for more 
detail, see Materials and Methods). [B] Offspring of both treatment groups display tactile 
memory as indicated by a positive discrimination ratio >0. Saline and polyI:C rats failed to 
perform above chance at visual memory while only saline rats displayed crossmodal memory. 
[C] Schematic of the oddity arena and object layout. A white square arena contained three 
identical objects and one odd object. Rats were allowed to explore the arena for 5 min following 
three habituation sessions (for more detail, see Materials and Methods). [D] Spontaneous oddity 
preference was significantly impaired in the polyI:C offspring.  
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Table 3.1: Summary of CMOR task object exploration times in male 
offspring. 
 
 
 
 
 
 
 
Table 3.1: Total duration of object exploration during the sample and test phases for each 
variation of the CMOR task (mean ± SEM) for the adult offspring of dams treated with saline-or 
polyI:C on GD15 of pregnancy. No significant differences were seen in any groups during the 
sample or test phases. 
 
 
 
 
 
 
 
Treatment Task Phase Tactile Visual Crossmodal 
Saline Sample 44.97 ± 3.42 6.29 ± 0.45 44.68 ± 2.73 
Test 21.40 ± 1.52 3.40 ± 0.33 3.65 ± 0.55 
PolyI:C Sample 46.29 ± 2.36 7.10 ± 0.60 41.91 ± 2.67 
Test 19.64 ± 1.42 3.05 ± 0.40 3.10 ± 0.27 
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3.4.7 PolyI:C offspring have contrasting alterations in behavioural flexibility tasks 
 Saline (n=16 litters) and polyI:C (n=16 litters) offspring acquired the visual cue stage of 
OSST at the same rate (saline: 65.58 ± 10.93, polyI:C: 70.00 ± 12.20, p>0.05). The polyI:C 
offspring had significantly facilitated set shifting performance as indicated by fewer trials 
required to reach criterion (t(30)=2.73, p<0.05; Figure 3.5 B) and fewer total errors (t(30)=3.03, 
p<0.01; Figure 3.5C). Error breakdown revealed notable differences in perseverative errors with 
polyI:C offspring making marginally fewer (t(30)=1.90, p=0.07; Figure 3.5 C), as well as a 
significant reduction in regressive errors t(30)=2.04, p=0.05, but no difference in never reinforced 
errors (t(30)=1.85, p>0.05). There were no differences in reversal learning, or other parameters of 
the task, including the 20 reminder trials for visual cue discrimination included on the first day of 
set-shifting (additional statistics not shown). 
In the touchscreen PD/RL task, both groups learned the visual pairwise discrimination 
rule at the same rate with no differences in the number of days to criterion (DTC), total number 
of trials to criterion, total number of correction trials completed, or total number of errors made 
(statistics not shown). During reversal learning the polyI:C rats (n=17 litters) required 
significantly more DTC than the saline offspring (n=16 litters; t(31)=-2.19, p<0.05; Figure 3.5 C). 
No differences were seen for other measures. Reversal learning was then divided into early 
reversal (ER) which included all sessions before each rat achieved 50% correct during a single 
session, and late reversal (LR) which included all sessions afterwards (Bryce and Howland, 
2015). While there were no differences in ER, the polyI:C offspring required more DTC than the 
saline offspring in LR (t(31)=-2.68, p<0.05; Figure 3.5 E), required more TTC (t(31)=-2.14, 
p<0.05; Figure 3.5 F), completed more correction trials (t(31)=-2.04, p=0.05), and made more 
errors (t(31)=-2.38, p<0.05) than the saline offspring. 
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Figure 3.5: [A] Illustration of the operant chamber with lights (visual stimuli) and levers used in 
OSST. [B] PolyI:C and saline offspring performed visual cue learning at the same rate in OSST. 
PolyI:C offspring were significantly facilitated at set-shifting indicated by the fewer TTC 
required. The subsequent reversal learning was unaffected by maternal treatment. [C] PolyI:C 
offspring made fewer perseverative errors and fewer regressive errors during set-shifting 
compared to control rats. [D] Illustration of the touchscreen chamber and stimuli used in the 
PD/RL task. [E] Bar graphs displaying the number of days required to complete each stage of the 
PD/RL task. Saline and polyI:C offspring learned visual paired discrimination at equal rates 
whereas touchscreen reversal learning (RL) required significantly more days of training for 
polyI:C rats to reach criterion. When divided into early and late RL, no differences were seen in 
the early stage while polyI:C rats were significantly impaired in the late stage. [F] Comparisons 
of the total number of trials completed, correction trials completed, and errors made during the 
late RL phase showed that the polyI:C rats were impaired on all of these measures. 
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3.4.8 Correlations between maternal cytokines, indicators of maternal sickness, and 
offspring phenotypes 
Maternal serum concentrations of CXCL1 were related to acute weight changes in dams 
treated with polyI:C at 8 h post injection (r(17)=-0.51, p<0.05), but the effect was not robust when 
corrected for multiple comparisons (B-H p>0.05); see Table 3.2). No relationships were seen 
between CXCL1 levels and weight loss at 24 (r(17)=-0.22, p>0.05) or 48 hrs (r(17)=-0.23, p>0.05, 
see Figure 3.6) after injection, indicating greater weight loss in dams with the highest elevations 
of CXCL1. No weight-CXCL1 correlations were seen in the saline rats.  
Change in maternal body temperature at 8 h post treatment was related to neonatal pup 
mass in polyI:C-treated rats (r(17)=0.51, p<0.05) indicating a decrease in dam body temperature 
was related to the delivery of smaller pups; however this effect was not robust following 
adjustment for multiple comparisons (B-H p>0.05); see Table 3.2). No relationship was seen in 
saline rats. Dam weight change 48 h after polyI:C treatment was positively correlated with pup 
size at birth (r(17)=0.60, p<0.05; Figure 3.6), indicating a relationship between greater sustained 
weight loss in the dams and the delivery of smaller pups which was robust to the multiple 
comparison adjustment (B-H p<0.05); see Table 3.2). No relationship was found in the saline 
group. Pup mass at birth was then negatively correlated with oddity discrimination performance 
(percent odd object exploration) in the polyI:C offspring only (r(15)=-0.59, p<0.05), interestingly 
showing smaller pups at birth had greater preference for the odd object despite reduced oddity 
preference as a group, although this effect is not seen following adjustment for multiple 
comparisons (B-H p>0.05); see Table 3.2). Oddity preference was also not correlated to pup size 
in saline offspring. Other behaviour effects were examined for relationships to sickness effects 
and maternal serum cytokines but no other relationships were found (Representative results 
presented in Figure 3.6 A; Bivariate correlation data of distance travelled by polyI:C offspring 
following MK-801 administration with CXCL1: r(13)=0.34, p>0.05; Dam weight change 8 h: 
r(13)=0.30, p>0.05; Dam weight change 48 h: r(13)=0.23, p>0.05; Pup size: r(13)=-0.07, p>0.05; 
and see Table 3.2 for B-H adjusted p-values); Figure 3.6 B; Trials to criterion in late reversal 
learning from PD/RL task; CXCL1: r(17)=-0.30, p>0.05; Dam weight change 8 h: r(17)=0.003, 
p>0.05; Dam weight change 48 h: r(17)=-0.04, p>0.05; Pup size: r(17)=-0.05, p>0.05; and see 
Table 3.2 for B-H adjusted p-values). 
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Figure 3 .6: Representative plots indicating maternal cytokine levels did not 
correlate with male offspring behaviour outcomes. 
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Figure 3.6: [A] Overlaid regression plots showing the relationships between acute maternal 
weight loss at 48 hours post polyI:C treatment and pup size, maternal CXCL1 concentration and 
distance travelled following MK-801 administration in polyI:C dams and offspring. Locomotor 
activity, used as an indicator of sensitivity to psychotomimetic compounds was increased in the 
polyI:C offspring, but no relationship to the measured indicators of inflammation or sickness in 
the pregnant dams was found. Weight change in the pregnant dams 48 h after polyI:C treatment 
was significantly correlated with pup size at birth (r(17)=0.60, p<0.05). Serum CXCL1 was not 
related to weight change at 48 h (r(17)=-0.23, p>0.05). Distance travelled by the offspring in the 
locomotor task was not related to any of these (CXCL1: r(13)=0.34, p>0.05; Weight change 8 h: 
r(13)=0.30, p>0.05; Weight change 48 h: r(13)=0.23, p>0.05; Pup size: r(13)=-0.07, p>0.05; see also 
Table 3.2). [B] Overlaid regression plots showing the relationships between acute maternal 
weight loss at 48 hours post polyI:C treatment and pup size, maternal CXCL1 concentration and 
trials to criterion in late reversal learning in polyI:C dams and offspring. Late reversal learning 
was chosen as a representative cognitive behaviour test that was altered in the polyI:C offspring 
yet was not related to the measured indicators of inflammation or sickness in the pregnant dams 
(CXCL1: r(17)=-0.30, p>0.05; Weight change 8 h: r(17)=0.003, p>0.05; Weight change 48 h: 
r(17)=-0.04, p>0.05; Pup size: r(17)=-0.05, p>0.05; see also Table 3.2).  
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3.5 Discussion 
This study describes the acute effects of IV administration of polyI:C to pregnant rats and 
relationships between individual maternal serum cytokine concentrations and behavioural 
outcomes in the adult offspring. PolyI:C administration elevated maternal serum concentrations 
of CXCL1 and IL-6, and caused weight loss. We did not observe an effect of polyI:C treatment 
on maternal body temperature at 8, 24, or 48 h after treatment, in accordance with several studies 
(Howland et al., 2012; Sangha et al., 2014; Ballendine et al., 2015), but not others (Zhang et al., 
2012). Pups of polyI:C-treated dams weighed less than controls on PND1. In young adulthood, 
offspring behaviours were assessed using a behaviour battery related to symptoms of 
psychopathology. PolyI:C offspring demonstrated behavioural changes in most tasks and serum 
cytokine levels in the pregnant dams correlated with weight loss, and bivariate correlations link 
this with offspring birth weight, however these effects appear to lack strong relationships with 
long-term offspring behaviour effects.  
One potential limitation of our results is the use of timed pregnant rats shipped to our 
facility on GD7. The effects of shipment during pregnancy on the dams and unborn offspring are 
a valid concern (Stewart and Kolb, 1988; Ogawa et al., 2007; Kuwagata et al., 2009; Meyer et 
al., 2009; Moriyama et al., 2013); nonetheless, the behavioural effects in the present cohort are 
comparable to those from in-house bred rat offspring, particularly on MK-801 induced 
locomotor behaviour in the males (Zuckerman and Weiner, 2005; Vorhees et al., 2012). Timed-
pregnant dams have been used in numerous similar studies that examine the roles of adverse 
gestational conditions and long-term effects on the offspring and constitute valuable 
contributions to the literature (Lodge and Grace, 2001; Du and Grace, 2013, 2016a; Van den 
Eynde et al., 2014)   
 
3.5.1 Effects of polyI:C on pregnant dams and neonatal offspring 
The double-stranded polyI:C molecule is recognized by the innate immune system in a 
similar manner as dsRNA via TLR3. Subsequent nuclear factor kB-dependent signaling is best 
known for the induction of interferons; however, elevated serum concentrations of other immune 
proteins including IL-6, CXCL1, TNF-a and IL-1b have been reported (Alexopoulou et al., 
2001; Ballendine et al., 2015). Our results corroborate previous research with significant 
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elevations of IL-6 and CXCL1 in maternal serum 3 h post polyI:C injection (Ballendine et al., 
2015). A discrepancy exists in the effects of polyI:C on TNF-a as previous research reports 
Long Evans rats, as well as Wistar rats that lost weight post treatment, showed elevated serum 
TNF-a (Missault et al., 2014; Ballendine et al., 2015). However, the polyI:C-treated Sprague 
Dawley dams did not have significantly elevated TNF-a levels in the present cohort. Elevated 
TNF-a is a well-established consequence of systemic inflammation when induced by polyI:C or 
other means such as LPS (Patterson, 2009; Mattei et al., 2014; Missault et al., 2014; Ballendine 
et al., 2015), although observance appears to depend on timing. A previous study demonstrated 
elevated TNF-a 2 h post LPS treatment which returned to control levels by 4 h. Both 3 and 6 h 
time points have been used by other groups, and show mixed results (Smith et al., 2007; Cui et 
al., 2009; Missault et al., 2014; Ballendine et al., 2015). Given these variable results and the 
necessity of using a single time point in the present study, we cannot be certain whether TNF-a 
levels reached significant elevation at any time point in the polyI:C treated dams. Weight loss 
following polyI:C treatment is robust in rats (Wolff and Bilkey, 2010; Piontkewitz et al., 2011b; 
Howland et al., 2012; Zhang et al., 2012; Missault et al., 2014; Sangha et al., 2014; Ballendine et 
al., 2015; Vorhees et al., 2015), consistent with established rodent sickness behaviours 
(Cunningham et al., 2007; Palin et al., 2009). We found that higher CXCL1 levels may be related 
to increased weight loss 8 h after polyI:C treatment although a greater sample size is needed to 
reduce the risk of type 1 error. 
Maternal polyI:C-treated dams delivered pups with significantly lower body weight on 
PND1 compared to controls. While previous research in Long Evans rats did not show this effect 
(Howland et al., 2012; Ballendine et al., 2015), low birth weight in humans is a risk factor for the 
development of psychopathologies including schizophrenia, affective psychosis, autism spectrum 
disorders, attention deficit/hyperactivity disorders, and impulsivity with conduct disorders (Jones 
et al., 1998; Moilanen et al., 2010; Moore et al., 2012; Grissom et al., 2014; Laurens et al., 2015; 
Van Lieshout et al., 2015; Mathewson et al., 2017). Increased maternal IL-6 during pregnancy is 
associated with lower birth weights in humans (Atta et al., 2016) and our correlation data 
revealed a robust relationship between sustained maternal weight loss (48 h) and lower offspring 
birth weight in a rat model as well.  
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3.5.2 PolyI:C-treated offspring have behaviour abnormalities associated with 
psychopathology 
 PPI is commonly used to assess sensorimotor gating which is altered in many psychiatric 
conditions and can be disrupted through the administration of DAergic and glutamatergic 
agonists. Earlier studies that assessed PPI in models of MIA showed PPI disruptions (reviewed 
in Meyer et al., 2009), however more recent work has failed to reproduce this effect (Missault et 
al., 2014; Van den Eynde et al., 2014; Vorhees et al., 2015). In agreement with several recent 
papers, our data showed no appreciable effect of MIA on PPI in the offspring.     
PolyI:C offspring showed heightened sensitivity to MK-801. This finding replicates 
previous studies which report hyperlocomotion following MK-801 (Zuckerman and Weiner, 
2005; Howland et al., 2012; Giovanoli et al., 2013) although some other studies have observed 
hypolocomotion (Vorhees et al., 2012, 2015; Missault et al., 2014). As the administration of 
NMDA receptor antagonists increases striatal DA efflux, exaggerated locomotor activity 
following MK-801 may relate to the positive symptoms of the disorder and increased striatal DA 
in schizophrenia patients (Usun et al., 2013; Laruelle, 2014).  
Abnormal social functioning is seen in many neurological conditions (Kennedy and 
Adolphs, 2012) and we demonstrated a sociability deficit in adult polyI:C-treated offspring. 
Illnesses with a neurodevelopmental component like autism and schizophrenia have social 
deficits as a central feature, which is fitting with our finding that an early developmental insult 
impacted this behaviour domain. Normal social functioning is dependent on neurodevelopmental 
processes as shown by the particularly deleterious effects of early life insult (Lee and Green, 
2016). Early life deletion of the NR1 subunit, but not post adolescent deletion in mice results in 
impaired social preference and early childhood PFC damage in humans is associated with 
impaired sociability (Anderson et al., 2000). The network of regions with known roles in social 
cognition and social behaviours is diffuse, and include the PFC as well as the temporal lobe and 
amygdala, involved in facial and emotional recognition respectively, both of which are known to 
be altered in autism and are believed to contribute to the characteristic social deficits (Kennedy 
and Adolphs, 2012). The developmental effects of maternal inflammation are broad, and the 
impairments seen in our study could be related to the impact of developmental immune insult in 
one or several of these areas. NMDA receptor hypofunction induced by pharmacologic, genetic, 
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and optogenetic means in mice disrupts preference for a stranger conspecific, and there is prior 
evidence for NMDA receptor disruption in MIA offspring as well as structural changes in the 
brain regions required for typical social proficiency, particularly the PFC (Samuelsson et al., 
2006; Piontkewitz et al., 2011a; Lee and Green, 2016).     
 
3.5.3 PolyI:C administration during pregnancy results in altered performance in cognitive 
behaviour tasks in the adult offspring 
 The CMOR task assesses multisensory integration and the ability to form complex, 
multimodal representations of stimuli (Cloke et al., 2015; Jacklin et al., 2016). Previous research 
showed rats are capable of tactile-visual crossmodal memory indicated by greater visual 
exploration of a novel object compared to an object preciously experienced tactilely (Winters 
and Reid, 2010). The role of the perirhinal cortex (PRh) and posterior parietal cortex (PPC) in 
visual and tactile recognition memory respectively is well known (Zhou and Fuster, 1997; 
Buckley and Gaffan, 1998; Murray and Richmond, 2001; Buckley, 2005; Albasser et al., 2011), 
although lesion studies have shown bilateral ablation of the PFC (medial PFC and OFC) results 
in selective disruption of CMOR while leaving the control visual-visual and tactile-tactile 
memory tasks intact. More precise lesions reveal the necessary role of the OFC in mnemonically 
demanding situations (Winters and Reid, 2010; Reid et al., 2014; Cloke et al., 2015). We have 
previously demonstrated polyI:C offspring show specific deficits in CMOR in polyI:C offspring 
male Long-Evans rats (Author references to be included following peer review). The present 
study with Sprague-Dawley rats found a deficit in both visual and crossmodal domains of the 
task, effects suggesting maternal inflammation altered function of the OFC and PRh.        
 Oddity discrimination is a recently developed task that may assess the function of the 
ventral visual stream (VVS) and temporal lobe memory system in a spontaneous exploration 
paradigm. The Perceptual-Mnemonic/Feature-Conjuction neural network model suggests the 
PRh is situated at the most distal end of the VVS where it supports complex representations of an 
object comprised of simpler visual components which are hierarchically maintained in the more 
caudal regions of the VVS (Murray and Bussey, 1999; Bussey and Saksida, 2005; Bussey et al., 
2005; Bartko et al., 2007a). Visual learning and memory was highlighted as one of seven 
cognitive domains impaired in schizophrenia (Young et al., 2009), and inactivation of the PRh 
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impairs oddity discrimination in rodents (Bartko et al., 2007a), while structural abnormalities in 
the temporal lobe are seen in patients with schizophrenia as well as animal models including 
MIA (Piontkewitz et al., 2012). The oddity discrimination task reveals that polyI:C-treated 
offspring are impaired at performing a non-mnemonic visual discrimination with no delay, 
suggesting altered function of the VVS which feeds into the temporal lobe memory system, 
including the PRh. We observed a possible relationship where smaller pups had greater oddity 
preference, but this was not robust when controlled for multiple comparisons. A suggestion for 
resilience could be that small offspring received greater maternal care. A previous study [Author 
reference] found no changes to maternal behaviour in dams treated with polyI:C, however that 
cohort did not show a difference in pup size which limits the ability to make direct comparisons.   
 Cognitive flexibility enables the direction of appropriate behavioural responses following 
changing environmental demands. Set-shifting and reversal learning are related, yet dissociable 
behaviours used to measure cognitive flexibility (Floresco et al., 2009). In rodents, the operant 
set-shifting and reversal learning task (OSST) has been heavily studied and assesses both of 
these measures following the learning of a simple rule. Set-shifting requires inhibition of the 
initial behaviour response pattern and adoption of a new strategy (extradimensional shift, EDS), 
and subsequently reversal learning requires performing the opposite behaviour within the same 
dimension as the previous stage (intradimensional shift, IDS). In the paradigm used for this 
study, rats learned to press a lever indicated by an illuminated light (visual cue), strategy set-shift 
to press either the left or right lever regardless of visual stimuli (spatial cue), and finally reverse 
their behaviour to press the opposite lever (Floresco et al., 2008, 2009; Thai et al., 2013; 
Ballendine et al., 2015; Brady and Floresco, 2015). We used a similar procedure in touchscreen 
operant chambers where rats learn to select one of two visual stimuli on a screen (pairwise 
discrimination) followed by reversal which required selection of the opposite stimuli (Bryce and 
Howland, 2015). Set-shifting behaviour is known to depend on the mPFC while reversal is 
orbito-frontal dependent (Floresco et al., 2009).  
We observed a facilitation of performance in the set-shifting portion of OSST, 
characterized by less perseveration, less regression, and more rapid acquisition of a novel 
behaviour strategy with no significant effect on RL. These results are inconsistent with some 
prior studies (Zuckerman and Weiner, 2005; Savanthrapadian et al., 2013). Impaired strategy set-
  
91 
shifting has been reported in the offspring of polyI:C-treated Long Evans rats (Zhang et al., 
2012; Ballendine et al., 2015). Another previous study however, reports subchronic ketamine 
administration prior to OSST resulted in reduced perseveration during set-shifting, however this 
was accompanied with impaired learning of the initial discrimination and impaired reversal 
learning with increased perseveration when the present study reports no effect on initial cue 
learning or RL in this task paradigm (Floresco et al., 2009). In further contrast, polyI:C offspring 
were impaired in late reversal in the touchscreen PD/RL task. The specificity of impairment to 
late reversal suggests the polyI:C-treated offspring have difficulty identifying the new rule once 
they have ceased perseverating during early reversal learning, and impaired reversal learning in 
polyI:C offspring has been previously reported in spatial memory dependent tasks 
(Savanthrapadian et al., 2013, but see Zuckerman and Weiner, 2005). The role of DA in 
cognitive flexibility and behaviour shifting is complex, where previous work suggests PFC DA 
depletion can facilitate EDS, yet blockade of D1 and D2 in the mPFC is known to impair with a 
specific increase in perseveration (Roberts et al., 1994; Ragozzino, 2002b; Floresco et al., 2006). 
The complex role of DA in cognitive flexibility is seen where the administration of AMPH in 
rats results in impairments in set shifting, or impaired reversal learning with no effect on set 
shifting when compared across several studies (Weiner and Feldon, 1986; Russig et al., 2003; 
Fletcher et al., 2005). Abnormalities in DA transmission have been reported in MIA models 
including increased DA turnover and increased D2 binding (Ozawa et al., 2006). These results 
generally support that MIA results in offspring abnormalities in PFC DA.       
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Table 3.2: Grouped bivariate correlation data.  
Grouping Correlation Treatment Uncorrected 
p-value 
B-H Adjusted 
p-value 
Maternal-
Maternal 
CXCL1-Dam Weight 8h Saline 0.28 0.40 
PolyI:C 0.04* 0.19 
CXCL1-Dam Weight 24h Saline 0.063 0.19 
PolyI:C 0.40 0.40 
CXCL1-Dam Weight 48h Saline 0.30 0.40 
PolyI:C 0.38 0.40 
Maternal-
Neonate 
Dam Temp 8 h-Pup Mass 
PND1 
Saline 0.36 0.36 
PolyI:C 0.04* 0.07 
Dam Weight Loss 48h-Pup 
Mass PND1 
Saline 0.35 0.36 
PolyI:C 0.01* 0.04* 
Neonate-
Behaviour 
Pup Mass-% Oddity 
Preference  
Saline 0.16 0.32 
PolyI:C 0.02* 0.08 
Pup Mass-Locomotor PolyI:C 0.81 0.81 
Pup Mass-TTC LR PolyI:C 0.25 0.33 
Maternal-
Behaviour 
Dam Weight 8h-Locomotor PoyI:C 0.32 0.64 
Dam Weight 48h-
Locomotor 
PolyI:C 0.46 0.69 
Dam Weight 8h-TTC LR PolyI:C 0.99 0.99 
Dam Weight 8h-TTC LR PolyI:C 0.89 0.99 
CXCL1-Locomotor PolyI:C 0.26 0.64 
CXCL1-TTC LR PolyI:C 0.25 0.64 
 
Note: TTC RL – Trials to Criterion Late Reversal; Locomotor = distance travelled following 
MK-801 administration in the locomotor activity task 
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Table 3.2: Summary of the notable correlations between maternal and offspring measures taken 
in the present study. Correlations were grouped into 4 families to apply the B-H adjustment for 
multiple comparisons. The unadjusted p-values (a=.05) are presented alongside the False 
Discovery Rate (Benjamini-Hochburg) corrected p-values. Significance in each column is 
indicated with an asterisk (*). 
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3.5.4 Maternal serum cytokine levels following polyI:C treatment are not strongly related 
to offspring behaviour outcomes 
 Prospective human studies suggest elevated cytokines in the maternal serum during 
pregnancy contribute to an increased risk of developing schizophrenia (Brown et al., 2004a, 
2004b; Brown, 2012, 2006; Ellman et al., 2010). In one sample, human IL-8 (and not IL-6, TNF-
a, or IL-1β) was elevated in the serum of pregnant women whose offspring went on to develop 
schizophrenia (Brown et al., 2004) and correlated with brain changes in the offspring (Ellman et 
al., 2010). In rodent models of MIA, maternal IL-6 released in response to MIA is necessary for 
schizophrenia-like symptoms in the mouse model (Smith et al., 2007) and administration of IL-6 
alone to pregnant rats is sufficient to cause behavioural changes in the offspring (Samuelsson et 
al., 2006). Ballendine and colleagues (2015) also used an antagonist (G31P) for CXCL1 
receptors (CXCR1/R2) in an attempt to block the behavioural effects of polyI:C in Long Evans 
rats with mixed results. We sought to determine the relationship between individual maternal 
serum cytokine levels following an inflammatory insult and offspring phenotype to better 
understand the mechanisms underlying the behavioural effects of MIA (Meyer, 2014). Cytokines 
play diverse roles in brain development and affect functions such as induction and renewal of 
neuroepithelial cells which form scaffolding for migrating neurons, and neuronal migration (see 
Deverman and Patterson, 2009; Stolp, 2013 for comprehensive reviews). IL-6 influences fate 
switching and cell differentiation in development while IL-6- and CXCL1-related signaling 
influences brain development by regulating neurogenesis, maturation, and survival (Ip, 1998; 
Nakashima et al., 1999; Cho and Miller, 2002; Ragozzino, 2002a; Gregg and Weiss, 2005; 
Deverman and Patterson, 2009; Arrode-Brusés and Brusés, 2012; Garay et al., 2013; Stolp, 
2013).  
In our study, the offspring of rats that experienced an immune challenge in pregnancy 
displayed a variety of behaviour abnormalities that are associated with psychiatric and 
neurological disease, yet individual maternal serum cytokines measured acutely following 
treatment with polyI:C were not strongly related to these effects. The altered behaviours are 
known to depend largely on overlapping brain regions including the mPFC, OFC, striatum, 
amygdala, perirhinal cortex and post parietal cortex. Positive symptoms are often attributed to 
hyperactivity of the mesolimbic DA system while hypoactivity of mesocortical DA is linked to 
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negative and cognitive symptoms (Abi-Dargham and Moore, 2003; Laruelle et al., 2003; 
Winterer and Weinberger, 2004; Guillin et al., 2007; Jarskog et al., 2007; Meyer and Feldon, 
2009). Mechanisms by which LPS- and polyI:C-induced inflammation during pregnancy may 
influence development have been explored, and inflammatory events can lead to increased TH in 
the NAc of offspring, elevated DA, and reduced DA receptors in the PFC (Bacopoulos and 
Bhatnagar, 1977; Borrell et al., 2002; Romero et al., 2007; Meyer et al., 2008a, 2008b; Meyer 
and Feldon, 2009). These DA-related changes may be associated with increased IL-6 in 
development (Okubo et al., 1997a, 1997b; Meyer et al., 2008b, 2008a; Meyer and Feldon, 2009). 
Cognitive impairment is also linked to NMDA receptor signaling (Moghaddam et al., 1997; 
Moghaddam and Adams, 1998; Vinson and Conn, 2012). IL-6 elevations in late gestation 
increases NR1 expression in the adult hippocampus, although polyI:C induced maternal 
inflammation produced the opposite effect in the offspring (Samuelsson et al., 2006). The effort 
to identify individual causal inflammatory mediators may be challenging due to the diffuse 
effects of systemic inflammation in pregnancy. Multiple inflammatory and anti-inflammatory 
signaling pathways are initiated by TLR3 stimulation and the effects on neurodevelopment may 
still not be fully appreciated. We found significant correlations between acute serum CXCL1 and 
acute maternal weight loss although these failed to translate to the broad offspring behaviour 
abnormalities observed. Thus, our results suggest measures other than levels of individual 
circulating maternal inflammatory cytokines may be more informative of long-term behavioural 
outcomes of the offspring. For example, future experiments including multivariate analyses of an 
array of maternal inflammatory markers may provide more valuable predictive information about 
offspring behaviour. 
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CHAPTER 4 
MATERNAL IMMUNE ACTIVATION DURING PREGNANCY ALTERS 
THE BEHAVIOUR PROFILE OF FEMALE OFFSPRING OF SPRAGUE-
DAWLEY RATS3 
4.1 Abstract 
Sex differences are documented in psychiatric and neurological disorders, yet most 
preclinical animal research has been conducted in males only. There is a need to better 
understand of the nature of sex differences in brain disease in order to meet the needs of 
psychiatric patients. We present the behaviour profile of adult female offspring produced using a 
maternal immune activation model where pregnant rats receive an immune stimulant and the 
offspring typically show various abnormalities consistent with psychiatric illnesses such as 
schizophrenia and autism. The results in female offspring were compared to a previously 
published cohort of their male siblings (Lins et al. 2018). We examined PPI, sociability, MK-801 
induced locomotor activity, CMOR, and oddity discrimination; behaviours relevant to the 
positive, negative, and cognitive symptoms of schizophrenia. No between-treatment differences 
in PPI or locomotor activity were noted. Tactile memory was observed in the control and treated 
female offspring, visual recognition memory was deficient in the polyI:C offspring only, and 
both groups lacked crossmodal recognition. PolyI:C offspring were impaired in oddity 
preference and had reduced preference for a stranger conspecific in a sociability assay. Systemic 
maternal CXCL1, IL-6, and TNF-a levels at 3 h post polyI:C treatment were determined, but no 
relationship was found between these cytokines and the behaviour seen in the adult female 
offspring. Overall, female offspring of polyI:C-treated dams display an array of behaviour 
 
3 Lins BR, Marks WN, Zabder NK, Greba Q, Howland JG (2019) Maternal immune activation during pregnancy 
alters the behaviour profile of female offspring of Sprague Dawley rats. eNeuro.0437-18.2019  
 
Lins organized and led the experiments, collected and analyzed data, and co-wrote the manuscript; Marks, Zabder, 
and Greba collected behaviour data and contributed to data scoring and data analysis; Howland supervised the 
experiments and co-wrote the manuscript. This manuscript is peer-reviewed and published. 
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abnormalities relevant to psychiatric illnesses such as schizophrenia similar to those previously 
reported in male rats. 
 
4.1.1 Significance statement 
 Sex differences are documented in mental illness and include differences in disease 
prevalence, symptom presentation, and response to treatment. Despite this, the majority of 
animal research has been conducted in males only. This study demonstrates the effects of 
maternal inflammation in pregnancy on long-term behaviour outcomes in female offspring, 
revealing a behaviour profile similar to male counterparts. We use a uniquely broad behaviour 
testing battery to show that female offspring from inflammation-exposed pregnancies display an 
array of abnormal behaviours related to symptom domains of schizophrenia, similar to their male 
littermates. Maternal cytokine concentrations did not correlate with the severity of these 
behaviour changes suggesting other factors may better indicate long-term disease risk in the 
offspring.  
 
4.2 Introduction  
 Adverse events in utero and early life are linked to the development of psychiatric illness. 
Inflammation during pregnancy is associated with increased risk of psychiatric illnesses 
including autism, schizophrenia, and major depression in the offspring (Patterson, 2011; Jiang et 
al., 2016; Brown and Meyer, 2018; Gustafsson et al., 2018). The relationship between 
inflammation and psychopathology is often studied with models of maternal immune activation 
(MIA) where an immune stimulant such as polyI:C is administered to pregnant rodents 
(Piontkewitz et al., 2012; Brown and Meyer, 2018). Offspring of treated dams display 
behavioural and neuropathological profiles consistent with psychiatric illness in humans (Brown 
and Meyer, 2018). The majority of MIA studies focus on the male offspring or lack 
consideration of sex as a biological variable despite policies by the National Institute of Health 
(NIH) and other grant funding agencies that require the examination of sex as a factor in 
biomedical research (Clayton and Collins, 2014; Coiro and Pollak, 2019). This is particularly 
concerning for studies of MIA given the sex differences noted in the human psychiatric disorders 
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associated with MIA as a risk factor (Klein and Corwin, 2002; Arad et al., 2017; Brown and 
Meyer, 2018; Coiro and Pollak, 2019). 
 Previous studies of the effects of MIA during pregnancy in rats has resulted in extensive 
knowledge of behaviour effects in male offspring. Maternal treatment with polyI:C during 
gestation results in male offspring with reduced working memory span capacity, dysregulated 
fear responses, and impaired associative (object-in-place) and crossmodal memory while simple 
object recognition and object-location memory are largely unaffected, although impaired novel 
context recognition has also been reported (Wolff and Bilkey, 2010; Wolff et al., 2011; Sangha 
et al., 2014; Ballendine et al., 2015; Murray et al., 2017). Other studies on adult male offspring 
from polyI:C-treated pregnancies have found reduced levels of GAD67 in the dorsal 
hippocampus which appears to coincide with a loss of coherence with the mPFC and correlate 
with PPI deficits (Dickerson et al., 2010, 2013, 2014; Wolff and Bilkey, 2010). PPI has been 
studied extensively in MIA rat models, yet the results are mixed with several studies showing 
deficits, no effect, or indicate the timing and type of inflammatory agent determines PPI 
outcomes (Fortier et al., 2004, 2007, Wolff and Bilkey, 2008, 2010; Ballendine et al., 2015; 
Hadar et al., 2015). Other studies with offspring of both sexes or sex unspecified report mixed 
results on PPI as well (Howland et al., 2012; Klein et al., 2013; Van den Eynde et al., 2014; 
Vorhees et al., 2015).  Further MIA studies including male and female rat offspring report altered 
behaviours such as spontaneous hypolocomotion (Van den Eynde et al., 2014), latent inhibition 
(Zuckerman and Weiner, 2003, 2005; Zuckerman et al., 2003), and reduced startle (Van den 
Eynde et al., 2014). Other studies show no change in spontaneous locomotion but reduced 
sensitivity to the hyperlocomotive effects of AMPH treatment (Bronson et al., 2011) or 
hyperlocomotion following AMPH (Zuckerman et al., 2003; Vorhees et al., 2012) or MK-801 
(Zuckerman and Weiner, 2005; but see also Howland et al., 2012). In some tasks, male rat 
offspring of MIA dams show greater impairments in tasks such as operant conditioning-based set 
shifting and earlier onset of latent inhibition deficits, reflecting the earlier onset of abnormal 
developmental trajectories (Piontkewitz et al., 2011a; Zhang et al., 2012; Patrich et al., 2016). 
While male MIA rats have impaired object-in-place memory, neither control nor MIA females 
perform this task, possibly reflecting sex-specific differences in baseline task performance 
(Howland et al., 2012; Ballendine et al., 2015). In a related rat model of MIA, inflammation 
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induced in lactating dams, resulting in the development of distinct sex-dependent phenotypes in 
the suckling offspring, where the females offspring displayed a depressive phenotype and male 
offspring displayed a psychiatric phenotype (Arad et al., 2017). Taken together, the complicated 
and often conflicting results from these studies demonstrate the need for sex by treatment 
analyses in future MIA research (Coiro and Pollak, 2019; Kentner et al., 2019). 
The present study aims to contribute to the necessary evaluation of sex effects in the MIA 
model by highlighting female offspring behaviour outcomes in tasks related to the symptoms of 
schizophrenia and analyzing these results in conjunction with previously published results in 
their male littermates. The male MIA offspring from the same cohort display hyperlocomotion 
following MK-801 administration, reduced sociability, impaired visual recognition memory, 
impaired oddity preference, altered set shifting, and facilitated reversal learning. Using a 
prospective design, we showed that these behavioural changes did not correlate with acute 
elevations in a selection of maternal serum cytokines collected 3 h post polyI:C treatment (Lins 
et al., 2018). We hypothesized that behaviour abnormalities would be less severe or absent in 
early adulthood in accordance with previous literature (Piontkewitz et al., 2011a; Zhang et al., 
2012; Patrich et al., 2016). We also correlated behaviour of the female offspring with the acute 
cytokine concentrations from prospectively collected maternal blood and other measurements 
related to polyI:C treatment to assess relationships between acute maternal cytokine levels, other 
treatment effects, and offspring behaviour including an oddity discrimination task not previously 
examined in female rats (Lins et al., 2018). 
  
4.3 Materials and methods 
4.3.1 Animals 
Timed-pregnant Sprague-Dawley rats (n=43, Charles River, Quebec) arrived at the animal 
holding facility on GD7. Primiparous dams were mated between 8 – 10 weeks of age and the 
presence of a vaginal plug considered GD1. Sires were a minimum of 10 weeks of age at time of 
mating and their specific breeding history (number of matings, successful pregnancies, mating 
design, or time between matings) was not guaranteed by the provider. Upon arrival, pregnant 
dams were housed individually in standard ventilated (395 x 346 x 227 mm) polypropylene 
cages. Food (Purina Rat Chow) and water were available ad libitum. The colony room is 
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temperature, but not humidity, controlled (21°C) and maintained on an automatic 12/12 h 
light/dark cycle with lights on at 07:00 h. Dams were undisturbed until they received treatment 
on GD15. Behaviour testing was conducted on adult female offspring (total n=71). All 
procedures were carried out during the light phase and were conducted in accordance with the 
Canadian Council on Animal Care guidelines for humane animal use and were approved by the 
University of Saskatchewan Animal Research Ethics Board. 
 
4.3.2 Maternal treatments and blood samples 
Maternal treatment followed previously established protocols in Long-Evans and Sprague 
Dawley rats (Howland et al., 2012; Zhang et al., 2012; Sangha et al., 2014; Lins et al., 2016; 
Paylor et al., 2016; Lins et al., 2018; Figure 4.1 A). Additional information is included to 
improve the scientific rigor of the MIA model as discussed by Kentner and colleagues (2018). 
These details also apply to our recent companion publication which tested male rat offspring 
from the same litters as described here (Lins et al. 2018).  
Dam baseline weight (mean = 346.5 g) and rectal temperature were recorded on GD15 
immediately prior to anesthesia with isoflurane (5% induction, 2.5% maintenance, for 
approximately 3 minutes) to receive a single intravenous (i.v.) tail vein injection of 0.9% saline 
or polyI:C (4 mg/kg, high molecular weight, InVivoGen, San Diego, CA, USA, thawed from 
storage at -20 °C). Dams were anesthetized a second time (as above, approximately 10 minutes) 
3 h following initial treatment and a blood sample (<1.5 mL total and <6% total blood volume) 
was collected using a sterile catheter (BD Insyteä Autogaurdä, 24 GA 0.75 IN 0.7 x 19 mm, 
REF 381412) from the opposite tail vein used to inject polyI:C or saline. Warm saline was 
administered once following initial treatment (3 mL), and a second time after blood collection 
(equal in volume to the collected blood sample). Blood samples coagulated at room temperature 
for 1 h then centrifuged at 10,000xG for 5 min and serum was stored at -80 °C until analysis. 
ELISAs for CXCL1 (GROα/KC; R&D Systems, Minneapolis, MN), CXCL2 (GROβ/MIP-2; 
R&D Systems), IL-6 (PeproTech, Rocky Hill, NJ), and TNF-a (PeproTech) were performed 
according to the manufacturer’s instructions and these results are published elsewhere (Lins et 
al., 2018).  
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Dams had weight and rectal temperature measured 8, 24 and 48 h post treatment and then 
were undisturbed for the remainder of their pregnancy. Treatment was administered to n=43 
dams, but 8 developed hypothermia and were euthanized within 48 h of treatment. Four 
additional dams experienced body temperature below 36°C but lacked additional indicators of 
severe sickness or suffering and these were given access to a warming pad on their home cage 
until their temperature returned to normal (within 24 h). 2 dams did not produce viable litters and 
2 litters had no female offspring. Ultimately, offspring from a total of n=31 litters were included 
(n=16 polyI:C treated dams and n=15 saline treated dams, Table 4.1). On postnatal day (PND) 1, 
litters were weighed, sexed, and culled to a maximum of 10 (4 females where possible). Standard 
husbandry included cage changes twice per week with one additional cage change during 
PND14-21. Prior to weaning, all cage changes, feeding, and monitoring of pups was performed 
by a single investigator to minimize disturbances. On PND23, pups were weaned and housed in 
same-sex sibling groups of 2 or 3 in standard housing as previously described with a PVC tube 
for enrichment.  
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Figure 3.1: Timelines of maternal treatments and female offspring behaviour 
testing. 
 
Figure 4.1: [A] Schematic detailing the time line of maternal treatment and initiation of 
offspring behaviour testing. Schematic has been published previously (Lins et al., 2018). [B] 
Flow chart depicting the order of the behaviour test battery for female offspring. 
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Table 4.1: Summary of dams’ treatment, adverse events and litter data. 
Treatment Total Dams 
Treated 
Dams 
Euthanized 
Dams w/ No 
Litter 
Litters 
Included 
Viable 
Offspring 
Saline 18 0 2 (+1 no ♀) 15 11.94 ± 0.76 
PolyI:C 25 8 0 (+1 no ♀) 16 12.00  ± 0.81 
 
Table 4.1: 8 dams were euthanized within 48 h of polyI:C administration because they 
developed low body temperature and showed sickness behaviours beyond what is acceptable as 
outlined in our Humane Intervention Protocol. One litter per treatment included male, but no 
female offspring, resulting in exclusion from the final count of litters included in this chapter. 
The 2 saline-treated control dams that did not produce litters showed no evidence of pregnancy. 
Viable offspring count per dam includes all surviving offspring of both sexes present on PND1 
prior to culling to a maximum of 10, excludes dams that did not give birth, and is presented as µ 
± SEM. All additional data presented on the dams only includes those that produced viable 
offspring. 
 
 
 
 
 
 
  
104 
4.3.3 Behavioural testing 
Behaviour tests were conducted according to published protocols. One or two female offspring 
per litter were included in each test, except PPI where all available females were included (Table 
4.2 a-c). To control for the inherent relationships between siblings, effects from littermates were 
averaged and one value per litter was used (Zorrilla, 1997; Lazic, 2013). Estrous phase was 
determined daily between the hours of 07:00 and 08:30 prior to behaviour testing. A single 
investigator used lavage with a p200 pipette and 20 µL of sterile physiological saline to collect 
cells from the vaginal wall for immediate visual examination with a light microscope. Proestrous 
was defined by the presence of uniform nucleated cells, while unnucleated cornified squamous 
cells were characteristic of estrous, densely packed leukocytes indicated metestrous, and 
scattered leukocytes alongside nucleated cells indicated diestrous (Hubscher et al., 2005). 
Estrous determination began 5 days prior to behaviour testing and continued throughout 
experimentation. All rats displayed a typical 4 - 5 day cycle. Additional handling included 
exposure to investigators and emphasized picking up and moving the rats until these motions 
could be carried out with ease, as well as habituation to transport between the housing and 
testing locations. All animal work occurred during the light phase (07:00-19:00 hrs) with the 
majority of behaviour testing performed between 08:30-17:00. Testing began at 8 weeks of age 
(young adulthood) and was completed by 15 weeks of age. The order of testing was PPI, CMOR, 
Sociability, Oddity Discrimination, and finally MK-801 induced locomotor activity (Figure 4.1 
B). Ethanol (40%) was used to clean all behaviour testing equipment between rats. 
PPI: PPI measures the percent attenuation of motor response to a startling tone when the tone is 
preceded by a brief prepulse (Figure 4.2 A; Lins et al., 2018). Two SR-LAB startle boxes (San 
Diego Instruments, San Diego, CA, USA) were used. Each session had constant background 
noise (70 dB) and began with 5 min of acclimatization, followed by 6 pulse-alone trials (120 dB, 
40 ms). Pulse-alone (6), prepulse + pulse (36) and no stimulus (6) trials were then presented in a 
pseudorandom order, followed by 6 additional pulse-alone trials. Prepulse + pulse trials began 
with a 20 ms prepulse of 3, 6, or 12 dB above background (70 dB). Prepulse–pulse intervals 
(time between the onset of the prepulse and the 120-dB pulse) were short (30 ms) or long (80 
ms). The inter-trial interval varied randomly from 3 to 14 s (Meyer et al., 2009; Howland et al., 
2012; Ballendine et al., 2015).   
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Sociability Task: The testing apparatus was a rectangular arena (150 x 40 cm) of black 
corrugated plastic divided into three compartments, one middle start compartment (30 x 40 cm) 
and two ‘stranger’ compartments on either side (60 x 40 cm, see Figure 4.3 A; Henbid et al., 
2017; Lins et al., 2018). The walls dividing the middle compartment from the stranger 
compartments were clear Plexiglas (extend 12 cm from each wall leaving a 16 cm opening 
allowing travel between compartments) and removable black opaque barriers which, when 
inserted, prevented entry into the stranger compartments. Each stranger compartment contained a 
circular mesh cage (18 cm diameter, 20 cm height) with hinged lid (3/4” plywood, painted matte 
black). The height of the cage was extended 20 cm with vertical metal rods to discourage 
climbing. The task began with 10 min habituation with the barriers removed. The test rat was 
then contained in the middle section with the barriers in place and a stranger rat was placed in 
one of the mesh cages. The barriers were removed, and the test rat explored for an additional 10 
min. Video recording and locomotor activity tracking was done with EthoVision software, and 
videos were manually scored with a stopwatch by a trained investigator blind to treatment status, 
and the opaque cage roof obscured the location of the stranger rat. Stimulus exploration was 
scored when the test rat directly approached (watching, contacting, sniffing, or circling) each of 
the cages, with the face of the rat oriented toward the cage at a maximum distance of 2 cm. All 
stranger rats were sex, age, and treatment matched to the test rat (Bitanihirwe et al., 2010; 
Henbid et al., 2017).  
MK-801 induced locomotor activity: The apparatus was a square arena (40 x 40 x 60 cm) made 
of black corrugated plastic (Figure 4.3 D; Lins et al., 2018). A camera mounted to the ceiling 
recorded all activity and EthoVision software was used to track activity. Rats were tested 4 at a 
time, with each rat placed in 1 of 4 separate arenas for 30 min of habituation. Immediately 
following, rats were administered MK-801 (0.1 mg/kg; i.p.) and placed back into the arena for an 
additional 120 min. Activity was recoded with Noldus Ethovision XT 11.5 software. 
Visual, tactile, and CMOR: This task uses spontaneous exploratory behaviour to assess visual 
memory, tactile memory, and visual-tactile sensory integration (Winters and Reid, 2010; Jacklin 
et al., 2012). The testing apparatus was a Y-shaped maze with 1 start arm and 2 object arms (10 
× 27 cm) made of white corrugated plastic (Figure 4.4; Lins et al., 2018; Paylor et al., 2018). A 
white plastic guillotine-style door separated the start arm from the object arms, and Velcro at the 
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distal end of the object arms fixed objects in place. A removable, clear Plexiglas barrier could be 
inserted in front of the objects. A tripod positioned above the apparatus held a video camera that 
recorded the task activity. Rats were habituated to the apparatus twice for 10 min. Lighting 
alternated during habituation between white light (during visual phases) and red light (during 
tactile phases) for 5 min each with the order counterbalanced, and the clear barriers were in place 
for one day of habituation and removed for the other with order counterbalanced. Test days 
consisted of a 3 min sample phase with two identical copies of an object attached with Velcro to 
the maze, a 60 min delay, and then a 2 min test phase with a third copy of the original object and 
a novel object placed in the maze. Rats began each phase in the start arm; the guillotine door was 
opened and closed once the rat entered the object arms. This task consisted of 3 distinct tests 
performed on 3 separate days in the following sequence: tactile memory (day 1; Figure 4.4 A), 
visual memory (day 2; Figure 4.4 C) and crossmodal memory (day 3; Figure 4.4 E). Red light 
illuminated the tactile phases allowing the rats’ behaviour to be recorded while preventing the 
rats’ visual assessment of the objects and the removal of the clear barriers allowed for tactile 
exploration. White light was used during visual phases, but clear Plexiglas barriers in front of the 
objects prevented tactile exploration. CMOR had a tactile sample phase (red light, no barriers) 
and a visual test phase (white light, clear barriers). Recognition memory was defined as 
significantly greater exploration of the novel object than the familiar object. Behaviour 
recordings were manually scored with a stopwatch by investigators blind to the treatment status 
of the rats and identity of the objects (Winters and Reid, 2010; Ballendine et al., 2015). 
Oddity discrimination: The testing apparatus was a square arena (60 x 60 x 60 cm) constructed of 
white corrugated plastic with Velcro in each of the 4 corners. Two days of habituation to the 
arena (10 min sessions) preceded the test day. On test day, 3 identical objects made of glass or 
plastic and one different, or ‘odd’ object were fixed to the Velcro locations (Figure 4.5; Lins et 
al., 2018) and the rats’ activity were recorded for 5 min using a video camera mounted to the 
ceiling. Object exploration times were manually scored using a stopwatch by an investigator 
blind to the treatment status of the rats (Bartko et al., 2007a). Object examination was counted 
when a rat’s face was oriented toward the object at a maximum distance of 2 cm.  
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Table 4.2: Summary of the litters and offspring included in behaviour testing.  
 
 
Treatment 
Total 
Number 
PPI CMOR Sociability 
Oddity 
Preference 
Locomotor 
Activity 
Rats Litters Rats Litters Rats Litters Rats Litters Rats Litters Rats Litters 
Saline 36 15 36 15 22 15 22 15 22 15 14 11 
PolyI:C 35 16 35 15 24 15 24 15 24 15 20 13 
a) All female offspring from n=31 litters completed PPI, while all other tasks included 1 or 2 
offspring per litter. The unexpected death of 1 polyI:C rat with no female littermates reduced the 
number of litters tested to 15. Locomotor activity n was reduced due to some rats being diverted 
to concurrent research. The number of offspring per litter in each task is further summarized 
below. Behaviour scores for littermates were averaged for a single value per litter. 
 
Treatment n=5 n=4 n=3 n=2 n=1 
Saline 1 5 1 0 8 
PolyI:C 1 0 7 1 7 
b) Number of litters with n=5 or fewer offspring included in PPI. 
 
Treatment n=2 n=1 
Saline 7 8 
PolyI:C 9 6 
c) Number of litters with n=1 or n=2 offspring in CMOR, Sociability, and Oddity. 
 
Treatment n=2 n=1 
Saline 3 8 
PolyI:C 7 6 
d) Number of litters with n=1 or n=2 offspring tested in MK-801 Induced Locomotor Activity. 
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4.3.4 Statistical analyses 
A between-subjects design was used, and analyses were conducted with independent 
samples t-tests, one sample t-tests, and ANOVAs using Statistical Package for the Social Science 
version 22 (IBM, Armonk, NY). Outliers were defined as having a performance metric falling 
more than 2 standard deviations from the mean and were removed from analysis on a case by 
case basis. Outliers were identified and removed prior to calculating litter averages to prevent 
excessive exclusion of data points. 1 saline and 2 polyI:C rats were removed from visual 
recognition memory, but all litters remained represented. 2 polyI:C litters were excluded from 
analysis for startle to the P120 tone, 1 polyI:C litter was removed from the analysis for PPI 30 
ms Interval and PPI 80 ms Interval. No litters or individuals were removed from the Oddity, 
Sociability, or Locomotor task analyses. Estrous phase was incorporated into analysis as a 
covariate; however no consistent patterns were observed, potentially due to a low n of rats in 
each phase. Sphericity violations were accounted for using the Greenhouse-Geisser adjustment 
and degrees of freedom were adjusted when Levene’s Test was violated. The use of one- and 
two-tailed tests is specified for each task. Relationships between maternal serum cytokine 
concentrations and long-term offspring outcomes were determined using bivariate correlations 
followed by a Benjamini-Hochburg adjustment to control for multiple comparisons (Benjamini 
and Hochberg, 1995). All data are presented as group means ± standard error of the mean (SEM) 
and asterisks indicate a significant difference between groups with a 95% confidence interval 
(p<0.05). The pound symbol (#) is used to indicate a significant difference from a chance result. 
 
4.4 Results 
The acute effects of saline and polyI:C treatment on this cohort of pregnant dams and 
neonatal pups have been published previously (Lins et al., 2018). Briefly, dams treated with 
polyI:C had reduced body weight compared to saline when followed up at 8, 24, and 48 h post 
treatment, but no significant change in body temperature at the same timepoints. Maternal serum 
collected 3 h post treatment was analyzed with ELISA for concentrations of cytokines CXCL1, 
CXCL2, IL-6, and TNF-a. CXCL1 and IL-6 were significantly elevated in polyI:C-treated dams. 
On PND1, the  average offspring mass (males and females pooled) from polyI:C-treated litters 
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was significantly less than controls but there was no difference in litter size between the groups 
(Lins et al., 2018).  
 
4.4.1 Maternal polyI:C treatment failed to significantly affect startle or PPI 
 Startle responses to acoustic stimuli were assessed by measuring startle alone and PPI in 
saline (n=15 litters) and polyI:C female offspring (n=15 litters). Startle to the 120 dB pulses 
alone decreased during the session (main effect of Time: F(1.35,36.45)=26.26, p<0.001; Figure 4.2 
B) but no Treatment or interaction was present. For prepulse trials with a 30 ms (short) interval, 
a main effect of Prepulse Intensity on PPI (F(2,56)=40.33, p<0.001; Figure 4.2 C) was found with 
no effect of Treatment. Overall, PPI was greater at 12 dB compared to 3 and 6 dB (p<0.001). For 
trials with an 80 ms (long) prepulse-pulse interval, a main effect for Prepulse Intensity was found 
(F(2,56)=89.37, p<0.001; Figure 4.2 D) for PPI, but no effect of Treatment and no interaction. 
Overall, PPI increased with louder prepulses. 
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Figure 4.2: There was no effect of maternal PolyI:C treatment on startle and 
PPI in female offspring. 
 
Figure 4.2: [A] Schematic illustrating a startle response to a 120-dB tone (top panel) versus the 
typical reduction in startle reactivity when a prepulse of 3, 6, or 12 dB precedes the startling tone 
(bottom panel). Schematic has been published previously (Lins et al., 2018). [B] Startle 
reactivity decreased over the course of the PPI testing protocol and polyI:C offspring had 
significantly higher reactivity at the “after” timepoint (p<0.05, indicated by an asterisk, *). [C] 
There were no differences between groups in % PPI for the short (30 ms) prepulse-pulse interval 
but % PPI increased with increasing prepulse intensity where the 12 dB prepulse had higher PPI 
than 2 or 6 dB prepulses. [D] There were no differences between groups in % PPI for the long 
(80 ms) prepulse-pulse interval but % PPI increased with increasing prepulse intensity (3 dB < 6 
dB < 12 dB, p<0.05, indicated by asterisks, *). 
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4.4.2 PolyI:C offspring have sociability deficits 
 Both groups of female offspring (n=15 saline litters, n=15 polyI:C litters) displayed a 
significant preference for the cage containing an unfamiliar rat compared to the empty cage when 
analyzed using a within-subjects design (saline: t(14)=14.18, p<0.001; polyI:C: t(14)=8.11, 
p<0.001). When the results were compared between treatment groups, female polyI:C rats had a 
significantly lower discrimination ratio (DR, calculated as ExplorationStranger - ExplorationEmpty / 
ExplorationTotal; t(28)=2.61, p<0.05; Figure 4.3 B) and spent significantly more time exploring the 
empty cage compared to the saline controls (t(28)=-2.59, p<0.05; Figure 4.3 C). There was no 
difference in total exploration times (p>0.05). 
 
4.4.3 Both groups of offspring increase locomotor activity following MK-801 
administration 
Locomotor data comparing female polyI:C (n=13 litters) and saline (n=11 litters) 
offspring were analyzed with a mixed repeated measures ANOVA (Figure 4.3 E). Results 
revealed a main effect of Time (F(2.47,62.24)=62.24, p<0.001; Figure 4.3 E) but no treatment effect 
and both groups displayed increased locomotion after MK-801 administration.  
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Figure 4.3: Schematic of the apparatuses for the sociability task and 
locomotor activity task, as well as the effects of maternal polyI:C treatment on 
these behaviours in female rats.  
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Figure 4.3: [A] Schematic representing the black, three-chambered arena used to conduct the 
sociability task. The chambers on either side of the center start chamber contain identical holding 
cages, one of which would contain a social stimulus (an age, sex, and treatment matched stranger 
rat) while the test rat was free to explore. Schematic has been published previously (Henbid et 
al., 2017; Lins et al., 2018). [B] When the exploration data is presented as a discrimination ratio, 
both groups show significant preference for the stranger rat; however, polyI:C offspring show 
significantly less preference when compared to saline offspring. [C] There was no significant 
difference between groups in total exploration or exploration of the social stimulus, although 
polyI:C rats spent more time exploring the non-social stimulus than saline rats.  [D] Schematic of 
the black, square arena where rats’ activity was monitored before and after administration of 
MK-801. Schematic has been published previously (Lins et al., 2018). [E] Graph displaying 
locomotor activity as distance travelled per 10 min time bin. Both groups had elevated locomotor 
activity following MK-801 administration, but there was no effect of maternal treatment. 
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4.4.4 PolyI:C offspring perform tactile, but not visual, object recognition memory and 
neither group display crossmodal recognition 
 All CMOR data is presented as a discrimination ratio (DR; explorationnovel – 
explorationfamiliar / explorationtotal) for the first minute of the test phase. One-tailed single sample 
t-tests compared each group’s exploration to chance (DR of 0). Both groups demonstrated 
significant tactile object recognition memory (saline: t(14)=3.00, p<0.01; polyI:C t(14)=11.53, 
p<0.001; Figure 4.4 B). PolyI:C females did not perform above chance for visual memory 
(polyI:C: t(13)=0.49, p>0.05), although saline offspring showed significant preference for the 
novel object (t(15)=2.72, p<0.05). In the crossmodal phase, both groups of female rats failed to 
show a preference for the novel object (saline females: t(14)=0.46, p>0.05; polyI:C females: 
t(14)=1.71, p>0.05). There were no differences in total object exploration times between groups in 
any of the sample and test phases (Table 4.3). 
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Figure 4.4: Maternal polyI:C treatment impairs visual, but not tactile, 
recognition memory in female offspring. Neither group show crossmodal 
memory. 
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Figure 4.4: Schematic of the Y-maze arena for the CMOR task. In each sample phase there are 
two identical objects located at each arm of the Y-maze while the test phase uses a third, 
identical copy of the object from the sample phase plus a novel object. [A] The Y-maze 
assembled to conduct the tactile phase in red light conditions where the rat is able to explore 
objects via touch. [B] Both groups of offspring display robust novelty preference in the tactile 
phase with novel object exploration significantly greater than chance levels. [C] The Y-maze 
assembled for the visual phase which is conducted in white light conditions with the addition of a 
clear, plexiglass window to prevent tactile exploration of the objects, limiting the rats to visual 
observation. [D] Saline offspring demonstrated visual memory with novel object exploration 
significantly greater than chance but polyI:C offspring did not perform above chance levels. [E] 
The Y-maze assembled for the crossmodal phase which has a tactile sample phase and visual test 
phase. [F] Both groups failed to display crossmodal recognition memory as novel object 
exploration was equal to chance. The pound symbol (#) indicates significant difference from 
chance exploration (DR=0, p<0.05) in a single sample t-test. Schematic has been published 
previously (Lins et al., 2018; Paylor et al., 2018). 
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Table 4.3: CMOR task exploration. 
Treatment Task Phase Tactile Visual Crossmodal 
Saline Sample 61.10 ± 2.49 6.41 ± 0.56 66.21 ± 4.73 
Test 36.71 ± 2.41 3.50 ± 0.61 3.36 ± 0.36 
PolyI:C Sample 60.32 ± 3.07 7.18 ± 0.83 58.61 ± 4.43 
Test 34.57 ± 3.42 2.72 ± 0.28 3.84 ± 0.27 
 
Table 4.3: Exploration times (s) for each phase of the CMOR task, presented as µ ± SEM. 
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4.4.5 PolyI:C-treated offspring have reduced oddity preference compared to saline 
offspring  
Saline (n=15 litters) and polyI:C (n=14 litters) offspring both explored the odd object at a 
greater than chance level (saline: t(14)=5.27, p<0.001; polyI:C: t(13)=2.66, p<0.05; Figure 4.5 B) 
when analyzed with a single sample t-test against a value of 25%. When the groups were 
compared directly, saline offspring spent a significantly greater % exploration with the odd 
object compared to polyI:C offspring (t(27)=2.24, p<0.05; Figure 4.5 B). There was no difference 
in total exploration time between saline (97.53±4.08 s) and polyI:C rats (98.94±4.79 s, t(27)=-
0.23, p<0.05). 
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Figure 4.5: Maternal polyI:C treatment impairs odd object discrimination in 
female offspring. 
 
Figure 4.5: [A] Schematic of the white square arena used to conduct the oddity discrimination 
task showing the arrangement of three identical objects and one different, or “odd” object. 
Schematic has been published previously (Lins et al., 2018). [B] Bar graph displaying the 
percent of total object exploration spent examining the odd object. PolyI:C offspring displayed 
significantly less oddity preference than saline offspring (p<0.05, indicated by an asterisk, *) 
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4.4.6 Correlations between measurements taken of the dams during pregnancy and 
offspring outcomes  
 Measurements taken during pregnancy were correlated with long-term behaviour 
outcomes in the female offspring. Serum cytokine concentrations of CXCL1, CXCL2, IL-6 and 
TNFa were determined from blood samples collected from the dams 3 h post treatment and 
analyzed with ELISA. Additional effects of treatment were determined through monitoring with 
weight and rectal temperature measurements taken 8, 24, and 48 h post treatment (Lins et al., 
2018). These data were correlated to behaviour of the offspring using bivariate correlations. 
Maternal weight changes following treatment (anesthesia with saline or polyI:C administration 
and blood sampling) was the only variable associated with offspring behaviour. Greater weight 
loss in polyIC-treated dams 8 h post treatment was associated with reduced startle response in 
their female offspring during the initial tone-alone trials (r=0.623, p<0.05, B-H p<0.05), and this 
was not seen in the saline group (r=0.44, p>0.05). Weight loss in the saline dams at 24 h post 
treatment was correlated to lower %PPI at the 80 ms interval (r=-0.555, p<0.05, B-H p<0.05). 
Saline dam weight loss 8 h after treatment was related to the DR in the sociability task (r=0.716, 
p<0.01, B-H p<0.05). The importance of these relationships is difficult to gauge due to no 
significant effects of saline treatment on weight, and the lack of treatment effects in startle or 
PPI. Previous studies have also shown mixed results regarding maternal weight changes and 
offspring behaviour outcomes (Wolff and Bilkey, 2010; Vorhees et al., 2012). Dedicated studies 
will be necessary to determine the reliability and potential importance of these results.  
 
4.4.7 Male and female offspring show similar behavioural profiles in response to MIA 
The data presented in this paper were further analyzed in conjunction with the male 
littermates from Lins and colleagues (2018) with Sex and Treatment as factors using 2x2 
factorial ANOVAs. It should be noted that this analysis necessitates including 2 values per litter 
(for each sex) which violates the assumption that subjects are independent because littermates 
are inherently related. No main effect of Treatment (F(1,60)=0.59, p>0.05) or Sex (F(1,60)=0.25, 
p>0.05), and no Sex by Treatment interaction (F(1,60)=0.11, p>0.05) was found for 30 ms interval 
PPI. For 80 ms interval PPI trials, no main effect of Treatment (F(1,56)=0.10, p>0.05) or Sex 
(F(1,56)=0.82, p>0.05) was found, but a Sex by Treatment interaction was shown (F(1,56)=4.07, 
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p<0.05). A Tukey HSD post hoc test revealed saline females had lower PPI than saline males 
(p<0.05). Main effects of Treatment (polyI:C offspring have a lower DR than saline offspring; 
F(1,58)=9.55, p<0.01) and Sex (female offspring have a lower DR than male offspring; 
F(1,58)=4.87, p<0.05) were found for sociability, with no significant interaction (F(1,58)=0.13, 
p>0.05). Tactile object recognition memory did not differ by Treatment (F(1,59)=0.30, p>0.05) or 
Sex (F(1,59)=1.06, p>0.05); however, but a significant Sex by Treatment interaction was revealed 
(F(1,59)=4.25, p<0.05). Tukey HSD post hoc testing failed to reveal any significant differences 
between individual groups. Visual object recognition memory was not affected by Treatment 
(F(1,56)=3.60, p>0.05) or Sex (F(1,56)=0.21, p>0.05), and no interaction was present (F(1,55)=0.003, 
p>0.05). Crossmodal object recognition memory was not affected by Treatment (F(1,58)=0.17, 
p>0.05) or Sex (F(1,58)=0.01, p>0.05) and there was no interaction between these factors 
(F(1,58)=3.98, p>0.05). A main effect of Treatment (F(1,55)=19.30, p<0.001, polyI:C offspring 
explore the odd object less than saline offspring) was found for oddity, in the absence of a main 
effect of Sex (F(1,55)=0.03, p>0.05) or Sex by Treatment interaction (F(1,55)=1.88, p>0.05). 
Locomotor activity was not analyzed for Sex by Treatment interactions due to known differences 
in MK-801 metabolism and the use of different doses in males and females (Andiné et al., 1999). 
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Table 4.4: Summary of the effects of MIA on female offspring alongside the 
male offspring from the same cohort in a previously published companion 
paper (Chapter 3). 
Behaviour Test Males Females 
PPI - - 
MK-801 Locomotion ­ 47.72% n.d. 
Sociability ¯ 22.97% (n.s.) ¯ 21.13% 
Tactile Memory - - 
Visual Memory ¯ 90.33% ¯ 87.87% 
Crossmodal Memory ¯ 93.71% - 
Oddity Preference ¯ 31.57% ¯ 18.69% 
  
(-) = no significant change compared to controls 
(n.d.) = not determined 
 
Table 4.4: ‘­’ indicates heightened response or facilitation while ‘¯’ indicates diminished 
response or impaired performance in comparison to a control group. A ‘–’ symbol indicates no 
significant change. Percent change was calculated as a comparison to the equivalent control 
group ((saline – polyI:C / saline) x 100). Male locomotor data was calculated from the total 
distance travelled after MK-801 administration. For consistency, both male and female 
sociability percent change was calculated using the discrimination ratio data, although it should 
be noted the DR was a non-significant (n.s.) effect in the males and they instead spent 
significantly less time (s) exploring the social stimulus than controls. 
 
   
 
  
123 
4.5 Discussion  
 The adult female offspring of rat dams that received an immune stimulant during 
pregnancy displayed various behaviour abnormalities compared to the offspring of saline-treated 
dams. The polyI:C-treated offspring had reduced sociability, impaired visual discrimination, and 
lack of preference for an odd object compared to offspring from control litters. Both treatment 
groups displayed heightened locomotor activity in response to MK-801 administration and tactile 
recognition memory was intact in both groups. Neither group of offspring demonstrated 
crossmodal memory, and there were no treatment effects on PPI. These results complement a 
companion paper that assessed the male offspring (Lins et al., 2018), and by directly analyzing 
sex by treatment interactions where possible, we shown that MIA during pregnancy had similar 
effects on both sexes of offspring. 
A significant limitation of this study is the use of timed-pregnant dams. Several studies 
show an impact of travel stress on the dams and offspring. For example, Moriyama and 
colleagues (2013) examined the effect of transport stress on seizure susceptibility in the offspring 
and found an increase in variability in those transported during gestation; however, maternal care 
behaviour had a greater impact than transport stress on seizure susceptibility (Moriyama et al., 
2013). We have previously reported no observed changes to maternal behaviour following 
polyI:C administration (Zhang et al., 2012), but we did not assess this directly in this cohort or 
strain. Shipment stress also increases susceptibility to the valproate-induced developmental 
toxicity model of autism (Ogawa et al., 2007; Kuwagata et al., 2009). We are unable to confirm 
if shipment stress had a similar impact in our study. Despite these limitations, many comparable 
studies on development and gestational adverse events have relied on the use of timed-pregnant 
dams (Lodge and Grace, 2001; Du and Grace, 2013, 2016a, 2016b; Van den Eynde et al., 2014; 
Ballendine et al., 2015; Lins et al., 2018). Recently, Kentner and colleagues (2018) highlighted 
that consideration of all MIA protocols will enable comprehensive understanding of their 
impacts on offspring outcomes. Thus, we believe our results are of value. 
 
4.5.1 Lack of sex-specific effects of polyI:C treatment on behaviour of the offspring 
 We previously reported that male polyI:C offspring from this cohort displayed greater 
startle to the 120 dB tone at the end of the PPI protocol compared to saline males. Although the 
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effect in the males was small and limited to a single parameter, the female data presented here 
shows no effect of MIA on any measure of PPI and acoustic startle response. The effects of MIA 
on PPI in rodent models are mixed with many studies showing PPI impairments in the offspring 
of immune challenged rats (Borrell et al., 2002; Romero et al., 2007; Wolff and Bilkey, 2010, 
2008, Dickerson et al., 2010, 2013, 2014; Howland et al., 2012; Klein et al., 2013; Ballendine et 
al., 2015; Hadar et al., 2015) and mice (Ozawa et al., 2006; Smith et al., 2007) including 
impairments seen in both sexes (Meyer et al., 2009; Howland et al., 2012; Basta-Kaim et al., 
2015). Other studies show no effects of MIA on PPI, similar to our observations (Missault et al., 
2014; Van den Eynde et al., 2014; Vorhees et al., 2015; Lins et al., 2018). Sex effects in PPI in 
general have been reviewed and the influence of female sex hormone fluctuations have been 
studied (Kumari, 2011). High estrogen phases of the menstrual cycle have been associated with 
lower PPI, although this is not consistently observed (Swerdlow et al., 1997; Jovanovic et al., 
2004; Kumari et al., 2008). Additionally, PPI disruption by a 5HT1A agonist can be prevented by 
administration of exogenous estrogen and progesterone in rats which may imply a protective role 
of sex hormones against PPI disruption (Gogos and Van den Buuse, 2004). The results from the 
present study do not support the claim of a strong influence of estrous phase on PPI performance; 
however, it should be noted that estrous was not controlled for and the ability of the present 
study to detect an effect may be underpowered. 
 In the sociability task, polyI:C treated male offspring spent less time exploring a same-
sex, unfamiliar conspecific compared to saline controls (Lins et al., 2018). We observed a 
different pattern of reduced sociability in the female polyI:C offspring, indicated by a 
significantly lower discrimination ratio compared to the saline offspring which was driven by 
significantly more time exploring the empty cage on the opposite side of the apparatus. The 
social exploration data is presented as a comparison between the saline and polyI:C offspring 
(comparing the relative degree of social preference), while others have presented the data as a 
within-subjects comparison to report either the presence or absence of social preference 
(Silverman et al., 2010). We believe comparing treatment groups allows the detection of subtle 
behaviour differences that could be missed in instances where stimuli with a substantial 
difference in salience (such as an unfamiliar rat versus an empty cage) result in high 
discrimination ratios, and this natural preference would need to be abolished to show a treatment 
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effect. Natural preference for social stimuli versus objects is documented in rodents (Lee and 
Green, 2016). Presenting the data as a between groups comparison also allows direct evaluation 
alongside previously published sociability data from our lab, including that of the male 
littermates from this cohort (Henbid et al., 2017; Lins et al., 2018). The use of single sample 
comparisons may be best suited to tasks that are challenging for control animals to complete, 
such as the complex visual discrimination tasks including visual and crossmodal recognition 
memory where visual stimuli are less salient and the resulting DRs tend to be lower (Winters and 
Reid, 2010). Both strategies of data analysis are common in behaviour literature, and factors 
such as strength or salience of stimuli and task difficulty should be considered when representing 
data. Overall, both male and female polyI:C offspring display a deficit in sociability compared to 
controls, but this presents in a subtly different manner depending on sex and may be related to 
previously observed differences in PFC development (Piontkewitz et al., 2011b; Paylor et al., 
2016), The direct significance of MIA-induced developmental trajectory differences to the 
aberrant social behaviour observed here remains to be determined.  
 The effects of MK-801 administration on locomotor activity have been reported in 
previous studies with mixed results (Zuckerman and Weiner, 2005; Howland et al., 2012; 
Vorhees et al., 2012; Missault et al., 2014). The male siblings in this cohort were significantly 
affected by a dose of 0.2 mg/kg (i.p) indicated by heightened locomotor activity which was not 
seen in the control males (Lins et al., 2018). The females in this paper were given a lower dose of 
0.1 mg/kg comparable to other studies (Andiné et al., 1999; Howland et al., 2012; Zhao et al., 
2013). Unfortunately, both the saline and polyI:C females showed increased locomotion which 
confounds the ability to discern whether prenatal polyI:C treatment affected sensitivity to MK-
801.   
 In the CMOR task, both saline and polyI:C females demonstrated object recognition in 
the tactile phase of the test, similar to what was seen in males of the same cohort (Lins et al., 
2018) and Long Evans males (Ballendine et al., 2015). PolyI:C treated offspring were impaired 
in the visual phase, and neither group performed significantly different from chance exploration 
in the crossmodal phase, a notable distinction from the crossmodal memory exhibited by saline-
treated males (Lins et al., 2018). Previous studies on MIA offspring have shown reduced 
discrimination in object memory behaviour tasks in females and lower discrimination ratios are 
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common in the crossmodal task, possibly reflecting task difficulty (Howland et al., 2012; 
Ballendine et al., 2015; Marks et al., 2016). Visual and crossmodal memory depend on the 
perirhinal cortex while the posterior parietal cortex is necessary for tactile memory, suggesting 
there may be regionally specific deficits as a result of MIA (Winters and Reid, 2010; Jacklin et 
al., 2016). 
 Oddity preference and perception have been assessed in several tasks using rats and mice 
(Bussey et al., 2005; Bartko et al., 2007a, 2007b; Cowell et al., 2010; Cloke et al., 2016; Marks 
et al., 2018; Paylor et al., 2018); however, to our knowledge this is the first study to assess this 
oddity task in female rats. Improved understanding of the nature of oddity discrimination is 
relevant for the successful management of cognitive impairment in conditions such as 
schizophrenia, a symptom domain highly related to patient functional outcomes (Cloke et al., 
2016). Prenatal polyI:C treatment affected females in the same manner as males with a 
significant reduction in oddity preference compared to saline offspring (Lins et al., 2018). The 
successful performance of oddity preference depends on multisensory integration similar to 
CMOR, yet distinct in that visual and tactile associations can be formed simultaneously and there 
is no mnemonic demand in the oddity task (Cloke et al., 2016). Multisensory integration is 
disrupted by NMDA receptor antagonism using ketamine in the OFC and reversed with a4b2 
nicotinic acetylcholine in a GABAA dependent mechanism (Cloke et al., 2016) and abnormalities 
in these brain regions and receptor types may be good candidates to explore in future studies of 
MIA and oddity preference.    
The degree to which these behavioural effects replicate or contradict previous data varies. 
The MIA literature displays a lack of reproducibility, which may be due to variety of protocols 
used. Procedural variations in model species and strain, timing of inflammatory insult, 
inflammatory agent, and dose and route of administration have the potential to alter experimental 
outcomes. Other details such as rodent housing (bedding type, pathogen-free status, temperature, 
etc.), parental age, maternal experience, food and water quality, cage companions, and age at 
weaning, which are not commonly reported, may influence outcomes and reduce reproducibility 
of the model (Smolders et al., 2018; Kentner et al., 2019). The basic protocol used here is 
relatively common in MIA literature, yet very similar protocols yield contrasting behaviour 
responses; for example, hypo- versus hyperlocomotion in an open field (Van den Eynde et al., 
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2014; Lins et al., 2018). Comparison in this case is complicated by the use of spontaneous vs. 
drug-enhanced locomotor paradigms and the collection of maternal blood samples (Van den 
Eynde et al., 2014; Lins et al., 2018). Indeed, distince neuopathological alterations were noted 
with microglia activation in MIA offspring found in one study (Van den Eynde et al., 2014), 
while previous work from our group has found no changes in microglia in offspring generated in 
our laboratory (Paylor et al., 2016). These results support the notion that enhanced reporting of 
such variables is warranted and dedicated future studies should assess the effects of such 
procedural differences directly (Goldstein et al., 2014; Careaga et al., 2018; Kentner et al., 2019; 
Mac Giollabhui et al., 2019). 
 
4.5.2 Implications for sex differences in the maternal immune activation model 
 MIA caused by polyI:C administration resulted in altered behaviour in female offspring 
in multiple behaviour tasks including sociability, visual and crossmodal memory, and oddity 
preference.  Overall, the present data do not provide strong evidence for sex differences in 
response to polyI:C treatment. Inflammation in pregnancy relates to the etiology of sexually 
dimorphic disorders, notably schizophrenia and autism (Davis and Pfaff, 2014; Goldstein et al., 
2014; Patel et al., 2018). The lack of overt sex differences observed in the present study suggest 
the MIA model in rats may be limited in this respect, though others have shown more promising 
results in this regard (Piontkewitz et al., 2011a; Zhang et al., 2012).  
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CHAPTER 5 
GENERAL DISCUSSION 
The work in this dissertation used 3 distinct rat models to produce behaviour 
abnormalities characteristic of psychiatric illness such as schizophrenia in order to better 
understand neuropathology and disease risk factors, as well as putative treatments.   
 
5.1 Summary of major thesis findings  
1.  The l-, but not d-, enantiomer of novel compound GOV reversed PPI deficits in an acute 
hyperDAergic model induced by systemic apomorphine, as well as an acute NMDA receptor 
hypofunction model induced by systemic MK-801. These data support further examination of 
GOV for the management of psychiatric illness.  
2. PolyI:C treatment on GD15 of pregnancy results in male offspring with behaviour 
abnormalities in all three symptom domains of schizophrenia; positive, negative, and cognitive. 
3. Female offspring displayed similar behavioural effects as their male siblings with the 
exception of locomotor activity where an effect in the females could not be established. 
4. Serum concentrations of cytokines CXCL1, CXCL2, IL-6, and TNFa collected from pregnant 
dams 3h post polyI:C administration do not correlate to the severity of offspring behaviour 
abnormalities. 
 
5.2 Acute and neurodevelopmental disease models 
 This thesis included the use of both pharmacological and neurodevelopmental models. 
The advantages and disadvantages of each type of model are introduced in their respective 
sections of the introduction. Briefly, the acute systemic administration of APO and MK-801 as 
pharmacological models of schizophrenia are advantageous due to their ease of use, reliable 
effects, and ability to link effects to the known receptor targets of each compound. The major 
disadvantage is a lack of etiological validity. Neurodevelopmental models such as MIA have a 
much better claim towards achieving etiological validity as inflammatory events in utero are well 
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established to increase schizophrenia risk, yet they are time consuming and therefore expensive 
to produce (Nestler and Hyman, 2010).  
 
5.2.2 Validity and replication in modeling psychiatric illness 
 A recurring theme throughout this dissertation is achieving valid representations of 
complex psychiatric illness in experimental rodent models. Ideally, a model is able to achieve 
validity on multiple levels, notably face validity, construct validity, etiological validity, and 
predictive validity (Nestler and Hyman, 2010). While these concepts are frequently discussed in 
the context of animal models, they are also used to assess behaviour tasks (Young et al., 2009). 
The extent to which the models used in these studies achieve validity have been discussed 
throughout the general introduction with the general conclusion that the MIA model’s inclusion 
of an etiologically-relevant risk factor and a neurodevelopmental time course contribute to 
greater overall validity than the acute pharmacological models. 
A notable drawback of the MIA model is poor reproducibility. Reproducibility is 
important in research. The inability to reproduce an effect generally introduces doubt 
surrounding the original findings or suggests a failure in methodological rigor either on the part 
of the original investigators in outlining their procedures or the subsequent researchers’ ability to 
reproduce the conditions necessary for success. The lack of reproducibility following MIA is 
concerning, though perhaps not surprising. As discussed in Chapter 3, and reviewed by Kentner 
and colleagues (2019), there has been little standardization in the procedures used to generate 
MIA offspring and the are many opportunities for procedural variations. Additionally, the 
impacts of factors typically out of the investigators’ control, such as the pathogen-free (or not) 
status of the animal care facilities, cage dimensions/materials, and others. Across laboratories, 
numerous procedural differences are reported, many of which are known to influence behaviour 
outcomes (Kentner et al., 2019). Various laboratories use different species and strains of rats and 
mice, and differing behaviour results are often seen across strains (Swerdlow et al., 2000). The 
timing of administration of the inflammatory agent influences which developmental processes 
are most vulnerable to disruption, and while some timepoints are more commonly used in 
generating MIA models, other timepoints are used as well and distinct offspring behaviour 
outcomes are reported based on earlier or later exposures. The inflammatory agent used also 
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varies, with polyI:C the most commonly seen but the use of LPS and influenza virus are also 
seen, while other studies administer specific cytokines (Smith et al., 2007; Chlodzinska et al., 
2011). Further still, the use of different manufacturers or molecular weights of polyI:C may also 
result in distinct behaviour outcomes in the offspring (Kentner et al., 2019).  
Despite the presence of many confounding factors resulting in poor replication within the 
literature, it could be argued this contributes to validity of the MIA model. A recent study that 
examined clinical populations found timing of gestational insult and offspring sex were relevant 
in the psychopathological phenotypes observed in the offspring during childhood (Mac 
Giollabhui et al., 2019). The variability seen across animal studies, likely due to procedural 
variations, may create conditions representative of the diverse circumstances that contribute to 
the development of complex human psychiatric illness, implying that validity can exist despite 
poor reproducibility.  Overall, the MIA model is vulnerable to circumstances that have increased 
its propensity for poor reproducibility, yet these procedural variations could reveal an immense 
amount of information surrounding the impact of environmental risk factors in the development 
of psychopathology (Kentner et al., 2019). 
 
5.2.3 Modelling psychiatric illness in the research domain criteria era 
A recent shift in the conceptualization of psychopathology is changing the way 
psychiatric illness is classified. The traditional approach detailed in the DSM-5 is based on the 
practice of using clinical observations to classify clusters of symptoms into an established 
nosological category; for example, defining a patient as having schizophrenia and excluding 
other diagnoses such as bipolar disorder. A limitation of this approach is the common occurrence 
of comorbid psychiatric and mood disorders. As reviewed by Sanislow and colleagues (2010), 
the decision that co-occurring symptoms in a patient should be attributed to multiple conditions 
as opposed to a single, or related, underlying mechanism is contentious. This is exemplified by 
the heterogeneous diagnostic criteria for schizophrenia; two patients with entirely different 
symptoms can receive the same diagnosis. In a seeming contradiction, criteria also overlap 
between conditions, so two patients with the same symptom may receive different diagnoses 
(Sanislow et al., 2010). This is significant because a common mechanism may be involved in 
several disorders and several mechanisms may be involved in one disorder, yet the DSM-5 fails 
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to consider these scenarios. Perhaps the most consequential limitation of the conventional 
diagnostic approach is that it emerged solely from clinical observation, isolated from preclinical 
neuroscience research. In turn, preclinical neuroscience research has approached 
psychopathology in the context of complex clinical diagnoses that have not been integrated with 
preclinical findings and that are challenging, if not impossible, to observe in non-human animals. 
The current paradigm of separation of clinic from research may be hindering advancement of the 
field (Sanislow et al., 2010). The emerging alternative is a classification system proposed by the 
National Institute of Mental Health (NIMH) known as the Research Domain Criteria (RDoC) 
initiative. RDoC proposes the use of transdiagnostic constructs that underlie the core 
psychopathological mechanisms of mental illness with the goal of improving the integration of 
preclinical behavioural neuroscience and clinical practice (Sanislow et al., 2010; Shankman and 
Gorka, 2015).  
RDoC has outlined five domains of psychological processes with the goal to relate these 
to biological mechanisms that explain psychiatric symptoms; Arousal/Regulatory Systems, 
Negative Valence System, Positive Valence System, Systems for Social Processes, and 
Cognitive Systems. Behavioural, genetic, and neurophysiological research were considered in 
defining these domains (Sanislow et al., 2010; Shankman and Gorka, 2015). The intentionally 
broad domain categories are further divided into constructs and sub-constructs (Shankman and 
Gorka, 2015).  
The use of animal models within the RDoC framework, and arguably other frameworks 
as well, will benefit from avoiding anthropomorphism of animal behaviours and instead interpret 
behaviour as an observable output representative of a biological process, in this case one of the 5 
RDoC domains (Anderzhanova et al., 2017). Additionally, behaviour must be interpreted in a 
species-specific manner; traits such as excessive aggression are maladaptive for modern humans 
but may be adaptive in rodents and therefore not indicative of pathology (Anderzhanova et al., 
2017). The RDoC era will likely have implications for how animal models are described and 
related to human disease. 
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5.3 Potential mechanisms of behaviour disruption 
 The primary outcomes measured throughout this thesis were behavioural abnormalities 
observed in the experimental treatment groups (acute APO, acute MK-801, or MIA-exposure in 
utero). The experiments included on offspring of polyI:C treated dams do not directly assess 
mechanisms of the observed behaviour abnormalities. Other research groups have explored 
potential mechanisms that may underlie the manifestation of the abnormal behaviour seen in 
inflammation-exposed offspring and pertinent findings are included below.  
 
5.3.1 Selective deficits in interneuron populations 
 GABAergic interneurons are increasingly recognized as important mediators of 
pathology in psychiatric illness. Schizophrenia patients have reduced cortical levels of proteins 
glutamate decarboxylase 67; altered levels of vGAT1, a GABA transporter; and altered levels of 
GABA receptor subunits (Canetta et al., 2016). These abnormalities are most frequently 
observed in parvalbumin (PV) interneurons, a population of cells that are essential for the 
maintenance of cortical gamma oscillations (Bartos et al., 2007). Several lines of evidence have 
demonstrated rodent MIA offspring display abnormalities in PV interneuron populations, which 
are related to changes in behaviour. In mouse MIA offspring, inhibitory signalling between PV 
neurons and cortical pyramidal cells was reduced, but this was not the case for two other 
populations of interneurons (calretinin and somatostatin). These MIA mice were also impaired in 
a set-shifting behaviour task and showed increased anxiety-like behaviour in the elevated plus 
maze. The role of deficient PV cell populations in the emergence of a psychiatric phenotype is 
further demonstrated by optogenetic inhibition of PV neurons, which recapitulates these 
behaviour findings (Canetta et al., 2016).  
 
5.3.2 Interleukin 17a 
 An objective of this thesis was to explore the relationship between maternal serum 
cytokine levels and offspring behaviour, with a focus on inflammatory cytokines CXCL1 and IL-
6. A correlation between these cytokines and offspring behaviour was not found; however; 
another inflammatory cytokine called IL-17a has been investigated with regard to emergent MIA 
offspring behaviour abnormalities. As previously mentioned, polyI:C administration to pregnant 
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mice results in elevated IL-6; administration of polyI:C or IL-6 alone to pregnant mice results in 
offspring  behaviour abnormalities; and blocking IL-6 in polyI:C-treated mice is sufficient to 
prevent behaviour abnormalities in MIA offspring (Smith et al., 2007). IL-6 is required for T 
helper cell 17 differentiation, which is followed by downstream production of IL-17a. In MIA 
mouse offspring that were treated with a blocking antibody for IL-17a, MIA-induced 
abnormalities in cortical development (such as disorganized cortical layers) were prevented 
(Choi et al., 2016). The abnormal cortical organization in MIA offspring is localized to the 
somatosensory cortex, secondary motor cortex, and temporal association area, and a reduction in 
PV interneurons is a notable characteristic of these abnormal cortical “patches”. Whole cell patch 
clamping revealed reduced miniature IPSCs in pyramidal cells, as well as increased c-fos (Shin 
Yim et al., 2017). These methods were not employed in this thesis work and similar effects may 
be seen in rats.  
 MIA mice display behaviour abnormalities including pups producing abnormal levels of 
ultrasonic vocalizations when separated from their mother, decreased social interaction, and 
enhanced marble burying; all behaviours considered to be associated with an autism-like 
phenotype. These behaviour effects were normalized to control levels in pups who’s mothers 
were administered a blocking IL-17a antibody prior to polyI:C (Choi et al., 2016). Studies 
further implicated IL-17a by administering polyI:C to genetic KO mice that lack RORgt, a 
regulator of IL-17a signalling, resulting in offspring with a normal behaviour phenotype. Finally, 
administration of IL-17a alone is sufficient to produce offspring with disrupted laminar 
organization of the cortex and the same behaviour phenotype seen in MIA offspring (Choi et al., 
2016). Examination of the somatosensory cortex “patches” with reduced PV cell expression 
revealed a relationship between patch size and the presence of ASD-like behaviour 
abnormalities, and KO of neuron-specific expression of IL-17a in MIA offspring prevented both 
patch development and behaviour abnormalities (Shin Yim et al., 2017). In the present thesis, 
maternal cytokine levels alone were not predictive of behaviour abnormalities, but perhaps a 
measure of anatomical abnormalities, such as cortical ‘patch’ size in the offspring would better 
predict behaviour. 
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5.3.3 Cerebral ventricles and potential disruption of ion regulation  
 Among the most reliable anatomical abnormalities seen in patients with schizophrenia are 
intraventricular calcifications and enlarged cerebral lateral ventricles, and this is related to 
maternal serum levels of IL-8 during pregnancy (Ellman et al., 2010). While anatomical 
abnormalities were not assessed in this thesis, enlarged ventricles have been reported in MIA rat 
offspring (Piontkewitz et al., 2011). The ventricles house the choroid plexus, the site of CSF 
production and a key region of ion and metal transport within the brain (Smith and Rapoport, 
1986; Spector et al., 2015). Due to the critical role of ions concentrations in maintaining normal 
physiological function of neurons, disruptions in the ventricles may result in functional deficits 
in brain function (Lins et al., 2016). A case study assessed endogenous ion distribution around 
the ventricles in a MIA rat offspring with large ventricles and found increased levels of Cl-, 
decreased levels of K+, and punctate levels of high Ca2+, indicating ion transport around the 
ventricles may be disrupted in MIA offspring, although this effect remains to be corroborated 
with a higher number of replicates (Lins et al., 2016).  
 
5.3.4 Epigenetic factors 
As there is now extensive evidence to suggest psychiatric illness risk is influenced by 
genetic and environmental factors, epigenetics has emerged as an area of interest, and indeed 
changes in gene expression have been discovered in patients with psychiatric illness (Mirnics et 
al., 2006). One study tested MIA mice, the offspring of dams treated in pregnancy similarly to 
the rats in Chapters 3 and 4, and found epigenetic changes in the cortex including decreased 
expression of genes involved in glutamate signalling (Tang et al., 2013). Another study looked at 
the mPFC of mouse offspring and found genome-wide DNA methylation differences compared 
to controls, with differences seen when inflammation was induced on GD09 or GD17 (Richetto 
et al., 2017). These data indicate that MIA causes epigenetic modification of gene expression and 
this may contribute to the behaviour abnormalities seen.  
 
5.3.5 Altered perineuronal nets 
 Other studies have assessed the effects of MIA on extracellular matrix proteins known as 
perineuronal nets (PNNs). PNNs preferentially surround parvalbumin-containing interneurons 
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and regulate synaptic plasticity. Post-mortem brain samples from patients with schizophrenia 
show reduced PNNs in various regions including the PFC. PNNs are particularly relevant to 
developmental models of psychiatric illness as their levels increase during the postnatal period 
with the most rapid changes occurring in adolescence, corresponding to the critical period 
commonly associated with onset of psychiatric illness.  Rat offspring with a history of prenatal 
inflammation exposure had various alterations in PNN density throughout development, 
including decreased PNNs in young adulthood (Paylor et al., 2016). The consequences of 
variable changes in PNN density throughout development have yet to be fully elucidated, yet 
these data provide means by which an inflammatory event in early development may influence 
behaviour outcomes later in life.   
 One way to consider the models used in this thesis, namely acute effects of 
pharmacological agents versus the development of abnormities after an early life insult, is 
through the concept of traits versus states. A trait is a persistent underlying effect that is causal, 
or otherwise a contributor to disease pathology, while a state is an observable manifestation of a 
disease, or disease-like occurrence which may be transient (Chen et al., 2006). Acute drug 
administration as used in Chapter 2 is effective in creating a transient psychosis-like state and, 
within the short time frame (20 minutes or less) between drug administration and behaviour 
testing, persistent changes such as altered gene regulation or PNNs have not had time to occur. In 
contrast, the data described above support that MIA produces persistent traits that are 
reminiscent of those seen in psychiatric illness. These concepts are similar to those with further 
discussion in section 5.2.3. Modelling psychiatric illness in the research domain criteria era, 
regarding the current nosology of psychiatric illnesses and how the system of diagnosing, 
describing, and prescribing could be improved. 
 
5.3.6 Application of potential mechanisms to thesis behaviour tasks 
 The experiments in chapters 3 and 4 focused on behaviour effects in MIA offspring. The 
mechanisms previously outlined in this section may be applicable to understanding the behaviour 
abnormalities induced by maternal treatment with polyI:C. Both male and female polyI:C rats in 
the present studies displayed sociability deficits, similar to those reported in mice by Choi and 
colleagues (2016) and Shin Yim and colleagues (2017), which were reversed by blocking IL-17a 
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signalling and increasing inhibitory transmission in PV cell-deficient cortical patches, and 
similar mechanisms may be present in MIA rats.  
 Deficiencies in inhibitory signalling can result in enhanced DA transmission (Tse et al., 
2015). The behavioural index of this effect used in this thesis is locomotor activity, which was 
found to be significantly elevated in male MIA offspring after systemic administration of MK-
801. Due to the direct and indirect excitatory projections from the PFC to midbrain DA neurons, 
PFC disinhibition may result in striatal DA elevations, and hyperlocomotive behaviour (Tse et 
al., 2015). 
 Cognitive performance and sensory processing have been linked to cortical gamma 
oscillatory activity. These synchronized oscillations are dependent on fast-spiking, PV 
interneurons, the same population of cells shown to be deficient in the MIA model  (Bartos et al., 
2007; Canetta et al., 2016). Gamma oscillations have been proposed for involvement in sensory 
binding of features into unified concepts (Bartos et al., 2007), which may be applicable to 
performance in sensory integration tasks such as oddity discrimination and visual, tactile, and 
crossmodal recognition, of which several domains were shown to be impaired throughout this 
thesis. Deficits in GABAergic transmission have also been shown to disrupt performance in 
operant set-shifting (Tse et al., 2015); although it should be noted that the data presented in this 
thesis revealed a facilitation in this behaviour, reversal learning was impaired and inhibitory 
signalling is known to influence cognitive flexibility which may have contributed to the observed 
effects.  
 There is extensive literature describing evidence of cortical disinhibition in MIA 
offspring. The behaviour abnormalities reported in this thesis have all be associated with 
disrupted inhibition. While functional and anatomical aberrations were not directly assessed, the 
behaviour data presented herein further support the presence of deficient inhibition in MIA.  
    
5.4 The future of treatment and prevention strategies 
 The currently available treatment options for psychiatric illnesses such as schizophrenia 
have a number of disadvantages, including high rates of treatment resistance, poor compliance or 
discontinuation, and severe adverse events (Lally and MacCabe, 2015). Neither FGA or SGA 
contribute to significant improvements in the cognitive and negative symptoms, both of which 
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are strongly related to patient functional outcomes, and while the adverse event profiles are 
different between the two main antipsychotic classes, equal rates of drug discontinuation suggest 
SGAs are not improved in this regard (Lieberman et al., 2005; Jones et al., 2006; Young et al., 
2009). Outcomes continue to be poor with many patients experiencing long-term disability 
(Lally and MacCabe, 2015). In addition, all new drugs have been modelled after clozapine in 
attempt to produce similar efficacy with an improved profile of adverse events, yet this aim 
remains unfulfilled. As discussed in section 1.2.3.1, Conventional antipsychotics, the failure of 
this strategy to improve patient care points to a critical need for innovative approaches to disease 
management (Lally and MacCabe, 2015). The work outlined in this thesis may contribute to 
innovation in the treatment of mental illness.  
 The work detailed in Chapter 3 approaches the issue of insufficient treatment options in a 
direct manner by assessing a putative therapeutic compound in a translationally relevant 
behaviour task. Of the two enantiomers tested, l-GOV’s ability to reverse PPI deficits induced by 
acute APO or MK-801 indicate promise for possible application as an antipsychotic. The basic 
pharmacological profile of l-GOV is similar to conventional FGAs due to its high affinity for D2 
receptors and antagonist activity. Targeting of D2 receptors is not innovative in itself, rather it 
reflects early treatment strategies such as haloperidol, but the efficacy seen in this thesis with the 
NMDA receptor antagonist model, as well as other studies that show promise in cognitive 
enhancement and latent inhibition (Lapish et al., 2012, 2014) suggest GOV may have benefits 
that have yet to be fully characterized with the potential for superior symptom reduction over 
conventional drugs. The investigation of compounds like GOV that originate from a long history 
in traditional Chinese medicine may also spur interest in exploring similar compounds in order to 
develop new treatments.  
Schizophrenia has been well established as a neurodevelopmental disease along with 
characterization of various environmental factors that increase risk, such as maternal 
inflammation during pregnancy. The presence of a large time frame between adverse ‘priming’ 
events in development or early life and the emergence of illness, typically in young adulthood, 
presents the potential for identifying individuals most at risk and introducing early interventions 
to lessen disease severity or even prevent the transition to overt psychosis. The ability to 
anticipate and prevent the occurrence of psychiatric disorders would have an immense impact on 
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the affected individuals and revolutionize mental health treatment. The goal of prevention 
requires understanding the associated risk factors in order to design treatments as well as 
recognize susceptible individuals (Brown and Patterson, 2011). Progress toward this aim has 
utilized the MIA model due to the ability to induce inflammation during pregnancy and directly 
compare treated and untreated groups, as well as control over the life experiences and risk factors 
the rodents are exposed to. Previous studies show MIA-exposed offspring begin to diverge from 
the typical neurodevelopmental trajectory seen in control rats around the same time that 
behaviour abnormalities emerge (young adulthood). Neurodevelopmental abnormalities 
previously reported in adults include smaller hippocampal volume and larger lateral ventricle 
volume. In MIA rat offspring that were treated with antipsychotics clozapine or risperidone 
between PND 34-47 these anatomical changes and accompanying behaviour abnormalities were 
prevented. These studies raise the exciting prospect that the transition to overt psychosis and 
chronic illness can be prevented and further research in this area promising for the future of 
improved management of schizophrenia and additional studies with a focus on identifying at risk 
populations and pharmaceutical compounds effective at preventing the emergence of psychosis 
have great potential clinical applications.  
The strategies used and reviewed by Piontkewitz and colleagues (2012) in preclinical rat 
studies have not yet faced the scrutiny of clinical trials, yet they may provide a way to improve 
outcomes for psychiatric patients by using existing treatments differently. Specifically, this 
would require a shift to using antipsychotics as a prophylactic in high-risk individuals. This 
approach has limitations, including the need to adequately determine risk, the cost of long-term 
treatment, the effects of treatment in young patients, selection of which antipsychotic to use, and 
how long treatment is required. Further, this approach does not address the limitations of the 
currently available compounds, in particular the lack of effect against negative symptoms and 
cognitive impairment, and patients would still experience the adverse events that accompany all 
known antipsychotic drugs.    
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5.5 Limitations of the thesis research 
5.5.1 Exclusive use of behaviour testing 
 An important limitation of the research in this thesis is the exclusive use of behaviour 
testing. While analysis of behaviour is critically important in models of psychiatric illness, 
diseases that are diagnosed and treated based on clinical observations of patient behaviour, 
preclinical research with animal models is amenable to further exploration in order to better 
understand the mechanisms of pathology (Silverman and Ellegood, 2018). The use of 
pharmacological agents with known targets in Chapter 2 allows some degree of certainty of the 
effects in the brain that result in PPI impairments, but the study of hyperDAergic and NMDA 
receptor hypofunction in disrupting PPI is well studied and not a novel contribution in itself. The 
more important and novel contribution of Chapter 2 is the effects of d- and l-GOV on the 
disrupted PPI, notably the attenuation of the effects of APO and MK-801 by l-GOV. The 
discussion of Chapter 2 includes speculation of the mechanisms by which l-GOV improves MK-
801-induced PPI disruptions when conventional antipsychotics do not, but this study did not test 
this.  
 In Chapters 2 and 3, maternal serum was drawn in order to test the hypothesis that 
maternal serum concentrations would provide insight into the behaviour abnormalities observed 
in the offspring as adults. Maternal cytokines concentrations were found to not correlate with the 
severity of the offspring’s behavioural phenotype, and the lack of other biological measurements 
left few other parameters to relate to the offspring behaviours aside from maternal weight, 
temperature, and offspring birthweight. The inclusion of measurements of anatomical, cellular, 
or electrophysiological data may have enabled a better understanding of the effects of 
inflammation during pregnancy on the neurobiology that underlie the offspring’s behaviour 
abnormalities.  
 
5.5.2 Impact of maternal nutrition on offspring behaviour outcomes 
Another limitation of the studies outlined in this thesis is the lack of consideration of 
maternal nutrition on the developing offspring. This concern extends to the majority of MIA 
research as most studies do not report maternal weight changes or food intake, yet weight loss in 
the polyI:C-treated pregnant dams is a reliable finding in our lab (Howland et al., 2012; Zhang et 
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al., 2012; Ballendine et al., 2015; Paylor et al., 2016), including the experiments presented in 
chapters 2 and 3. Another study reported higher cytokine levels (TNF-a) and behaviour deficits 
in the offspring of dams that lost weight following treatment compared to those that gained 
weight (Missault et al., 2014), but another study found no association between maternal weight 
loss in MIA dams and offspring behaviour, specifically looking at PPI deficits (Wolff and 
Bilkey, 2010). Similar to the literature on MIA and psychiatric outcomes, there is a body of 
evidence exploring the influence of maternal nutrition and various mental health outcomes in the 
offspring (Penner and Brown, 2007). Animal studies demonstrate that maternal malnutrition is 
sufficient for behaviour abnormalities in the offspring (Grissom et al., 2014). In Chapter 3, the 
only correlation between maternal effects and offspring outcomes that remained following the 
correction for multiple comparisons was that dams that lost the most weight after polyI:C 
administration delivered pups that were smaller on PND1, and this may be an important indicator 
that appropriate maternal weight gain and nutrition are implicated in the long-term behaviour 
effects seen in the offspring. Low birth weight in humans is associated with increased risk for 
various psychiatric diagnoses (Mathewson et al., 2017), although in the data presented in 
Chapters 3 and 4, pup size on PND1 did not have robust correlations with adult behaviour. The 
lack of data on maternal food intake and nutrition may have confounded the results of these 
experiments and could be a source of variability resulting in the poor reproducibility seen 
throughout the field (Kentner et al., 2019). Analysis that considers maternal nutritional state 
should be included in future studies. 
 
5.6 Future directions 
 The understanding of the risk factors and pathology of psychiatric illness is improving, 
with hope for more effective treatments and even preventative strategies. The work highlighted 
in this dissertation supports earlier evidence that maternal inflammation during pregnancy is 
associated with psychiatric behaviour profiles in the offspring and demonstrated the efficacy of l-
GOV in restoring PPI when disrupted by two pharmacological approaches. These experiments 
can inform future research to improve the management of psychiatric illnesses. 
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5.6.1 The effects of GOV in neurodevelopmental models of psychiatric illness 
 Following the assessments of GOV’s effects in normal rats as well as in acute 
pharmacological models as demonstrated here any by others (Lapish et al., 2012, 2014b; Ashby 
et al., 2015), assessing GOV’s effects in etiologically valid neurodevelopmental models is an 
option for future progression of the field. The data presented in Chapters 2 and 3 contribute to a 
body of evidence that the MIA model is capable of generating rats with all three symptom 
domains of schizophrenia and is etiologically valid. The ability of GOV to ameliorate these 
abnormalities would further support its position as a putative antipsychotic drug and contribute 
to the search for new therapeutics, particularly those that can improve the management of 
negative and cognitive symptoms. 
 
5.6.2 The ability of GOV to prevent the emergence of behavioural abnormalities in 
neurodevelopmental models of psychiatric illness 
In addition to the goal of improved management of psychiatric illnesses, the 
neurodevelopmental nature of schizophrenia and the ability to identify those at greatest risk 
presents an opportunity for early intervention and possible prevention (Insel, 2010).  Previous 
research using the MIA model has shown that administration of antipsychotic compounds prior 
to adulthood prevents the emergence of behaviour abnormalities (Piontkewitz et al., 2009, 
2011b, 2012). Further investigation of the effects of GOV, and other compounds, in the MIA 
model could contribute to a paradigm shift in how psychiatric illness is perceived and treated 
with great potential to lessen the burden of schizophrenia on individuals and society (Brown and 
Patterson, 2011).  
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